EDMS Doc. Number: [ADDRESS_249326]
Protocol  CC-[ZIP_CODE]- PSA-014 [COMPANY_010] Inc.
Confident ial and Propri etary 1 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249327] (CC -[ZIP_CODE]) ON MRI OUTCOM ES IN 
SUBJECTS WITH PSORIA
TIC ARTHRITIS
PROTOCOL NUMBER: CC-[ZIP_CODE] -PSA- 014
DATE FINAL: 14AUG 2018
DATE AMENDMENT No. 1FINAL : 21SEP 2018
DATE AMENDMENT No. 2 FINAL: 12 FEB 2019
DATE AMENDMENT No. 3 FINAL: 17MAY 2019
DATE AMENDMENT No. 4 FINAL: 04MAY [ADDRESS_249328] NUMBER: 2018- 002748- 10
IND NUMBER: 101761
NCTNo. [STUDY_ID_REMOVED]
SPONSOR NAME/ADDRESS: [COMPANY_010] Inc,
[COMPANY_010] Center Dr, Thousand Oaks, CA 
[ADDRESS_249329]/independent ethics committee/institutional scientific review board or 
equivalent. The information in this document cannot be used for any purpose other 
than the evaluation or conduct of the clinical investigation without the prior written 
consent of [COMPANY_010]. If you have questions regarding how this document may be used 
or shared, call the [COMPANY_010] Medical Information number: 1 -800-77
-AMGEN 
Approved  
  
EDMS Doc. Number: [ADDRESS_249330]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 2 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020MEDICAL MONITOR /EMERGENCY CONTACT [CONTACT_208855]:  MD
Title: Medical Director Global Development
[COMPANY_010] Inc.
Address: [COMPANY_010] Inc,
[COMPANY_010] Center Dr, Thousand Oaks, CA [ZIP_CODE]
[LOCATION_003]
Phone:
E-mail:
Note : Only call [COMPANY_010] Medical Information, if you are not able to reach the Clinical 
Research Physician(s) or Medical Monitor or designee for emergency calls. 
[COMPANY_010] Medical Information: 1- 800-77- AMGEN (1 800- 772-6436)
Approved  
  

EDMS Doc. Number: [ADDRESS_249331]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 3 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020CELGENE THERAPEUTIC AREA HEAD SIGNATURE [CONTACT_1783]
[See appended electronic signature [CONTACT_3264] ]
Signature [CONTACT_208918]
, Vice President and Head of Immuno logy &Fibrosi s Clinical 
Development
Printed Name [CONTACT_208919] [CONTACT_27616], I i ndicate I have reviewed this protocol and find its content to be 
acceptable. 
By [CONTACT_27616], I i ndicate I have reviewed this protocol and find its content to be 
acceptable. NOTE: Signed by [CONTACT_208856]. Number: [ADDRESS_249332]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 4 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020SITE PRINCIPAL INVESTIGATOR [INVESTIGATOR_27503]: _______________________________________
By [CONTACT_27616], I agree to personally  supervise the conduct of this study  at my  study  
site and to ensure i ts conduct is in compliance with the protocol, informed consent, 
Institutional Review Board (IRB)/Ethics Committee (EC) procedures, instructions from
[COMPANY_010] representatives, the Declaration of Helsinki, Internati onal C ouncil for
Harm onisat ion (ICH) Good Clinical Practices Guidelines, and local regulat ions 
governing the conduct of clinical studies.
Approved  
  
EDMS Doc. Number: [ADDRESS_249333]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 5 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020COORDINATING PRINCIPAL INVESTIGATOR [INVESTIGATOR_27504]: _______________________________________
By [CONTACT_27616], I agree the protocol has been written to comply  with ICH Good 
Clinical Practices guidelines and agree to offer guidance throughout the study  as 
needed.
Approved  
  
EDMS Doc. Number: [ADDRESS_249334]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 6 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249335] 
(CC-[ZIP_CODE]) on MRI Outcomes in Subjects w ith Psori atic Arthrit is
Indication
Psoriatic arthritis (PsA) i s a heterogeneous inflammatory  rheumatol ogic disord er characterized 
by[CONTACT_208857]
,affect ing 6 %to 39% of patients suffering fro m psori asis. PsA is classified 
as a seronegative spondyl oarthropathy  (SpA) because it shares certain features with other 
condi tions included in that group. Indeed, spi[INVESTIGATOR_208819]  
50% of patients with PsA. In addit ion, PsA is associated with enthesit is and dactylit is, which are 
extra -articular features commo n to SpA. Finally , the maj ority of patients with PsA are negat ive 
for the rheum atoid factor (Gladman, 2005 ; Kruithof, 2005 ).
Apremilast (CC -[ZIP_CODE]) i s an oral  phosphodi esterase enzyme (PDE) inhibitor. It is highly 
select ive for PDE4, whi ch is the dom inant PDE in inflammatory cells. Through inhibit ing PDE4, 
apremilast elevates intracellular cyclic adenosine mo nophosphate levels , leading to a parti al 
inhibit ion of the production of many pro -inflammatory mediators , as well as an increase in so me 
anti-inflammatory  mediators. Arecent study  in subjects with PsA indicated that apremilast was 
associ ated wi th reducti ons in tumor necrosi s factor –α (TNF - α) , interleukin ( IL)-17, IL -23, IL -6, 
IL-8, macrophage inflammatory protein -1β,and monocyte chemoattractant p rotein [ADDRESS_249336]
(Schafer, 2015 ). It is believed, therefore, that apremilast exerts its therapeutic benefits through 
the modulati on of  multiple inflammatory  pathways.  
Following a com prehensive clinical development program, apremilast has been approved for the 
treatm ent of PsA and it is under clinical investigat ion for the treatment of Behçet ’s syndro me and 
inflammatory  bowel  disease. 
Apremilast has been shown to be eff icacious in halting inflammat ionandreducing signs and 
symptoms of PsA, as well as improving physical funct ion (Cutol o, 2016 ; Edwards, 2016 ; 
Kavanaugh, 2014; Nash, 2018). A question that remains to be addressed is whether apremilast 
can impact the structural progression of the disease. In addit ion, the extent of its structure 
modifying effects rem ains to be characterized using axial PsA specific imaging techniques and 
meth odologies.  
Magnet ic resonance imaging (M RI)has gained importance as a promising tool for early  
diagnosis and increasing acceptance as an outcome measure in clinical trials of different 
inflammatory  arthri tides. It is highly  sensi tive(Altho ff, 2007 ; Braun, 2004 ; Herm ann, 2005 ; 
Herm ann, 2006 )and superior to convent ional radiography  in depi[INVESTIGATOR_208820]. Moreover, it candetect soft ti ssue 
inflammat ion, bone erosion ,and proliferat ion. As such, this study  is designed to assess the 
efficacy  of apremilast on MRI outcomes in subjects with active PsA, with less than 5 years of 
disease durati on (since diagnosis), and who are naïve to biologic therapi [INVESTIGATOR_014].
Approved  
  
EDMS Doc. Number: [ADDRESS_249337]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 7 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249338] ive
To evaluate the efficacy  of apremilast 30 mg twice per day  (BID) on inflammat ion 
indices , assessed by [CONTACT_208858]
To evaluate the efficacy  of apremilast 30 mg BID on imaging outcomes associated 
with structural  progressi on, assessed by  [CONTACT_208859]
To evaluate t he efficacy o f apremilast [ADDRESS_249339] ionality, assessed by [CONTACT_208860]
To evaluate t he efficacy o f apremilast 30 mg BID on inflammat ion indices of 
peripheral  arthri tisand enthesi tis, total  (sum  of arthri tis and enthesit is) and separately, 
assessed by  [CONTACT_28760] -body  MRI (WB -MRI) 
To evaluate t he efficacy o f apremilast 30 mg BID on PsAID -12
To evaluate t he safet y and tol erabili ty of apremilast [ADDRESS_249340] 
(CC- [ZIP_CODE]) either in mo notherapy  or wi th stable methotrexate (MTX) on MRI outcomes in 
subjects wi th active PsA wit h up to 5years of disease duration (since diagnosis). 
Approved  
  

EDMS Doc. Number: [ADDRESS_249341]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 8 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249342] 30 mg BID , after a 5 -day titration period , 
with or wi thout stable MTX . All subjects will be permitted to take nonsteroidal ant i-
inflammatory  drugs (NSAIDs) and/or low- dose oral  glucocorti coids (prednisone ≤ 10 mg/day or 
equivalent) throughout the study .The NSAIDs and low -dose oral  glucocorti coids must be on a 
stable regimen for at least 4 weeks prior to baseline. MTX (≤ 25 m g/week) will be permitted if 
durati on of  treatm ent is ≥[ADDRESS_249343] be 
continued fro m Day 1through the W eek 24 Visit. Change in doses, increase or decrease, and/or 
discontinuat ion will  not be allowed e xcept for safety  reasons or for l ack of availabilit y. After the 
Week 24 Visit, the doses of MTX, NSAIDs ,or glucocortico ids may be adj usted as clinically 
requi red.
This is a 56- week study  com prising of3 phases:
Screening Phase –up to 4 weeks
Single-arm, Open-label Treatment Phase –Weeks 0 to 48
[ADDRESS_249344] 30 mg BID (after a 5 -day titration period) for 
the ent ire durati on of  this phase.
All subjects who complete the study  or di scont inue early will part icipate in the [ADDRESS_249345] of male or female subjects, ≥ [ADDRESS_249346] not been previously treated with TNF blockers 
or other bio logic disease -modifying antirheumat ic drugs ( DMARDs ).Prior treatm ent wi th 2 non-
biologic conventional synthetic DMARDs ( csDMARD s)is permitted. Subjects who are taking 
MTX ( ≤25 m g/week) for at least [ADDRESS_249347] one day  prior to thei r Baseli ne Visit (ie, Vi sit 
2; Day  1), except for those subject s taking MTX, lefluno mide, and cyclosporine .Subjects taking 
MTX at screening who do not meet the criteria above will require a [ADDRESS_249348] s 
taking lefluno mide will require a 12- week washou t or treatment with cho lestyramine in 
accordance with the lefluno mide prescribing label (ie, [ADDRESS_249349] yramine 3 times daily  for 11 
days). Subjects taking cyclosporine at screening will require a [ADDRESS_249350] or any  
Approved  
  

EDMS Doc. Number: [ADDRESS_249351]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 9 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249352] a documented diagnosis of PsA based on the
Classificat ion Cri teria for Psori atic Arthri tis (CASPAR), wi th disease durati on ≥ 3 m onths and 
≤[ADDRESS_249353] ≥3 swollen (out of 76) AND ≥ 3 tender (out of 78) 
joints, wi th hand invo lvement (defined as ≥ 1swollen jo int or dac tylitis [each clinically act ive 
joint of a dactylit icdigitis count edas one jo int]),and at least 1 active enthesit issite (either one 
of the Spondylo arthri tis Research Consortium of Canada orLeeds Enthesit is Index sites )at 
screening. Subjects may  or may not have axial involvement in conjunct ion with peripheral  PsA. 
Length of Study
Subjects will spend up to a total of 56 weeks in th is study: up to [ADDRESS_249354] that is 
requi red for primary, secondary ,and/or expl oratory  analysis, as prespecified in the protocol , 
whichever i s the l ater date .
Study Treatments
Apremilast will be provided in blister cards for a5-daytitration peri od.Dose titration cards will 
be provided at W eek 0 to all subjects. 
After the 5-daytitration, subjects will be required to take one 30 mg tablet twice daily (morning 
and evening), approximately [ADDRESS_249355] supplied in high
-densit y polyethylene bottl es unt il the end of study  or early 
discontinuat ion. 
Overview of Key Efficacy Assessments
Overview of Efficacy Assessments on Imaging
The fo llowing will be used for assessing clinical efficacy on MRI outcomes:
Outcom e Measures in Rheumatol ogy(OM ERACT )Psoriat ic Arthri tis Magnet ic 
Resonance Im aging Score (PsAMRIS)
WB-MRI generated indices ,such as WB -MRI inflammat ion indices of peripheral 
arthri tis and enthesit is,the Canada-Denmark and the Spondylo arthri tis Research 
Consortium of Canada (SPARCC) Magnet ic Resonance Imaging Scoring Indices for 
the axial invo lvement (Krabbe, 2017; Maksymowych, 2005 ), the Hip Inflammat ion 
Magnet ic Resonance Imaging Scoring System (HIMRISS) (Maksymowych, 2016 ), 
the Knee Inflammat ion Magnet ic Resonance Imaging Scoring System (KIMRISS)
(Jarem ko, 2017 ), and the OMERACT Heel Enthesi tis Magnet ic Resonance Imaging 
Scoring Sy stem
Approved  
  

EDMS Doc. Number: [ADDRESS_249356]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 10 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020Overview of Clinical Efficacy Assessments
The fo llowing will be used for assessing clinical efficacy:
76 Swollen Jo int and 78 Tender Joint Score
Clinical Disease Act ivity Index for Psoriat ic Arthritis (c -DAPSA)
Spondyloarthrit is Research Consortium o f Canada (SPARCC) Enthesi tis Assessment
(Maksym owych, 2009 )
Leeds Enthesit is Index (LEI)
Leeds Dact ylitis Index (LDI)
Psori atic Arthri tis Disease Activit y Score (PASDAS) (Coates, 2014 )
Patient’s (Subject ’s) and Physician’s (Eva luator’s ) Global Assessmen tof Disease 
Activity
Subject ’s Pain Assessment 
Health Assessment Questi onnaire –Disabilit y Index (HAQ -DI)
Bath Ankylosing Spondylit is Disease Act ivity Index ( BASDAI ),for subjects deem ed 
to have PsA spondylit is by [CONTACT_208861] i tem 2 ≥ [ADDRESS_249357] of disease, fat igue, 
and work productivit y:
Psori atic Arthri tis Im pact of Disease 12-domain questi onnaire(PsAID - 12)
Overview of Key Safety Assessments
The fo llowing will be used for assessing safet y:
Adverse events /
Physical examinat ion, vital signs, weight
Clinical laboratory  evaluat ions
Approved  
  

EDMS Doc. Number: [ADDRESS_249358]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 11 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020Statistical Methods
Sample size calculat ion for this single -arm study  was based on the confidence interval (CI) 
approach. Efficacy parameters incl uding MRI, clinical, and subject -reported outcomes will be 
analyzed descript ively and 95% CIs will be provided as appropriate. Safet y analyses will be 
perform ed for all  subjects who re ceive at least one dose of study medicat ion.
Approved  
  
EDMS Doc. Number: [ADDRESS_249359]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 12 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249360] .............................................................................................................. 20
1.2.2. Key Findings from Clinical Studies ........................................................................ 21
[IP_ADDRESS]. Efficacy .................................................................................................................. 22
[IP_ADDRESS]. Safety..................................................................................................................... 29
1.3. Rationale ................................................................................................................ 34
1.3.1. Study  Rati onale and Purpose .................................................................................. 34
[IP_ADDRESS]. Unmet Medical Need .............................................................................................. 34
[IP_ADDRESS]. Magnet ic Resonance Imaging (MRI) in PsA and Study Rat ionale........................... [ADDRESS_249361] ion............................................. 37
2. STUDY OBJECTIVES AND ENDPOINTS ........................................................... 38
3. OVERALL STUDY DESIGN ................................................................................ 44
3.1. Study  Design .......................................................................................................... 44
3.2. Study  Durati on for Subj ects.................................................................................... 46
3.3. End of Trial ............................................................................................................ 46
4. STUDY POPULATION ......................................................................................... 47
4.1. Medical and Disease History .................................................................................. 47
4.2. Number of Subjects ................................................................................................ 47
4.3. Inclusio n Cri teria.................................................................................................... 47
4.4. Exclusio n Cri teria................................................................................................... 48
5. TABLE OF EVENTS ............................................................................................. 51
6. PROCEDURES ...................................................................................................... 56
6.1. Screening Period ..................................................................................................... 56
6.2. Treatment Period .................................................................................................... 57
6.2.1. End of Treatment/Early  Terminat ion Visit .............................................................. 58
Approved  
  
EDMS Doc. Number: [ADDRESS_249362]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 13 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May [ZIP_CODE].3. Observational Fo llow-up Peri od............................................................................. 59
6.3.1. Safety Follow-up .................................................................................................... 59
6.4. Efficacy Assessments ............................................................................................. 59
6.4.1. Magnet ic Resonance Imaging (MRI) ...................................................................... [ADDRESS_249363] Affected Hand ............................................................................. 60
6.4.3. WB-MRI ................................................................................................................ 60
[IP_ADDRESS]. Definit ion of WB-MRI Indices ............................................................................... 60
......................................................... 60
......................................................... 60
6.4.5. Clinical Efficacy Assessments ................................................................................ 61
[IP_ADDRESS]. Joint Assessments ................................................................................................... 61
[IP_ADDRESS]. Subject and Evaluator’s Global Assessments of Disease Act ivity............................ 62
[IP_ADDRESS]. Subject’s Pain Numeric Rat ing Scale ...................................................................... 62
[IP_ADDRESS]. HAQ -DI................................................................................................................. 62
....................................................................... 63
.................................................. 63
[IP_ADDRESS]. Enthesit is................................................................................................................ 63
[IP_ADDRESS]. Dactylit is................................................................................................................ 64
[IP_ADDRESS]. Clinical Disease Act ivity Index for Psori atic Arthriti
s (c-DAPSA) .......................... 64
[IP_ADDRESS]. Psori atic Arthri tis Disease Activit y Score (PASDAS) ............................................. 64
[IP_ADDRESS]. PASI and BSA ........................................................................................................ 65
[IP_ADDRESS]. Bath Ankylosing Spondylit is Disease Act ivity Index (BASDAI) ............................ 65
6.5. Safety Assessments .................................................................................................65
6.5.1. Ser um and Urine Pregnancy Tests for Females of Childbearing Potential ............... 65
6.5.2. Vital Signs, Hei ght and Weight ............................................................................... 66
6.5.3. Com plete/Limit ed Physical Examinat ion................................................................ 66
6.5.4. Psychiatri c Evaluat ion............................................................................................ 66
6.5.5. Diarrhea, Nausea and Vomit ing.............................................................................. 66
6.5.6. Tuberculosis ........................................................................................................... 67
6.5.7. Clinical Laboratory  Evaluat ions.............................................................................. 67
6.5.8. Adverse Events ....................................................................................................... 67
6.6. Biomarkers ............................................................................................................. 68
Approved  
  

EDMS Doc. Number: [ADDRESS_249364]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 14 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249365] of  Disease 12- domain Questi onnai re (PsAID - 12)............ [ADDRESS_249366](s) ................................................................ [ADDRESS_249367] Accountabilit y and Disposal .............................................. 71
7.5.1. Dosing .................................................................................................................... 72
[IP_ADDRESS]. Study  Medicat ion Dispensing and Count ing........................................................... [ADDRESS_249368] Disposit ion.................................................................................................76
9.6. Efficacy Analysis .................................................................................................... 77
9.6.1. Primary Endpo int.................................................................................................... 77
9.6.2. Secondary  Endpo ints.............................................................................................. 77
Approved  
  

EDMS Doc. Number: [ADDRESS_249369]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 15 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249370] Compliance (Tablets) ......................................................... 78
9.8.2. Concomitant Therapy ............................................................................................. 78
9.8.3. Steering Committee ................................................................................................ 78
10. ADVERSE EVENTS .............................................................................................. 79
10.1. Moni toring, Recording, and Reporting of Adverse Events ...................................... 79
10.1.1. Moni toring, Recording, and Reporting AEs of Diarrhea .......................................... 79
10.2. Evaluat ion of Adverse Events ................................................................................. 80
10.2.1. Seriousness ............................................................................................................. 80
10.2.2. Severit y/Intensi ty.................................................................................................... [ADDRESS_249371] ice............................................................................................ 89
Approved  
  
EDMS Doc. Number: [ADDRESS_249372]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 16 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249373]/Independent Ethics Committee Review and 
Approval ................................................................................................................ [ADDRESS_249374]/ Ethics Co mmit tee................ 91
13.8. Terminat ionof the Study ........................................................................................ 91
14. DAT A HANDLING AND RE CORDKEEPI[INVESTIGATOR_1645] ..................................................... 92
14.1. Data/Documents ..................................................................................................... [ADDRESS_249375] Complaint to [COMPANY_010]: ...................................................... 95
16. PUBLICATIONS ................................................................................................... 96
17. REFERENCES ....................................................................................................... 97
18. APPENDICES ...................................................................................................... 103
APPENDIX A. TABLE OF ABBREVIATIO NS.................................................................. 104
APPENDIX B.THE CLASSIFICATION C RITERIA FOR PSORIATI C ARTHRITIS 
(CASPAR) CRITERIA ......................................................................................... 108
APPENDIX C.JOINT ASSESSMENT ................................................................................ 109
APPENDIX D. NUMERICAL RATING SCA LES............................................................... 110
APPENDIX E.DISABILITY INDEX OF THE HEALTH ASSESSMEN T 
QUESTIONNAIRE (HAQ -DI)............................................................................. 111
APPENDIX F.LEEDS ENTHESITIS IND EX (LEI) ............................................................ 114
APPENDIX G. THE SPONDYLOARTHRITI S RESEARCH C ONSORTIUM OF 
CANADA (SPARCC) ENTH ESITIS INDEX ....................................................... 115
APPENDIX H. LEEDS DACTYLITIS IND EX (LDI) .......................................................... 116
APPENDIX I.PSORIASIS AREA SEVER ITY INDEX (PASI) ........................................... 118
APPENDIX J.BATH ANKYLOSING SPON DYLITIS DISEASE ACTI VITY INDEX 
(BASDAI) ............................................................................................................ 119
Approved  
  
EDMS Doc. Number: [ADDRESS_249376]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 17 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249377] OF DISEASE 12 
DOMAINS (PSAID- 12) QUESTIONNAIRE ....................................................... 120
............................. 125
.............. 126
............. 130
......135
APPENDIX P.PSORIATIC ARTHRITIS MAGNETIC RESONANCE I MAGING 
SCORING SYSTEM (PSAM RIS) ........................................................................ 137
APPENDIX Q. WHOLE -BODY (WB) –MRI ASSESSMENTS ............................................ [ADDRESS_249378] CONFIGU RATION FOR THE TITRA TION 
PERIOD ............................................................................................................... 142
APPENDIX T.CONTRACEPTION EDUCAT ION ............................................................. 143
APPENDIX U. SAMPLE SERIOUS ADVER SE EVENT REPORT FORM ........................ 144
APPENDIX V. PREGNANCY NOTIFICATI ON FORM ..................................................... 147
APPENDIX W. LACTATION NOTIFICATI ON FORM ..................................................... 148
Approved  
  

EDMS Doc. Number: [ADDRESS_249379]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 18 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249380] OF TABLES
Table 1: Apremilast Phase 3 and 3b Studies ......................................................................... 21
Table 2: Primary (ACR20) and Major Secondary  Endpoints of Studi es 
CC-[ZIP_CODE]- PSA-002 (Palace 1), CC - [ZIP_CODE] -PSA-003 (Palace 2), and 
CC-[ZIP_CODE]- PSA-004 (Palace 3) (Ful l Analysis Set) ................................................. 22
Table 3: Primary and Major Secondary  Endpo ints of Study  CC-
[ZIP_CODE]- PSA-005 (Full 
Analysis Set) .......................................................................................................... 24
Table 4: Summary  of Secondary  Efficacy  Endpoints Rel ated to Enthesit is and 
Dactylit is at Week 16 (FAS; LOCF) ....................................................................... 25
Table 5: ACR 20/50/70 Responses at Weeks 16 and 24 During the Placebo -controlled 
Period in Study CC-[ZIP_CODE]- PSA-006 (FAS; NRI) ................................................... 26
Table 6: HAQ -DI Score (0 to 3) Change From Baseline at Weeks 16 and 24 (FAS; 
MMRM) ................................................................................................................. 27
Table 7: Gladman Enthesit is Index Change From Baseline at Weeks [ADDRESS_249381] ing 
Enthesopathy  (FAS; MMRM) ................................................................................. 28
Table 8: Treatment -emergent Adverse Events Reported in 2% of Subjects in Any  
Treatment Group, First 16 Weeks of Exposure (Studies CC
-[ZIP_CODE]- PSA-002, 
CC-[ZIP_CODE]- PSA-003, CC - [ZIP_CODE]- PSA-004, and CC - [ZIP_CODE]- PSA-005; 
Subjects As Treated) ............................................................................................... 30
Table 9: Treatment -emergent Serious Adverse Events Reported in >[ADDRESS_249382] 16 Weeks of Exposure (Studies CC-[ZIP_CODE]- PSA-002, 
CC-[ZIP_CODE]- PSA-003, CC - [ZIP_CODE]- PSA-004, and CC - [ZIP_CODE]- PSA-005; 
Subjects As Treated) ............................................................................................... 31
Table 10: Frequency of Co mmo n AEs Over 208 Weeks of Exposure ..................................... 32
Table 11: Study  Objectives ..................................................................................................... 38
Table 12: Study  Endpo ints..................................................................................................... 39
Table 13: Table of Events ....................................................................................................... 51
Table 14
:Treatment Schema for Dose Titration at Baseline ................................................... 70
Table 15: Abbreviat ions and Specialist Terms ...................................................................... 104
Approved  
  
EDMS Doc. Number: [ADDRESS_249383]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 19 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249384] OF FIGURES
Figure 1: Overall Study  Design .............................................................................................. 45
................. 62
Approved  
  

EDMS Doc. Number: [ADDRESS_249385]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 20 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May [ZIP_CODE]. INTRODUCTION
1.1. Disease Background 
1.1.1. Psoriatic Arthritis
Psoriatic arthritis (Ps A)is a heterogeneous inflammatory  rheumatol ogic disorder characterized 
by [CONTACT_208862], enthesit is, dact ylitis and spondylit is, affect ing 6 %to 39% of the 
patients suffering fro m psori asis. 
The exact prevalence of PsA is unknown. Estimates of incidence vary fro m 0.3% to 1% of the 
popul ation.Disease onset ty pi[INVESTIGATOR_208821] 30 and 55 y ears,and affects both 
genders equally (Gladman, 2005 ).
PsA is classified as a seronegative spondyloarthropathy  (SpA) because it shares certain features 
with other condi tions included in that group. Indeed, spi[INVESTIGATOR_208822] 50% of  patients wi th PsA. In addit ion, PsA is associated with enthesit is and 
dactylit is, which are extra -articular features common to SpA. Finally, the majorit y of patients 
with PsA are nega tive for the rheumatoi d factor ( RF) (Gladman, 2005 ; Kruit hof, 2005 ).
Recent studi es have challenged the assert ion that PsA is a more benign disease than rheumatoid 
arthritis (RA). There i s an increasing body  of evidence that suggests that PsA patients experience 
progressive jo int destructi on over a relatively  short peri od of  time. The results from these studies 
indicate that PsA is erosive and deforming in nearly halfof the patients, wi th joint dam age 
appearing in the first y ears of disease onset. Other investigators later confirmed that 4 1% of the 
patients developed erosive disease wit hin 2 years of onset of symptoms (Helliwell, 2015).
PsA is also associ ated wi th a high burden of disease. PsA ha sbeen shown to have a similar 
impact on phy sical function, qualit y of life (QoL) and abilit y to work asRA. 
When co mpared to 
patients wi th psoriasis alo ne, patients with PsA had a furt her diminished QoL. Lastly, PsA was 
associ ated wi th a significant ly higher (60%) ri sk of m ortali ty than that of the general population; 
the risk increased with increasing severit y of the disease (Gladman, 2008 ; Rosen, 2012; Sokoll, 
2001) . 
1.2. Compound Background 
1.2.1. Apremilast
Apremilast (CC -[ZIP_CODE]) i s an oral  phosphodi esterase enzyme (PDE) inhibitor. It is highly 
select ive for PDE4, whi ch is the dominant PDE in inflammatory  cells. Through inhibit ingPDE4, 
apremilast elevates intracellular cyclic adenosine mo nophosphate levels , leading to a parti al 
inhibit ion of the production of many pro -inflammatory mediators , as well as an increase in so me 
anti
-inflammatory  mediators. Indeed, a recent study  in subj ects wi th PsA indicated that 
apremilast was associated with reductions in tumor necrosi s factor –(TNF -), interleukin ( IL) -
17, IL -23, IL -6, IL -8, macrophage inflammatory protein- 1β, and monocy te chem oattractant 
protein [ADDRESS_249386] (Schafer, 2015). I t is believed , therefore, that apremilast exerts its therapeutic 
benefits through the modulat ion of mult iple inflammatory  pathways. 
Approved  
  
EDMS Doc. Number: [ADDRESS_249387]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 21 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249388] has been approved for the 
treatm ent of PsA and psori asis. It is under clinical investigat ion for the treatm ent of Behçet ’s 
syndro me and inflammatory  bowel  disease. 
Whether apremilast can impact the structural progressio n of PsA has yet to be addressed . In 
addition, the extent of its effects on axial imaging parameters remains to be characterized in 
subjects wi th axial PsA.  
1.2.2. Key Findings from Clinical Studies
The safet y and efficacy  of apremilast for the treatment of PsA were demonstrated i n a 
comprehensive clinical development program. Subjects enrolled in Phases 3 and 3b studies 
included disease -modifying antirheumat ic drug ( DMARD )-naïve, DMARDs -experienced, 
biologic-naïve ,and bio logic-experienced subjects The results from these studies 
indicated that apremila st is safe and effect ive, both as monotherapy  and in combinat ion with 
convent ional synt hetic DMARDs ( csDMARDs ). 
Table 1: Apremilast Phase 3 and 3b Studies
Study Population Treat ment ArmsSubjects 
Randomized Who 
Received 1 Dose 
of Study Medication
PALACE 1 /
CC-[ZIP_CODE]- PSA-
002csDMARD- and/or 
biologic -experiencedApremilast 20 mg /30mg BID + 
concomitant csDMARDs vs. 
PBO + concomitant 
csDMARDs504
PALACE 2 /
CC-[ZIP_CODE]- PSA-
003csDMARD- and/or 
biologic -experiencedApremilast 20 mg /30mg BID + 
concomitant csDMARDs vs. 
PBO + concomitant 
csDMARDs484
PALACE 3 /
CC-[ZIP_CODE]- PSA-
004csDMARD- and/or 
biologic -experienced 
with > 1 psoriatic skin 
lesion > [ADDRESS_249389] 20 mg /30mg BID + 
concomitant csDMARDs vs. 
PBO + concomitant 
csDMARDs505
PALACE 4 /
CC-[ZIP_CODE]- PSA-
005csDMARD- naïve and 
biologic -naïveApremilast monotherapy vs. 
PBO527
ACTIVE /
CC-[ZIP_CODE]- PSA-
006Maximum [ADDRESS_249390] monotherapy vs. 
PBO219
BID = twice daily; csDMARD = conventional synthetic disease -modifying antirheumatic drug; PBO = placebo ; vs = versus.
Approved  
  

EDMS Doc. Number: [ADDRESS_249391]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 22 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May [ZIP_CODE].2.2.1. Efficacy
[IP_ADDRESS].1. Efficacy Data From Phase 3 Studies CC -[ZIP_CODE]- PSA -002 (Palace 1), 
CC
-[ZIP_CODE]- PSA -003 (Palace 2), and CC -[ZIP_CODE]- PSA -004 (Palace 3) Through 
Week 24 in Subjects With Prior csDMARDs and/or Biologic DMARDs
Apremilast was first evaluated in 3 mult icenter ,rando mized ,doubl e
-blinded , placebo -controlled,
Phase 3 pi[INVESTIGATOR_36491] (Studi es CC -[ZIP_CODE]- PSA-002 [Palace 1 ], CC- [ZIP_CODE]- PSA- 003 [ Palace 2 ], 
and CC -[ZIP_CODE]- PSA- 004 [ Palace 3 ]) (Cutolo, 2016 ; Edwards, 2016 ; Kavana ugh, 2014 ).The 
studi es were similar lydesign ed. Adul t subject s with active PsA ( ≥ 3 swollen and ≥ 3 tender 
joints) despi[INVESTIGATOR_208823]/or bio logic TNF therapy  were enrolled in the studies (TNF 
blockers efficacy  failures were limited to < 10% of subjects). Subjects were excluded if they  had 
previously failed > 3 agents for PsA or > 1 TNF inhibitor. Stable ba seline conco mitant 
methotrexate ( MTX [ ≤ 25 mg/week ]), sulfasalazine ( SSZ [≤ 2 g/day ]), leflunomide (LEF [≤ 20 
mg/day ]), low-dose oral  glucocorti coids (equivalent to ≤ 10 mg of prednisone a day), and/or 
nonsteroidal ant i-inflammatory drugs (NSAIDs) were allowed during the trials. 
Inthe [ADDRESS_249392] s were randomized equally to placebo (N =496), apremilast 
(APR ) 20 twice per day  (BID) (N=500), or APR 30 BID (N = 497). Placebo subject s whose 
tender and swo llen jo int count s(TJC and SJC, respectively) had not improved by  20% were re -
rando mized 1:[ADDRESS_249393] s rem ained on thei r initial treatm ent. 
All 3 studies achieved their primary  endpoint ( Table 2 );a stati stically significantly higher 
percentage of subjects in the APR 30 BID treatment group ach ievedthe primary  endpoint of 
American Co llege of Rheumatology ( ACR )[ADDRESS_249394] ion and 
improvements in skin manifestations at Week s16 and 24 among subjects with body surface area 
(BSA) for psori asis ≥ 3 % at baseline.
Table 2: Primary (ACR20) and Major Secondary Endpoints of Studies
CC
-[ZIP_CODE]- PSA -002 (Palace 1), CC -[ZIP_CODE]- PSA -003 (Palace 2), and 
CC
-[ZIP_CODE]- PSA -004 (Palace 3) (Full Analysis Set)
Study CC -[ZIP_CODE] -PSA-002 Study CC -[ZIP_CODE] -PSA-003 Study CC -[ZIP_CODE] -PSA-
004
Placebo
N =168APR 30 BID
N =168Placebo
N =159APR 30 BID
N =162Placebo
N =169APR 30 BID
N =167
ACR 20 –NRI
  Week 16 n (%) 32 (19.0) 64 (38.1) 30 (18.9) 52 (32.1) 31 (18.3) 68 (40.7)
  Week 24 n (%) 22 (13.1) 59 (35.1) *** 25 (15.7) 40 (24.7) * 26 (15.4) 52 (31.3) ***
ACR 50 –NRI
  Week 16 n (%) 10(6.0) 27 (16.1) ** 8 (5.0) 17 (10.5) 14 (8.3) 25 (15.0)
  Week 24 n (%) 7 (4.2) 32 (19.0) *** 14 (8.8) 19 (11.7) 13 (7.7) 27 (16.2) *
Approved  
  
EDMS Doc. Number: [ADDRESS_249395]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 23 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020Table 2: Primary (ACR20) and Major Secondary Endpoints of Studies 
CC
-[ZIP_CODE]- PSA -002 (Palace 1), CC-[ZIP_CODE]- PSA -003 (Palace 2), and 
CC
-[ZIP_CODE]- PSA -004 (Palace 3) (Full Analysis Set) (Continued)
Study CC -[ZIP_CODE] -PSA-002 Study CC -[ZIP_CODE] -PSA-003 Study CC -[ZIP_CODE] -PSA-
004
Placebo
N =168APR 30 BID
N =168Placebo
N =159APR 30 BID
N =162Placebo
N =169APR 30 BID
N =167
ACR 70 –NRI
  Week 16 n (%) 2 (1.2) 7 (4.2) 1 (0.6) 2 (1.2) 4 (2.4) 6 (3.6)
  Week 24 n (%) 1 (0.6) 17 (10.1) *** 5 (3.1) 4 (2.5) 6 (3.6) 9 (5.4)
HAQ –LOCFa
  Week 16 
mean change from 
Baseline (SE)b-0.086 
(0.0360)-0.244 
(0.0364) **-0.053 
(0.0358) **-0.193 
(0.0354)-0.065 
(0.0335)-0.192 
(0.0339) **
  Week 24 
mean change from 
Baseline (SE)b-0.076 
(0.0369)-0.258 
(0.0371) ***-0.085 
(0.0377)-0.206 
(0.0372) *-0.053 
(0.0350)-0.192 
(0.0353)**
BSA >3 at 
BaselinePlacebo
N= 68APR 30 BID
N = 82Placebo
N = 74APR 30 BID
N = 77Placebo
N = 89APR 30 BID
N = 90
PASI 50 –LOCF
  Week 16 n (%) 11 (16.2) 36 (43.9)*** 10 (13.5) 33 (42.9) *** 22 (24.7) 38 (42.2) *
  Week 24 n (%) 12 (17.6) 41 (50.0)*** 11 (14.9) 35 (45.5) *** 22 (24.7) 39 (43.3)**
PASI 75 – LOCF
  Week 16 n (%) 3 (4.4) 18 (22.0)** 2 (2.7) 17 (22.1)*** 7 (7.9) 20 (22.2)**
  Week 24 n (%) 3 (4.4) 17 (20.7)** 3 (4.1) 21 (27.3)*** 10 (11.2) 23 (25.6)**
ACR 20/50/70 = American College of Rheumatology 20%/50%/70% response; APR =apremilast; BID =twice daily; 
BSA =body surface area; DMARD = disease -modifying antirheumatic drugs; HAQ -DI=Health Assessment Questionnaire 
Disability Index (HAQ -DI score:  0 =best, 3 =worst; measures the subject’s ability to perform the following: dress/groom, arise, 
eat, walk, reach, grip, maintain hygiene, and maintain daily activity) ; LOCF =last observation carried forward; NRI =non-
responder imputation; PASI 50/75 = 50% /75% or greater improvement in the Psoriasis Area and Severity Index; SE =standard 
error.
***p < 0.[ADDRESS_249396] versus placebo.  **p < 0.[ADDRESS_249397] versus placebo.  *p < 0.[ADDRESS_249398] -squares mean (SE) and p -value based on an analysis of covariance model for the change from baseline at the respective 
time point, with treatment group and baseline DMARD use as fac tors, and (for Study PSA -004 only) involvement of ≥3% 
BSA with psoriasis at baseline as factors, and the baseline value as a covariate.
For subjects who discontinued from the study prior to Week 16, the last available postbaseline value observed prior to 
discontinuation was carried forward to Weeks 16 and 24. For subjects who entered early escape (EE) at Week [ADDRESS_249399] sufficient data
(observed or imputed) for a determination of response status at the respective visits were counted as non -responders .
Approved  
  
EDMS Doc. Number: [ADDRESS_249400]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 24 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May [ZIP_CODE].[IP_ADDRESS]. Efficacy Data From Phase 3 Study CC -[ZIP_CODE]- PSA- 005 (Palace 4) Through Week 
[ADDRESS_249401] igated in a 
multicenter, randomized, double -blinded, placebo -controlled Phase 3 study  
(CC-[ZIP_CODE]- PSA- 005 
[Palace 4] ) (Wells, 2013 ).Subjects enro lled had a diagnosis of PsA for [ADDRESS_249402] ive 
disease (defined by  ≥3 swollen and ≥3 tender j oints). Previous treatment with csDMARDs or 
biologics was not allowed. Subjects could receive stable doses of prednisone (equivalent to 
≤ 10 mg/day) and/or NSAIDs. The use of other csDMARDs, including MTX, SSZ, LEF, or 
biologics was prohibited during the trial. Subjects were randomized 1:1:1 to placebo, APR 20 
BID, or APR 30 BID treatment groups.  
In total , 527 subjects were randomized to the placebo (n =176), APR 20 BID (n =175), or APR 
30 BID (n = 176) group . Subjects whose TJCs and SJC s had not improved by ≥20% at Week 16 
were required to enter the early  escape ( EE) to blinded active treatment. Placebo subjects who 
met the EE criteria were re- randomized 1:[ADDRESS_249403] subjects remained on their init ial treatment.  
Astatistically significant ly higher percentage of subjects in the APR 30 BID treatment group 
achiev edthe primary  endpoint of ACR 20 at Week 16 compared with placebo ( Table 3). 
Apremilast was also associated with statist ically significant improvements in physical funct ion 
and improvements in skin manifestations at Week s16 and 24 among subjects with BSA for 
psori asis≥ 3% at baseline. 
Table 3: Primary and Major Secondary Endpoints of Study CC - [ZIP_CODE]- PSA -005 (Full 
Analysis Set)
Study CC -[ZIP_CODE]-
PSA-005
Placebo
N = 176APR 30 BID
N = 176
ACR 20 –NRI
  Week 16 n (%) 28 (15.9) 54 (30.7)**
  Week 24 n (%) 23 (13.1) 43 (24.4)***
ACR 50 –NRI
  Week 16 n (%) 8 (4.5) 20 (11.4)*
  Week 24 n (%) 11 (6.3) 22 (12.5)*
ACR 70 –NRI
  Week 16 n (%) 2 (1.1) 7 (4.0)
  Week 24 n (%) 7 (4.0) 8 (4.5)
HAQ -LOCFa
  Week 16 
  mean change from Baseline (SE)b 0.012 (0.0350) -0.205 (0.0350)***
  Week 24 
  mean change from Baseline (SE)b 0.012 (0.0370) -0.207 (0.0369)***
Approved  
  
EDMS Doc. Number: [ADDRESS_249404]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 25 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020Table 3: Primary and Major Secondary Endpoints of Study CC - [ZIP_CODE]- PSA -005 (Full 
Analysis Set) (Continued)
Study CC -[ZIP_CODE]-
PSA-005
BSA ≥3 at Baseline Placebo
N = 93APR 30 BID
N = 103
PASI 50 –LOCF
  Week 16 n (%) 18 (19.4) 51 (46.8)***
  Week 24 n (%) 23 (24.7) 53 (48.6)***
PASI 75 –LOCF
  Week 16 n (%) 10 (10.8) 29 (26.6)**
  Week 24 n (%) 11 (11.8) 28 (25.7)*
ACR 20/50/70 = American College of Rheumatology 20%/50%/70% response; APR =apremilast; BID =twice daily; 
BSA =body surface area; DMARD = disease -modifying antirheumatic drugs; HAQ -DI=Health Assessment Questionnaire 
Disability Index ;LOCF =last observation carried forward; NRI =non-responder imputation; PASI 50/75 = 50%/75% or greater 
improvement in the Psoriasis Area and Severity Index ;SE=standard error. 
***p < 0.[ADDRESS_249405] versus placebo.   **p < 0.[ADDRESS_249406] versus placebo.  *p < 0.[ADDRESS_249407] -squares mean (SE) and p -value based on an analysis of covariance model for the change from baseline at the respective 
time point, with treatment group and baseline DMARD use as factors, and (for Study PSA -004 only) involvement of ≥3% 
BSA with psoriasis at baseline as factors, and the baseline value as a cova riate.
Health Assessment Questi onnaire –Disabilit y Index ( HAQ -DI)score:  0 =best, 3 =worst; 
measures the subject ’s abilit y to perform the fo llowing: dress/groom , arise, eat, walk, reach, grip, 
maintain hygiene, and maintain daily  activi ty.
For subjects who discontinued from the study  prior to Week 16, the last available postbaseline 
value observed prior to discont inuat ion was carried forward to Weeks [ADDRESS_249408] sufficient data (observed or imputed) for a 
determinat ion of response status at the respective visit s were counted as non -responders .
Improvements in enthesit is and dact ylitis among subjects with baseline enthesit is and/or 
dactylit is at baseline are shown in Table 4. 
Table 4: Summary of Secondary Efficacy Endpoints Related to Enthesitis and 
Dactylitis at Week 16 (FAS; LOCF)
Secondary EndpointsPlacebo
N
= 176APR 30 BID
N = 176
MASES mean change from baseline (SE) -0.5 (0.24) -1.5 (0.25)**
MASES = 0 n (%) 22 (19.1) 41 (36.9)**
Dactylitis mean change from baseline (SE) -1.0 (0.25) -1.7 (0.26)*
Dactylitis score = 0 n (%) 30 (33.3) 34 (40.5)
Approved  
  
EDMS Doc. Number: [ADDRESS_249409]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 26 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020APR = apremilast; BID = twice daily; FAS = Full Analysis Set; LOCF = last observation carried forward; MASES = 
Maastricht Ankylosing Spondylitis Enthesitis Score ; SE = standard error . 
MASES evaluated only subjects with pre -existing enthesopathy (N = 115 a nd 111 for placebo and APR 30 BID, 
respectively).
Dactylitis score evaluated only in subjects in pre -existing dactylitis (N = 90 and 84 for placebo and APR 30 BID, 
respectively).
Note: **p < 0.[ADDRESS_249410] versus placebo. *p < 0.[ADDRESS_249411] vers us placebo.  
[IP_ADDRESS].3. Efficacy Data From Phase 3 CC –[ZIP_CODE]- PSA -006 (ACTIVE) Through Week 24 
in Subjects With an I nadequate Response to [ADDRESS_249412] s who had 
received ≤[ADDRESS_249413] swas demo nstrated in the ACTIVE study (CC -[ZIP_CODE]- PSA- 006) ( Nash, 
2018), a Phase 3b mult icenter, parallel -group study  with 1 active treatm ent; overall treatment 
durati on was2 years. The study  rando mized 219 patients (APR 30 m g,n=110; placebo [ PBO],
n=109). At Week 16 (time o f the primary  endpoint), all subjects whose improvement was <10% 
in both tender and swollen jo int counts were eligible to enroll into an EE to active treatment with 
apremilast [ADDRESS_249414] 30 mg BID. 
A separat ion in the proportion of ACR20 responders to APR versus PBO was noted at W eek 2 
(16.4% versus 6.4%; P=0.0252), the first Post-baseline Visit. Early onset of response to APR 
was observed across clinical assessments, with improvements in the Disease Act ivity Score 
(DAS )-28 C- reacti ve protein (CRP), SJC, HAQ- DI, enthesit is, and morning st iffness severit y. 
Dactylit is and skin res ponses were not assessed in CC -[ZIP_CODE]- PSA- 006.
A stati stically significant ly greater proportion of subjects in the APR 30 BID treatment group 
achieved the primary endpo int of ACR 20 response at Week 16 compared to placebo. A 
nominally significant ly greater proportion of subjects in the APR 30 BID treatment group 
achieved an ACR 50 or ACR 70 response at Week 16 than in the placebo group (Table 5). 
Significant reducti on in PsA disease activit y/manifestati ons versu s placebo w asalso 
demonstrated by  [CONTACT_208863] -28 (CRP) ( P<0.0001), SJC ( P≤0.0001) ,and HAQ -DI (Table 
6).
Table 5: ACR 20/50/70 Responses at Week s 16 and 24 During the Placebo -controlled 
Period in Study CC-[ZIP_CODE]- PSA -006 (FAS; NRI)
Study CC -[ZIP_CODE]- PSA- 006
Placebo
N = 109APR 30 BID
N = 110
ACR 20
  Week 16 n (%) 22 (20.2) 42 (38.2)**
  Week 24 n (%) 27 (24.8) 48 (43.6)**
Approved  
  
EDMS Doc. Number: [ADDRESS_249415]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 27 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020Table 5: ACR 20/50/70 Responses at Weeks 16 and 24 During the Placebo -controlled 
Period in Study CC
-[ZIP_CODE]- PSA -006 (FAS; NRI) (Continued)
Study CC -[ZIP_CODE]- PSA- 006
Placebo
N = 109APR 30 BID
N = 110
ACR 50
  Week 16 n (%) 5 (4.6) 20 (18.2)**
  Week 24 n (%) 12 (11.0) 22 (20.0)
ACR 70
  Week 16 n (%) 0 (0.0) 7 (6.4)*
  Week 24 n (%) 5 (4.6) 8 (7.3)
ACR 20/50/70 =American College of Rheumatology 20%/50%/70%; APR =apremilast; BID =twice daily; 
FAS =Full Analysis Set; NRI =non-responder imputation.
Note:  **p < 0.[ADDRESS_249416] versus placebo.  *p < 0.[ADDRESS_249417] versus placebo.  
Table 6: HAQ-DI Score (0 to 3) Change From Baseline at Weeks 16 and 24 (FAS; 
MMRM)
Visit
Treat ment Group naChange From Baseline
LS Mean (SE)b
Week 16
  Placebo 109 -0.055 (0.0513)
  APR 30 BID 109 -0.205 (0.0523)*
Week 24
  Placebo 109 -0.169 (0.0581)
  APR 30 BID 109 -0.273 (0.0572)
APR = apremilast; BID = twice daily; DMARD = disease -modifying antirheumatic drug; EE =early escape; FAS = 
Full Analysis Set; HAQ -DI=Health Assessment Questionnaire –Disability Index; LS =least-squares; 
MMRM =mixed -effects model of repeated measures; SE = standard error.
aSubjects with a baseline value and at least 1 postbaseline value (after exclusion of data for EE subjects) during the 
Placebo -controlled Phase are included in the MMRM analysis.
bThe LS mean (SE) and [ADDRESS_249418] use and baseline oral glucocorticoids
(prednisone or equivalent) use as factors and the baseline value as a covariate. An unstructure d covariance matrix 
that is homogeneous across treatment groups was used. The p-values in italics are < 0.[ADDRESS_249419] s with enthesit is at baseline, significant improvements from baseline in Gladman 
Enthesit is Index ( GEI)score were obs erved wit h APR 30 mg ( -1.1) versus placebo ( -0.4) at 
Week 2 (P=.0354), as well as at Weeks 16 and 24 ( Table 7).
Approved  
  
EDMS Doc. Number: [ADDRESS_249420]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 28 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020In addit ion, numerically  greater proporti ons of subjects treated with APR 30 m g (48.2%) 
compared to pl acebo (33.3%) ach ieved GEI scores of 0at Week 24.
Table 7: Gladman Enthesitis Index Change From Baseline at Week s 16 and 24 During 
the Placebo -
controlled Period in Subjects With Pre- existing Enthesopathy 
(FAS; MMRM)
Treat ment Group naChange From Baseline
Week 16
LS Mean (SE)bWeek 24
LS Mean (SE)b
Placebo 48 -0.4 (0.26) -0.5 (0.27)
APR 30 BID 49 -1.5 (0.26)** -1.5 (0.26)**
APR = apremilast; BID = twice daily; DMARD = disease -modifying antirheumatic drug; EE = early escape; FAS = 
Full Analy sis Set; GEI =Gladman Enthesitis Index; LS = least squares; MMRM = mixed -effects model for repeated 
measures; SE = standard error. 
aSubjects with a baseline value and at least [ADDRESS_249421] use and baseline oral glucocorticoids 
(prednisone or equivalent) use as factors and the baseline value as a covariate. An unstructured covariance matrix 
that is homogeneous across treatment groups was used. The p-values in itali cs are < 0.[ADDRESS_249422] secondary endpoint .
Note: **p < 0.[ADDRESS_249423] versus placebo. For subjects who EE at Week 16, data obtained after EE are 
excluded from the MM RM analysis. The GEI is a count from 0 to 6. A higher count represents greater enthesitis 
burden, and a negative change from baseline indicates improvement. Pre -existing enthesopathy was defined as 
subjects who had a baseline GEI score of greater than 0. J oints temporarily or permanently inaccessible at baseline 
were excluded from joint count. For other unassessed joints at baselin e, the joint assessment at the Screening V isit, 
if assessed, was used as the baseline assessment; otherwise, the joint was excluded from joint count. The last 
observed joint assessment (at baseline or postbaseline) is used for joints unassessed at the time point.
[IP_ADDRESS].4. Long -term Efficacy Data From Phase 3 Study CC -[ZIP_CODE]- PSA -002 (Palace 1)
The [ADDRESS_249424] and/or 
biologic anti -TNF therapy  was assessed using data from the Phase 3 Study  CC-
[ZIP_CODE] -PSA-002 
(Palace 1) (TNF blockers efficacy failures were limited to < 10% of subjects). Data were based 
on observed analyses fro m subjects who received apremilast 30 mg BID and who were still 
attending study  visits. 
ACR20/50/70 responses were achieved by  71.7%, 48.6% ,and 28.4% of subjects , respectively,
attending the Week 260 Visit(Kava naugh, 2018 ).Psori asis Area and Severit y Index ( PASI ) 50 
and 75 were achieved by 69.4% and 46.9% of subjects , respectively . At Week 260, 61.5% of the 
subjects achieved HAQ -DI improvements >0.3, which corresponds to the minimal clinically 
important diff erence (MCID) (Mease, 2004).
Apremilast was also associated with sustained responses and improvements in enthesit is and 
dactylit is amo ng subjects still attending study  visits. At 5 years, 54.5% of subjects achieved a 
Maastri cht Ankylo sing Spondylit is Enthesit is Score of 0 and 80% achieved a dactylit is count 
of0.
Approved  
  
EDMS Doc. Number: [ADDRESS_249425]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 29 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May [ZIP_CODE].[IP_ADDRESS]. Long -term Efficacy Data From Phase 3 Study CC -[ZIP_CODE]- PSA -005 (Pa lace 4) in 
csDMARD -naïve Subject s
The l ong-term efficacy  profile of APR mo notherapy  in DMARD -naïve subject s was reported for 
208 weeks. ACR20/5 0/70 responses were achieved by  68.2 %, 43.4 %,and 23.1
%of subjects , 
respectively ,attending the Week 208 Visit(Wells, 2017). PASI 50 and 75 were achieved by 
67.6%and 40.5 %. At Week 208, half o f the subjects achieved HAQ -DI improvements greater 
than 0.3, which correspond edto the MCID (Mease, 2004 ).
Apremilast m onotherapy  was also assoc iated with sustained responses and improvements in 
enthesit is and dactylit is amo ng subjects still attending study  visit s. 
[IP_ADDRESS].6. Long -term Efficacy Data From Phase 3 Study CC -[ZIP_CODE]- PSA -006 (ACTIVE) 
In bio logic-naïve PsA subject s who may have had exposure to [ADDRESS_249426] in monotherapy  among 
subjects still attending study  visits through Week 52: ACR20/50/70 responses were achieved by 
63.3%, 32.4% ,and 14.0% respectively (Nash, 2018
);also, 45.6% achieved HAQ -DI 
improvements >0.3, which corresponded to the MCID (Mease, 2004). It is noteworthy  that
62.8% of subjects who were init ially rando mized to receive APR 30 mg wit h baseline enthesit is 
(GEI >0) achieved a GEI of 0 at Week 52 .
[IP_ADDRESS]. Safety
[IP_ADDRESS].1. Pooled Safety 16- Week Data From Phase 3 Studies CC -[ZIP_CODE]- PSA -002 (Palace 
1), CC -
[ZIP_CODE]- PSA -003 (Palace 2), CC - [ZIP_CODE]- PSA-004 (Palace 3), and 
CC
-[ZIP_CODE]- PSA -005 (Palace 4)
The safet y data from  the Pal ace 1, 2, [ADDRESS_249427] (Celgene, 2017 ; Wells, 2013).
The analyses 
conducted on the ap remilast popul ation include dsubjects started on apremilast at baseline and 
subjects switched fro m placebo to apremilast at Weeks [ADDRESS_249428] ex posure 
started .
Approximately  half of the subjects (50.7%) experienced 1 treatm ent-emergent adverse event 
(TEAE )during the first [ADDRESS_249429] thanplacebo (42.9%) ( Table 8). The m ost frequent ly 
reported TEAEs were diarr hea, nausea, headache, and upper respi[INVESTIGATOR_208824]. The 
subject incidence of diarrhea, nausea, and headache was higher in the APR [ADDRESS_249430]. 
Approved  
  
EDMS Doc. Number: [ADDRESS_249431]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 30 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020Table 8: Treatment - emergent Adverse Events Reported in 2%of Subjects in Any 
Treatment Group, First 16 Weeks of Exposure (Studies CC -[ZIP_CODE]- PSA -002, 
CC-[ZIP_CODE]- PSA -003, CC -[ZIP_CODE]- PSA -004, and CC - [ZIP_CODE] -PSA -005; Subjects 
As Treated)
Preferred TermaWeeks [ADDRESS_249432] Treatmentb
Placebo 
Subjects
n (%)
(N= 671)APR 20 BID
n (%)
(N= 972)APR 30 BID
n (%)
(N= 973)APR Total
n (%)
(N= 1945)
Any TEAE 288 (42.9) 470 (48.4) 516 (53.0) 986 (50.7)
Diarrhea 17 (2.5) 86 (8.8) 128 (13.2) 214 (11.0)
Nausea 26 (3.9) 71 (7.3) 114 (11.7) 185 (9.5)
Headache 24 (3.6) 53 (5.5) 77 (7.9) 130 (6.7)
Upper Respi[INVESTIGATOR_208825] 16 (2.4) 42 (4.3) 37 (3.8) 79 (4.1)
Vomiting 5 (0.7) 17 (1.7) 29 (3.0) 46 (2.4)
Nasopharyngitis 12 (1.8) 28 (2.9) 17 (1.7) 45 (2.3)
Hypertension 15 (2.2) 17 (1.7) 25 (2.6) 42 (2.2)
Dyspepsia 8 (1.2) 21 (2.2) 19 (2.0) 40 (2.1)
Abdominal Pain Upper 1 (0.1) 19 (2.0) 18 (1.8) 37 (1.9)
AE=adverse event; APR =apremilast; BID =twice daily; MedDRA =Medical Dictionary for Regulatory 
Activities; TEAE =treatment -emergent adverse event.
aPreferred terms are coded using MedDRA Version [ADDRESS_249433] frequent ly 
reported TEAEs (ie, diarrhea, nausea, upper respi[INVESTIGATOR_53121] i nfect ion, and headache) were 
primarily mild in severit y.Severe diarrhea was reported by  1(0.1%) subject in the placebo 
group, 4 (0. 4%) in the APR 20 BID group, and 3 (0.3%) in the APR 30 BID group. Severe 
nausea was reported by  0subjects in the placebo group, 2 (0.2%) in the APR 20 BID group, and 
3 (0.3%) in the APR 30 BID group. Severe headache was reported by 1(0.1%) subject in the 
placebo group, 2 (0.2%) in the APR 20 BID group, and 1 (0.1%) in the APR [ADDRESS_249434] ions of depressio n. 
During the 0- to-16-week placebo -controlled period of Palace 1 , 2,and 3, 1.0% (10/998) of 
subject s treated with apremilast reported depression or depressed mood and 0.8% (4/495) treated 
with placebo.
Body  weight was m easured routinely in Studi es CC -
[ZIP_CODE]- PSA-002, CC - [ZIP_CODE] -PSA-003, 
CC-[ZIP_CODE]- PSA-004, and CC - [ZIP_CODE]- PSA-005. At the end of the placebo -controlled period, 
median (mean) weight change from baseline was 0.00 (0.13) kg in the placebo group, -0.50 
Approved  
  
EDMS Doc. Number: [ADDRESS_249435]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 31 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020(-1.05) kg in the APR 20 BID group, a nd -0.60 (- 0.97) kg in the APR 30 BID group. Weight loss 
>5% was observed in 2.1% of subjects in the placebo group, 4.7% in the APR 20 BID group, 
and 4.9% in the APR 30 BID group . 
Serious TEAEs were reported for 22 (3.3%) subjects who received placebo an d 44 (2.3%) who 
received apremilast during the first 16 weeks of exposure ( Table 9).The incidence of serious 
adverse events ( SAEs )was comparable across treatment groups, ie, 3.3% of subjects in the 
placebo group, 2.4% in APR 20 BID group, and 2.2% in the APR 30 BID group.
Table 9: Treat ment - emergent Serious Adverse Events Reported in >1Subject in Any 
Treatment Group, First 16 Weeks of Exposure (Studies CC-[ZIP_CODE]- PSA -002, 
CC-[ZIP_CODE]- PSA -003, CC -[ZIP_CODE]- PSA -004, and CC - [ZIP_CODE] -PSA -005; Subjects 
As Treated)
Preferred TermaWeeks [ADDRESS_249436] Treatmentb
Placebo
n (%)
(N= 671)APR 20 BID
n (%)
(N= 972)APR 30 BID
n (%)
(N= 973)APR Total
n (%)
(N= 1945)
Any SAE 22 (3.3) 23 (2.4) 21 (2.2) 44 (2.3)
Atrial Fibrillation 0 0 2 (0.2) 2 (0.1)
Acute Myocardial Infarction 1 (0.1) 2 (0.2) 0 2 (0.1)
Deep Vein Thrombosis 0 0 2 (0.2) 2 (0.1)
Myocardial Ischemia 0 2 (0.2) 0 2 (0.1)
Psoriatic Arthropathy 3 (0.4) 1 (0.1) 1 (0.1) 2 (0.1)
Hypertensive Crisis 2 (0.3) 0 1 (0.1) 1 (0.1)
Pancreatitis Acute 2 (0.3) 0 0 0
AE=adverse event; APR =apremilast; BID =twice daily; MedDRA =Medical Dictionary for Regulatory 
Activities; SAE =serious adverse event.
aPreferred terms are coded using MedDRA Version [ADDRESS_249437] 16 weeks, 1 death was reported in Study  PSA -002 (Pal ace 1). The event occurred 
in a subject randomized to the APR [ADDRESS_249438] cause of death was “mult iple organ failure,” 
specifying that severe B 12deficiency anemia led to the event of mult iple organ failure.
TEAEs l eading to drug withdrawal were reported in 3.6% of subjects in the placebo group, 4.5% 
in the APR 20 BID group, and 5.2% in the APR [ADDRESS_249439] frequent ly reported TEAE sthat led to drug 
Approved  
  
EDMS Doc. Number: [ADDRESS_249440]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 32 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249441] treatment when the incidence rate 
was adjusted for exposure.
[IP_ADDRESS].2. Long -term Safety Data From CC-[ZIP_CODE]- PSA -006 (ACTIVE), CC-[ZIP_CODE]- PSA -
002 (Palace 1
), CC -[ZIP_CODE]- PSA -003 (Palace 2) and CC -[ZIP_CODE]- PSA -004 (Palace 3)
The l ong-term safet y of apremilast m onotherapy  in subject s who had received ≤[ADDRESS_249442] 
was assessed in the ACTIVE study  over a peri od of  52 weeks (Nash, 2018 )
.The overall 
incidence of adverse events ( AEs)in the placebo -controlled period was generally similar for 
APR mo notherapy  and placebo. The most commo nly reported AEs ( ≥5% of pts) with APR 
versus placebo were nasopharyngit is (8.3% versus 6.4%, respectively ), nausea (8.3% versus
1.8%), headache (7.3% v ersus 3.7%), hy pertensi on (6.4% versus 6.4%), and diarrhea (subject -or 
investigator -reported) (14.7% v ersus 11.0%); using a protocol -defined characterizat ion of 
diarrhea ( ≥2 watery /liquid stool s/day), overall incidence was lower for APR and placebo (11.0 % 
and 8.3%). Serious AEs were lower with APR than placebo (2.8% v ersus 4.6%). No 
opportunist ic infect ions, reactivations of tubercul osis ( TB), or cases of marked depressio n were 
seen. In general, no increase was seen in AE incidence/severit y with longer -term exposure to 
APR up to [ADDRESS_249443] , with or wi thout concomitant csDMARDs, over 4 y ears was 
assessed in a pooled analysis o f the Pal ace 1, 2 ,and 3 studies (Mease, 2017
).Results fro m this 
analysis suggested a favorable and consistent safety  profile over time. Im portantly, the frequency  
of gastrointest inal AEs decreased with longer exposure to apremilast, and the fre quency of other 
commo n AEs either decreased or remained stable with prolonged exposure ( Table 10). The rates 
of infect ions didnot increase over time, nor did the data indicate a need for specific laboratory  
monitoring. Treatm ent wi th apremilast was associated with an increase in adverse reac tions of  
depressio n;0.3% (4/1441) of subject s treated wi th apremilast di scont inued treatment due to 
depressio n or depressed mood versus 0placebo -treated subject s (0/495). Depression was 
reported as ser ious in 0.2% (3/1441) of subject s exposed to apremila stversus 0 placebo -treated 
subjects (0/495). Two subject s who received placebo committed suicide versus
[ADDRESS_249444] s. Im portantly , the rates of depressio n rem ained l owover time . 
Table 10: Frequency of Common AEs Over 208 Weeks of Exposure
Weeks 
0 to ≤
52Weeks 
>52 to ≤ 104Weeks 
>104 to ≤ 156Weeks 
>156 to ≤ 208
Subjects, n (% )APR30
N=721APR30
n=520APR30
n=443APR30
n=401
≥1 AE 524 (72.7) 316 (60.8) 284 (64.1) 234 (58.4)
≥1 SAE 47(6.5) 35(6.7) 40 (9.0) 28 (7.0)
AE leading to drug withdrawal 56 (7.8) 13 (2.5) 7 (1.6) 7 (1.7)
Death 0 (0.0) 1§(0.2) 0 (0.0) 2‡,║(0.5)
Approved  
  
EDMS Doc. Number: [ADDRESS_249445]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 33 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020Table 10: Frequency of Common AEs Over 208 Weeks of Exposure (Continued)
Weeks 
0 to ≤ 52Weeks 
> 52 to ≤ 104Weeks 
> 104 to ≤ 156Weeks 
> 156 to ≤ 208
Subjects, n (% )APR30
N=721APR30
n=520APR30
n=443APR30
n=401
AEs in ≥5% of subjects, n (% )
Diarrhea 112 (15.5) 20 (3.8) 12 (2.7) 4 (1.0)
Nausea 108 (15.0) 11 (2.1) 10 (2.3) 3 (0.7)
Headache 75 (10.4) 17 (3.3) 12 (2.7) 7 (1.7)
Upper respi[INVESTIGATOR_1092] 60 (8.3) 27 (5.2) 24 (5.4) 21 (5.2)
Nasopharyngitis 41 (5.7) 31 (6.0) 20 (4.5) 26 (6.5)
AE = adverse event; APR30 = apremilast 30 mg twice daily; SAE = serious adverse event .
*Includes all subjects who received APR during the time interval relative to the start of APR treatment. §Motor 
vehicle accident on Day 489. ‡Cerebrovascular accident on Day 1,330 in a 69 -year -old man, considered unrelated 
to study drug; subject had hist ory of myocardial infarction, atrial fibrillation, and cerebrovascular accident. 
║Stroke on Day 1,224 in a 58-year -old woman, considered unrelated to study drug; subject had a history of chronic 
ischemic heart disease, hypertension, alcoholism, and atrial fibrillation. 
Most AEs were mild or moderate in severit y. Rates were very  low for major cardi ac events, 
malignant neoplasms, and serious opportunist ic infections. It is noteworthy thatsystemic 
opportunist ic infect ions did not occur with long -term exposur e to apremilast. Marked laboratory  
abnorm alities were infrequent, and most returned to baseline values wit h continued treatment.
In a pool ed analysis o f Palace 1, 2, 3 ,and 4 (Celgene, 2017 )for subjects receiving long -term 
treatment with APR 30 BID, the median (mean) weight change from  baseline was -1.00 ( -1.25) 
kg and -1.30 (- 1.68) kg , respectively, at Week 52,and -1.00 ( -1.70 kg) and - 2.00 (- 2.14) kg at 
Week 78.At the end of treatment, weight loss > 5% was observed in 14.8% of subjects receiving 
apremilast 20 mg BID and 16.5% receiving apremilast [ADDRESS_249446] was evaluated in a lo ng-term analysis o fthe Pal ace 1 study  
(Kavanaugh, 2018). No new safet y concerns were ident ified. For subjects entering the fift h year 
of apremilast 30 mg BID exposure, AEs occurring in ≥5% were upper respi[INVESTIGATOR_39738], 
nasopharyngit is, and urinary  tract infect ion; most AEs were mild or m oderate in sev erity. 
Apremilast [ADDRESS_249447] igator Brochure ( IB)for detailed informat ion concerning the available 
pharmaco logy, toxi cology, drug m etabo lism, cl inical  studi es, and adverse event profile of the 
investigat ional product ( IP).
Approved  
  
EDMS Doc. Number: [ADDRESS_249448]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 34 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May [ZIP_CODE].3. Rationale
1.3.1. Study Rationale and Purpose
[IP_ADDRESS]. Unmet Medical Need 
In 2016, the European League Against Rheumat ism and the Group for Research and Assessment 
of Psori asis and Psori atic Arthritis (GRAPPA) published updated recommendat ions for the 
management of PsA. The GRAPPA recommendations are based on the following goals of 
therapy : 1) To achieve the lowest possible level o f disease act ivity; 2) To optimize functional 
status and improve QoL, and prevent structural damage, and 3) To avoid or minimize 
complicat ions, both fro m untreated active disease and fro m therapy . 
Apremilast has been extensively invest igated for the treatment of PsA. It is associated with 
improvements in clinical outcomes across several core PsA domains, physical function and QoL.
However, its impact on imaging outcomes associated with structural  progressi on in patients with 
PsA remains to be determined. In addit ion, the extent of its effects on axial parameters remains 
to be characterized in subjects with axial PsA.
Importantly, recent studies have failed to demonstrate substant ial radiographic pro gressions in 
most PsA subjects studied over short periods of time (Gladman, 1995a ; Gladman, 1995b ; 
Quei ro-Silva, 2003). These studies enro lled subjects who were at high risk for structural disease 
progression, such as pat ients with 3swollen jo ints, elevated CRP ,and evidence of erosive 
disease of peri pheral  jointsat 
baseline. Subjects were treated with bio logics orJanus kinase 
(JAK)inhibitors, or were receiving placebo. Taken together, th e limited amount of radiographic 
progression observed in these studies may reflect a change in the expressio n of the disease over 
time, which can be explained by [CONTACT_208864] . This m ay also highlight the 
limitations of convent ional radiographic imaging to assess structural changes.
[IP_ADDRESS]. Magnetic Resonance Imaging (MRI) in PsA and Study Rational e
Magnet ic resonance imagi ng (MRI) has gained importance as a promising tool for early  
diagnosis and increasing acceptance as an outcome measure in clinical trials of different 
inflammatory  arthri tides(Ostergaard, 2009 ; Weber, 2007
; Weber, 2009). It is highly sensit ive
(Althoff, 2007 ; Braun, 2004; Hermann, 2005 ; Hermann, 2006 )and superi or to convent ional 
radiography  in depi[INVESTIGATOR_208826] l esions of  peripheral  arthri tis and theaxial  skeleton. 
Moreover, it can detect soft ti ssue inflammat ion, bone erosion ,and proliferation. Since there is 
lack of io nizing radiat ion, an MRI is also well suit ed for y oung pat ients and repetit ive follow-up 
exams.
Results fro m studi es in RA indicate that bone marrow edema (BME) is a predictor of erosive 
progression. A similar relat ionship is also suggested in PsA ( Poggenborg, 2015c ).Indeed, a close 
relationship between erosions and BME was found i n a cross -sectional MRI study  of erosive PsA 
patients. These data suggest that BME is a “forerunner ”of structural  joint dam age in PsA (Tan, 
2009). In a 48 -week longitudinal study  of PsA patients, BME detected by  [CONTACT_208865] (relative risk of erosion 
progression of 10 [95% CI ,2.1-
49] versusjoints wit hout BME ) (Poggenborg, 2014).
Approved  
  
EDMS Doc. Number: [ADDRESS_249449]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 35 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020The potential use of MRI to monitor treatment outcomes has encouraged research in this field. In 
2015, the Outcom e Measures in Rheumatology (OMERACT )Psoriat ic Arthri tis Magnetic 
Resonance Im aging Score (PsAMRIS) was validated in a ran domized pl acebo -controlled tri al 
with 40subject s who received placebo or abatacept for 6 months. The results showed numerical 
improvements in the inflammatory  variables of PsAMRIS, with high responsiveness ,especially  
for synovit is and tenosynovit is, during abatacept but not placebo therapy . The scoring system
(Glinatsi, 2015 )assesses metacarpophalangeal, proxim al interphalangeal ,and distal 
interphalangeal joints of fingers 2 to 5, quantifying synovit is (score 0 -3), flexor tenosynovit is 
(score 0 -3), periarticular inflammat ion (absent o r present), bone edema (score 0 -3), bone erosion 
(score 0 -10), and bone pr oliferation/enthesophy tes (absent or present). The PsAMRIS is a new 
outcom e measure for clinical trials (Coates, 2012 )
.The scoring system provides an object ive 
measure of disease activit y, being able to i dentify responses earlier than clinical assessments. 
Poggenborg ,et al (Poggenborg, 2014 )showed that MR I is useful  in quantifying improvements in 
tenosynovit is, synovit is,and osteit is after treatm ent wi th an anti -TNF agent. In con trast, in the 
same tri al, MRI scores of periart icular inflammat ion did not chang esignificant ly after [ADDRESS_249450] -enhanced MRI (DCE -MRI) is a dist inctMRI technique that quantifies the 
patterns of enhancement within pre -determined r egions of interest, after inject ion ofintravenous 
contrast agent (Cimmino, 2012 ).Such dynamic imaging allows t hecapture of the tissue 
vascularit y and quantif iesthe inflammat ion in the studied jo int. It has been validated in RA for 
measuring inflammat ion, but has been used less frequent ly in studi es in PsA. It seems to be a 
sensit ive tool to assess inflammat ion in PsA, correlating significantly wit h PsAMRIS total 
inflammat ion score (Poggenborg, 2012). In thi s study , DCE -MRI will be performed in the most 
affected hand as an opti onal assessment . Furthermore, we aim to compare standard MRI and 
DCE -MRI for monitoring inflammat ion, determining differences in responsiveness between 
both. 
Undoubtedly, p hysical examinat ion is the basis of clinical evaluat ion. Nevertheless, the routine 
clinical e xam, especially  of enthesit is, is often inconclusi ve, making the decisio n to init iate or 
adapt therapy  very  difficul t. Therefore, m ore obj ective methods demonstrating inflammat ion at 
tendons, ligaments ,and fascia at their insertion in bone and/or the adjacent soft tissue are needed
(Poggenborg, 2015a ).However, standard MRI can only be used to scan a small anatomical area 
at a time. This is a limitation when assessing PsA, which has a heterogeneous phenoty pe, being 
diverse and widespread in terms of disease manifestations. Whole-body  MRI (Althoff, 2007 )
(WB -MRI) is a pro mising method for improving enthesit is assessment by [CONTACT_208866] “head -to-toe” in one examinat ion (Mager, 2009 ; Meaney, 2010 ).A prospective, cross -
sectional pi[INVESTIGATOR_208827] (n=18) and axial SpA (n=18) by  [CONTACT_208867] -MRI ,with moderate agreem ent 
between WB -MRI and clinical examinat ion at the entheseal level (Poggenborg, 2015a ).Itis 
important to emphasize that, although clinical examinat ion is considered the gold standard, 
previous studies have documented a moderate reliabilit y of clinical assessment among 
rheumatol ogists wi th experti se in SpA. This undoubtedly  cont ributes to the lack of associat ion 
with MRI findings (Gladman, 2007 ).Poggenborg ’s study  showed that enthesit is was frequently 
Approved  
  
EDMS Doc. Number: [ADDRESS_249451]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 36 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249452] to choose the appropriate treatment
(Weckbach, 2011).
Involvement of the axial skeleton is a characteristic feature of spondylo arthri tis (SpA) . Itis 
present in between 25% (early  disease and clinical assessment only ) and 75% (l ate di sease and 
sophist icated imaging) of PsA patients, wi th an impact as great as that 
seen in ankylosing 
spondylit is(Jadon, 2017). MRI is widely accepted as the mos t sensit ive imaging modalit y to 
detect early  inflammatory  lesions of  the axial skeleton (Weber, 2008). WB-MRI iscapable o f 
detecting axial invo lvement in PsA patients, because it evaluates mult iple possib le areas of 
involvement in a single procedure. WB -MRI has been validated against standard MRI for 
scoring acute inflammatory  lesions in the sacro iliac joints of [ADDRESS_249453] ive disease (30 had primary ankylosing spondyli tis and 2 had Crohn’ s disease, all 
fulfilling the modified [LOCATION_001] criteria) (Weber, 2009 ).Results showed a strong cor relation 
and co mparable reliabilit y for the detecti on of  inflammatory  lesions. 
Thus , although rel atively new, WB -MRI i s a very  promising tool  for the assessment of disease 
activit y and dam age in PsA, wi th significant potential as a measure of the overall burden of the 
disease (Ostergaard, 2017 ; Poggenborg, 2015b ).As a result , WB -MRI will be used in the current 
study  to assess the impact of apremilast on MRI parameters of axial jo intsin subjects wi th 
suspected axial PsA. Its impact on enthes esand peri pheral  joints will also be invest igated.
The concept that MRI more accurate ly identifies clinically relevant synovit is than clinical 
assessment i s well  established. One hypothesis for why MRI might be a useful predictive 
biomarker for clinical response is that some patients may have elevated disease activit y measures 
driven by [CONTACT_208868], rather than so lely by  [CONTACT_208869] j oint inflammat ion (Baker, 2017 ).
Conversely , pati ents wi th greater MRI -detected activit y might be expected to have a big 
proporti on of  their clinical  disease activit y explained by  [CONTACT_208870]. Finally, since the evidence 
for the prognostic value of MRI in PsA is st ill scarce (Mathew, 2017), this study  intends to 
investigate the correlat ion between specific imaging features and structural progression in this 
popul ation.
1.3.2. Rationale for the S tudy Design
Psori atic arthritis may vary fro m a mild nonprogressive oligoarthritis to severe polyarticular 
disease, wi th great di sabili ty and reduced qualit y of life.  These diverse clinical manifestations 
undermine general predict ions regarding outcomes. Although PsA has been historically 
conceived as a more benign arthropathy , in som e pati ents i t follows a parti cularly  aggressive and 
deforming course. Hence, early  diagnosis and treatment may  have a significant beneficial effect 
on the natural course of this disease.
This study  is designed to determine the impact of apremilast on imaging outcomes, assessed by 
[CONTACT_208871] m ost affected hand and WB -MRI, in bi ologic-naïve subjects wi th active PsA, 
with ≥ 3 m onths and ≤ [ADDRESS_249454] on MRI outcom es and structural  progressi on of  the di sease. 
Approved  
  
EDMS Doc. Number: [ADDRESS_249455]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 37 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249456] changes in erosions with MRI .
Approved  
  
EDMS Doc. Number: [ADDRESS_249457]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 38 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May [ZIP_CODE]. STUDY OBJECTIVES AND ENDPOINTS
Table 11: Study Objectives
Primary Objective
The primary objective of the study is to evaluate the efficacy of apremilast 30 mg twice a day ( BID) on 
inflammation indices , assessed by [CONTACT_9252] ( MRI )of the hand .
Secondary Objective (s)
The secondary objectives of the study are to evaluate:
The efficacy of apremilast 30 mg BID on imaging outcomes associated with structural progression , 
assessed by [CONTACT_208859].
The efficacy of apremilast 30 mg BID on disease activity and functionality , assessed by [CONTACT_208872]
The efficacy of apremilast 30 mg BID on inflammation indices of peripheral arthritis and enthesitis , 
total (sum of arthritis and enthesitis) and separately, assessed by [CONTACT_28760]- body MRI (WB-MRI )
The efficacy of apremilast [ADDRESS_249458] of Disease 12 domains ( PsAID -12)
The safety and tolerabilit y of apremilast 30 mg BID 
Exploratory Objective(s)
Approved  
  

EDMS Doc. Number: [ADDRESS_249459]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 39 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020Table 12:Study Endpoints
Endpoint Name [CONTACT_208920]
(PsAMRIS )Inflammation Score 
ofbone marrow edema [ BME ]+ 
synovitis +tenosynovitisChange from baseline in the 
composite score of BME, synovitis ,
and tenosynovitis assessed by 
[CONTACT_208873] 24
Secondary Efficacy
PsAMRIS Inflammation Score of 
BME + S ynovitis + TenosynovitisChange from baseline in the 
composite score of BME, synovitis, 
and tenosynovitis assessed by 
[CONTACT_208873] 48
PsAMRIS BME + S ynovitis Change from baseline in the 
composite score of BME and 
synovitis assessed by [CONTACT_208873] 24
Week 48
PsAMRIS Total Inflammation 
Score (BME + Synovitis + 
Tenosynovitis + Periarticular 
Inflammation)Change from baseline in the 
PsAMRIS total inflammation scoreWeek 24
Week 48
PsAMRIS BME Change from baseline in BME 
assessed by [CONTACT_208873] 24
Week 48
PsAMRIS S ynovitis Change from baseline in synovitis 
assessed by [CONTACT_208873] 24
Week 48
PsAMRIS T enosynovitis Change from baseline in 
tenosynovitis assessed by [CONTACT_208873] 24
Week 48
PsAMRIS Periarticular 
InflammationChange from baseline in periarticular 
inflammation assessed by [CONTACT_208873] 24
Week 48
PsAMRIS Total Damage Score
(erosion + bone proliferation)Change from baseline in the 
PsAMRIS total damage score
(erosion + bone proliferation)Week 24
Week 48
PsAMRIS E rosion Change from baseline in bone erosion 
assessed by [CONTACT_208873] 24
Week 48
PsAMRIS Bone P roliferation Change from baseline in bone 
proliferation/enthesophytes assessed 
by [CONTACT_208873] 24
Week 48
Swollen Joint C ount ( SJC) Change from baseline in the SJC Week 24
Week 48
Tender Joint C ount ( TJC) Change from baseline in the TJC Week 24
Week 48
Approved  
  
EDMS Doc. Number: [ADDRESS_249460]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 40 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020Table 12: Study Endpoints (Continued)
Endpoint Name [CONTACT_208921] (c -DAPSA)Change from baseline in the c -
DAPSA ScoreWeek 24
Week 48
Spondyloarthritis Research 
Consortium of Canada 
(SPARCC)Change from baseline in SPARCC, in 
subjects with preexisting 
enthesopathyWeek 24
Week 48
Leeds Enthesitis Index (LEI) Change from baseline in the LEI, in 
subjects with preexisting 
enthesopathyWeek 24
Week 48
Enthesitis improvement to 0 Proportion of subjects with baseline 
enthesitis whose enthesitis improves 
to 0Week 24
Week 48
Leeds Dactylitis Index (LDI) Change from baseline in the LDI, in 
subjects with preexisting dactylitisWeek 24
Week 48
Dactylitis improvement to 0 Proportion of subjects with baseline 
dactylitis whose tender dactylitis 
count improves to 0Week 24
Week 48
Psoriatic Arthritis Disease 
Activity Score (PASDAS)Change from baseline in the PASDAS Week 24
Week 48
Evaluator’s Global Assessment of 
Disease ActivityChange from baseline in the 
evaluator’s global assessment of 
disease activityWeek [ADDRESS_249461]’s Global Assessment of 
Disease ActivityChange from baseline in the subject’s 
global assessment of disease activityWeek [ADDRESS_249462]’s Assessment of Pain Change from baseline in the subject’s 
assessment of painWeek 24
Week 48
Health Assessment 
Questionnaire -Disability Index 
(HAQ -DI)Change from baseline in physical 
function (HAQ -DI score)Week 24
Week 48
WB-MRI Peripheral Enthesitis
Inflammation IndexChange from baseline in the 
peripheral enthesitis inflammation 
index assessed by [CONTACT_2097] -MRIWeek 24
Week 48
WB-MRI Peripheral Joints 
Inflammation IndexChange from baseline in peripheral 
joints inflammation index assessed by 
[CONTACT_2097]-MRIWeek 2 4
Week 48
WB-MRI Total Peripheral 
Inflammation IndexChange from baseline in the total 
peripheral (joints and enthesitis) 
inflammation index assessed by [CONTACT_2097] -
MRIWeek 24
Week 48
Approved  
  
EDMS Doc. Number: [ADDRESS_249463]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 41 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020Table 12: Study Endpoints (Continued)
Endpoint Name [CONTACT_208922] 
(for subjects deemed to have PsA 
spondylitis by [CONTACT_208874] 2 ≥4 at baseline)Week [ADDRESS_249464] of Disease 12doma ins 
(PsAID -12)Change from baseline in the PsAID -
12Week 24
Week 48
Safety
The following parameters will be evaluated throughout the duration of the study:
Adverse events (AEs) Type, frequency, severity and 
relationship of AEs to study 
medication-
Discontinuation due to AEs Num ber of subjects who discontinue 
study medication due to any AE-
Clinically significant changes in 
physical examination, vital signs, 
and/or laboratory findingsFrequency of clinically significant 
changes in physical examination, vital 
signs, and/or laboratory findings-
Explorator y
Approved  
  

EDMS Doc. Number: [ADDRESS_249465]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 42 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020Table 12: Study Endpoints (Continued)
Endpoint Name [CONTACT_208923]. Number: [ADDRESS_249466]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 43 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020Table 12: Study Endpoints (Continued)
Endpoint Name [CONTACT_208923]. Number: [ADDRESS_249467]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 44 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May [ZIP_CODE]. OVERALL STUDY DESIGN
3.1. Study Design
The study  will be conducted in com pliance wi th the International Council on Harmo nisat ion 
(ICH) of Technical Requirements for Registration of Pharma ceuticals for Hum an Use/Good 
Clinical Practice (GCP) and applicable regulatory  requi rements. For all regio ns, the l ocal 
Regulatory  Label  must be fo llowed. 
This is a Phase [ADDRESS_249468] ive PsA with 
up to 5years of disease duration (since diagnosis).
Approximately  [ADDRESS_249469] 30 mg BID , after a 5 -day titration period,
with or wi thout stabl e MTX. All subjects will be permitted to take NSAIDs and/or low -dose oral  
glucocorti coids (predniso ne ≤ 10 m g/day  or equivalent) throughout the study .The NSAIDs and 
low-dose oral  glucocorti coidsmust be on a stable regimen for at leas t 4 weeks pri or to baseline. 
MTX (≤25 m g/week) will be permitted if treatm ent durati on is ≥[ADDRESS_249470] be cont inued from  Day  1through the W eek 24 Visit. Change 
in doses, increase or decrease, and/or discontinuation will not be allowed ,except for safet y 
reasons or for lack of availabilit y. After the Week [ADDRESS_249471] of 3 phases ,as shown in Figure 1:
Screening Phase –up to 4 weeks
Single-arm, 
Open-label Treatm ent Phase –Weeks 0 to 48
[ADDRESS_249472] 30 mg BID (after a 5 -daytitration peri od) for 
the ent ire durati on of  this phase
All subjects who complete the study  or di scont inue early will part icipate in the [ADDRESS_249473]-treatm ent Observational Follow-up P hase. Henceforth, this will be referred 
to as the Observational Fo llow-up Phase.
Approved  
  

EDMS Doc. Number: [ADDRESS_249474]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 45 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020Figure 1: Overall Study Design
                           Wk -
4            Wk 0      Wk 8       Wk 16         Wk 24             Wk 36                Wk 48          Wk 52
                                                                                            Primary Endpoint
BID = twice daily ; MTX = methotrexate; Wk = Week. Apremilast 30 mg BID with or without
MTXScreening Follow -up 
Approved  
  
EDMS Doc. Number: [ADDRESS_249475]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 46 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May [ZIP_CODE].2. Study Duration for Subjects 
Subjects who complete the study  will spend up to a total of 56 weeks in this study :
Up to 4 weeks in the Screening Phase
Weeks 0 to 48 (ie, 48 weeks) in the Open-label, Single -arm, Treatm ent Phase
[ADDRESS_249476] that is 
requi red for primary, secondary  and/or expl oratory analysis, as prespecified in the protocol , 
whichever i s the l ater date.
Study  com pletion is defined as the date of the last visit of the last subject in this clinical study.
Study  com pletion for an individual subject is defined as reaching Visit 7/[ADDRESS_249477] not meet ing this 
definit ion is considered under early discont inuat ion (see Secti on6.3).For the purpose of 
analys es, study  com pletion for an individual subject is defined as reaching the Week 48 Visit.
Approved  
  
EDMS Doc. Number: [ADDRESS_249478]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 47 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249479] m eet all inclusio n criteria (Secti on4.3) and must not have any o f the condi tions 
specifie d in the exclusi on cri teria (Secti on 4.4) to q ualify  for parti cipat ion in the study. The 
subject ’s source documents must support his/her qualificat ions for the study  (eg, if a female 
subject does not require pregnancy test ing and birth control because of a hysterectomy, the date 
of the hysterectomy mu st be included in the medical history ).
4.1. Medical and Disease History
Relevant medical history  shoul d be recorded, including smoking and alcohol  history , as well as 
previous relevant surgeries. Disease history  shoul d incl ude history  of psori asis and PsA. 
4.2. Number of Subjects 
Approximately [ADDRESS_249480] satisfy the fo llowing cri teria to be enro lled in the study:
1. Males or females, aged ≥ [ADDRESS_249481] understand and vo luntarily sign an informed consent document prior to any  study  
related ass essments/procedures being conducted
4. Able to adhere to the study  visit schedule and other protocol requirements
5. Have a docu mented diagnosis of PsA of ≥ 3 m onths AND ≤5 years in durati on, meet ing the 
CASPAR cri teria for PsA (Appendix B, Taylor, 2006 ) at the time of S creening Visit
6. Have ≥ 3 swollen AND ≥ 3 tender joints, with hand invo lvement (defined as ≥ 1swollen 
joint or dactylit is [each clinically  active jo int of a dactylit ic digit is count edas one jo int]).
7. Have at least 1 active enthesi tissite(one of the SPARCC or LEI sites )
8. Must not have been treated previously with a TNF blocker orother biolo gicdrug for PsA 
treatm ent
9. Must not have been treated with more than 2 csDMARDs
10. Subjects taking csDMARDs, wi th the except ion of MTX, cyclosporine ,orLEF (see Section
4.4,Exclusion Criterion 18, 19 and 20), do not require a washout period. However, they  
must di scont inue the csDMARD treatment at least one day prior to their Baseline Visit (ie, 
Visit 2, Day  1)
11.
Subjects who have been previously treated with MTX for <[ADDRESS_249482] 3 m onths will require a 28 -daywashout pri or to the Baseline Visit 
(ie, Vi sit 2, Day 1) to parti cipate in the study
Approved  
  
EDMS Doc. Number: [ADDRESS_249483]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 48 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249484] been previously treated with LEF will require a 12- week washout prior 
to the Baseline V isit (i e, Vi sit 2, Day 1), or treatm ent wi th chol estyramine, per LEF
prescribing label (ie, 8 g chol estyramine 3 times daily  for 11 day s)
13. Subjects who have been previously treated with cy closporine will  requi re a 28 -daywashout 
prior to the Baseline Visit (i e, Vi sit 2, Day 1) to parti cipate in the study
14. If taking MTX (≤25 m g/week) , continui ty of treatment will be allowed if durat ion of 
treatm ent is ≥ [ADDRESS_249485] 3 months prior to the Baseline Visit 
(ie, Visit 2, Day 1)
15. If taking oral glucocorti coids, must be on a stable dose of prednisone ≤ 10 mg/d ay or 
equivalent for at least 4 weeks prior to the Baseline Visit (ie, Visit 2, Day 1 )
16. If taking NSAIDs or narcotic analgesics, must b e on stable dose for at least 4 weeks prior to 
Baseline Visit (i e, Visit 2, Day 1 ) 
17. A female of childbearing potential (FCBP)†must hav e a negat ive pregnancy test at 
screening and b aseline. While on IPand for at least [ADDRESS_249486] use one of the approved 
contraceptive§optionsdescribed below:
Option 1: Any  one of  the fo llowing highly effect ive methods: hormonal contraception (oral, 
inject ion, implant, transdermal patch, vaginal ring ); intrauterine device; tubal ligation; or 
partner ’s vasectomy; 
OR
Option 2: Mal e or f emale condo m (latex condom  or non -latex condom NOT made out of 
natural  [animal] m embrane [for example, polyurethane]); PLUS one additional barrier 
method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) 
contraceptive sponge wit h spermicide.
Note: Opti on 2 may  not be acceptable as a highly effective contraception option in all 
countri es, per l ocal guidelines/recommendat ions.
†An FCBP is defined as a sexually mature female who 1) has not undergone a hysterectomy  (the surgical 
removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or 2) has not been 
postmenopausal for at least 24 consecutive months (that is, has had me nses at any  time during the preceding 24 
consecutive months).
§The female subject ’s chosen form of contraception must be effective by [CONTACT_58136] e the female subject is 
screen edinto the study (for example, hormonal contraception should be initiated at lea st 28 days before 
screening).
18. Must be in general good healt h (except for PsA) as j udged by [CONTACT_093], based on 
medical history , physical examinat ion, and clinical laboratories. (Note: The definit ion of 
good healt h means a subject does not have uncontro lled significant comorbid condit ions).
4.4. Exclusion Criteria
The presence of any o f the following will exclude a subject fro m enrollment:
1. Contraindicat ion to MRI examinat ion including, but not limited to, intracranial metal 
clips, heart pacemakers, insulin pu mps, im planted hearing aids, neurostimulators, metal 
hip replacements, profound claustrophobia or inabilit y to lie in the MRI m achine in an 
Approved  
  
EDMS Doc. Number: [ADDRESS_249487]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 49 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249488] agent
2. Severe renal impairment (creatinine clearance of less than 30 mL per minute estimated by 
[CONTACT_94486] –Gault equation), which would prevent the use of g adolinium enhancement
3. History  of clinically  significant (as determined by  [CONTACT_3170]) cardiac, endo crine, 
pulmo nary, neurol ogic, psychiatri c, hepat ic, renal, hematologic, immuno logic disease, or 
other m ajor uncontrolled disease
4. Any condit ion, incl uding the presence of laboratory  abnorm alities, which pl aces the 
subject at unacceptable risk if he/she were to participate in the study  
5. Prior history  of suicide attem pt at any  time in the subject ’s life time pri or to si gning the 
informed consent , or m ajor psy chiatri c illness requiring hospi[INVESTIGATOR_208828] [ADDRESS_249489] feeding
7. Active substance abuse or a history  of substance abuse within 6 mo nths prior to s creening
8. History  ofallergy or hy persensi tivityto any  com ponent of the IP
9. History  ofrare hereditary  problems of galactose intolerance, lapp lactase deficiency or 
glucose -galactose malabsorpti on
10. History  of posi tive human immunodeficiency virus (HIV) , or congenital or acquir ed 
immunodeficiency  (eg, Comm on Variable Immunodeficiency Disease)
11. Active tuberculosis or a history  of incompletely treated tuberculosis
12. Bacterial infect ions requiring treatment with oral or injectable ant ibiotics, or significant 
viral or fungal infect ions, within [ADDRESS_249490] 3years, except for treated (ie, cured) basal cell or squamous cell 
in situ skin carcino mas
14. Major surgery  (including j oint su
rgery ) within 8 weeks pri or to s creening or planned 
major surgery  within 6 m onths f ollowing Baseline Visit
15. Rheumatic autoimmune disease other than PsA, including, but not limited to: sy stemic 
lupus ery thematos us, mixed connective tissue disease, scleroderma, polymyosit is, or 
fibro myalgia
16. Prior history  of or current inflammatory  joint disease other than PsA (eg, gout, reactive 
arthritis, RA , ankyl osing spondyli tis, Lyme disease) , whi ch confounds the abilit y to 
interpret data from  the study
17. Prior treatm ent wi th any biologic DMARD
18. Prior trea tment wi th more than [ADDRESS_249491] s
Approved  
  
EDMS Doc. Number: [ADDRESS_249492]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 50 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249493] emic therapy (ies) wi thin 28 day sof the Baseline Visit (i e,Visit 
2, Day 1):cy cl osporine or other calcineurin inhibit ors, glucocortico ids exceeding 10 mg 
daily  prednisone equivalent, as well as myco phenolate
20. Use of MTX within 4 weeks of the Baseline Visit (ie, Visit 2, Day 1 ), unl ess subject i s on 
stable doses for at least 3 months and total treatment duration with MTX is ≥6 months
21. Use of LEF within 12 weeks o f the Baseline Visit (i e, Visit 2, Day 1), unl ess subject has 
taken cho lestyramine, 8 g three times daily 11 days afterstoppi[INVESTIGATOR_208829]
22. Previous treatment with a JAK inhibitor (including ty k2 inhibi tor)
23. Prior treatm ent wi th apremilast, or participat ion in a clinical study  involving apremilast
24. Useof intra-articular (IA) glucocorti coid injection within 8 weeks before the Baseline 
Visit (ie, Visit 2, Day 1). 
25. Use of any  investi gational drug wi thin 4 weeks of the Baseline Visit, or 5 
pharmacokinet ic/pharmacodynamic half -lives, if known (whichever is longer)
Approved  
  
EDMS Doc. Number: [ADDRESS_249494]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confid ential and Propri etary 51 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May [ZIP_CODE]. TABLE OF EVENTS
Table 13:Table of Events
Early 
Termination jObservational 
Follow -up
Visit Number1
Screening2
Baseline3 4 5 6 7Assessments
performed for 
Early 
Termination8 (or 
subsequent 
to Early 
Termination 
Visit)
Week Days -28 to 0 08
(+/-1 
week )16
(+/-1 week)24
(+/-1 
week )36
(+/-1
week)48
(+/-1
week)-Week 52 or 4 
weeks (+/-1 
week) after 
Early 
Termination)
Study Entry and General 
Assessments
Informed Consent x - - - - - - - -
Demographics x - - - - - - - -
Medical History x - - - - - - - -
Inclusion/Exclusion Criteria x x - - - - - - -
Prior/concurrent Medications x x x x x x x x x
Prior/concurrent Procedures x x x x x x x x x
Biomarkers and Safety Assessments
Vital Signs x x x x x x x x -
Height x - - - - - - - - 
Approved  
  

EDMS Doc. Number: [ADDRESS_249495]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confid ential and Propri etary 52 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020Table 13: Table of Events (Continued)
Early 
Termination jObservational 
Follow -up
Visit Number1
Screening2
Baseline3 4 5 6 7Assessments
performed for 
Early 
Termination8 (or 
subsequent 
to Early 
Termination 
Visit)
Week Days -28 to 0 08 
(+/-1 
week)16
(+/-1 week)24
(+/-1 
week)36
(+/-1 
week)48
(+/-1 
week)-Week 52 or 4 
weeks (+/ -1 
week) after 
Early 
Termination)
Weight x x x x x x x x -
Assessment of Diarrhea - x x x x x x x -
Complete Physical Examax - - - x - x x -
Limited Physical Exama- x x x - x - - -
Complete Blood C ount x x x x x x x x -
Serum C hemistries x x x x x x x x -
Hemogl obin A1c - x - - x - x x -
Urinaly sis x x - - x - x x -
Pregnancy T estc(FCBP only) x x - - - - x x -
Contraception Educationdx x - - - - - - -
Adverse Eventsex x x x x x x x x
Efficacy Assessment s
Tender Joint C ount (0 -78) x x x x x x x x -
Swollen Joint Count (0-76) x x x x x x x x -
Subject Global Assessment of 
Disease Activityx x x x x x x x- 
Approved  
  

EDMS Doc. Number: [ADDRESS_249496]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confid ential and Propri etary 53 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020Table 13: Table of Events (Continued)
Early 
Termination jObservational 
Follow -up
Visit Number1
Screening2
Baseline3 4 5 6 7Assessments
performed for 
Early 
Termination8 (or 
subsequent 
to Early 
Termination 
Visit)
Week Days -28 to 0 08 
(+/-1 
week)16
(+/-1 week)24
(+/-1 
week)36
(+/-1 
week)48
(+/-1 
week)-Week 52 or 4 
weeks (+/ -1 
week) after 
Early 
Termination)
Evaluator Global Assessment
of Disease Activity - x x x x x x x-
Subject Assessment of Pain x x x x x x x x -
HAQ -DI - x x x x x x x -
c-DAPSA (for eligibility)fx x - - - - - - -
SPARCC x x x x x x x x -
LEI x x x x x x x x -
Dacty litisAssessmentgx x x x x x x x -
BSA x x - - x - x x -
BASDAI h- x x - x - x x -
MRI of the Most A ffected Handi- x - - x - x x -
Whole -body MRI i- x - - x - x x - 
Approved  
  

EDMS Doc. Number: [ADDRESS_249497]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confid ential and Propri etary 54 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020Table 13: Table of Events (Continued)
Early 
Termination jObservational 
Follow -up
Visit Number1
Screening2
Baseline3 4 5 6 7Assessments
performed for 
Early 
Termination8 (or 
subsequent 
to Early 
Termination 
Visit)
Week Days -28 to 0 08 
(+/-1 
week)16
(+/-1 week)24
(+/-1 
week)36
(+/-1 
week)48
(+/-1 
week)-Week 52 or 4 
weeks (+/ -1 
week) after 
Early 
Termination)
SRO -
PsAID -[ADDRESS_249498] 
Accountability- - x x x x x x-
; ACR = American College of Rheumatology; BASDAI = Bath Ankylosing Spondylitis Activity Index; BSA = body surface area; c -
DAPSA = Clinical Disease Activity Index for Psoriatic Arthritis; CRP = C -reactive protein ; ;  
 FCBP = female of childbearing potential; HAQ -DI = Health Assessment Questionnaire –Disability Index; IP = investigational product ; LDI = 
Leeds Dactylitis Index ; LEI = Leeds E nthesitis Index; MRI = magnetic resonance imaging ; PASI = Psoriasis A rea and Severity Index;  
PsA = psoriatic arthritis; PsAID = PsA Impact of Disease; ; SPARCC = Spondyloarthritis 
Research Consortium of Canada; SRO = Subject -reported Outcomes; .
aDuring the Observational Follow -up Visit, a complete or limited physical exam may be done at the discretion of the study physician, although not required as per protocol.
bHigh -sensitivity CRP will also be performed as one of the efficacy assessments.
cAn FCBP† must hav e a negative pregnancy test at screening and b aseline. Serum beta human chorionic gonadotropin (β -hCG)pregnancy test will be perform ed at screening, and 
urine β -hCG pregnancy test will be performed at baseline. Urine pregnancy test will be performed to assess subject eligibility within [ADDRESS_249499] administration of 
IP(negative results required for dispensing IP). Pregnancy tests should be performed if the FCBP subject has missed a menstrual period or the contraception method has
changed. At the last treatment visit,or in case of early termination ,a serum β-hCG pregnancy test will be performed.
dSee Section 4.3andAppendix T. 
Approved  
  

EDMS Doc. Number: [ADDRESS_249500]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confid ential and Propri etary 55 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020eSee Section 6.5.8 .
fAt screening (and to be confirmed at baseline), c-DAPSA will be calculated ,for eligibility . Half of the subjects must have moderate disease activity or below . Eligibility for each 
patient will be confirmed by [CONTACT_10966].
gFor dactylitis assessment at screening, only a bin ary evaluation is needed (yes/no). As per incl usion criteria, subjects must have ≥ 3 swollen AND ≥ 3 tender joints, with hand 
involvement (defined as ≥1 swollen joint OR dactylitis). For the subsequent visits, LDI is needed.
hBASDAI will be performed for all subjects.
iThe clinical and the MRI assessments should be performed on the same day, with the MRI scans always performed after the clini cal visit. Exceptionally, MRI scans can be 
performed within [ADDRESS_249501] administration of IP. The subsequent MRIs should be 
performed at Week 24 + 7 days and Week 48 + [ADDRESS_249502] 8 weeks before the early termination visit. 
Approved  
  
EDMS Doc. Number: [ADDRESS_249503]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 56 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249504] igator’s discretion, however it is not required as 
per protocol.
The fo llowing will be performed at screening as specified in the Table of Events, after informed 
consent has been obtained:
Inclusio n/Exclusio n criteria
Medical history  (including specific i nformat ion regarding diagnosis and additional 
needed details )
Dem ographics (include year of birth, sex, race, and ethnicit y-if allowed by  [CONTACT_53345])
Prior disease therapi [INVESTIGATOR_014]: includes surgery ,systemic or any  other therapy  for the subject ’s 
disease
Com plete m edical history  (all relevant medical condit ions diagnosed/ occurrin g prior to 
screening should also be included)
Prior and conco mitant procedures (including all procedures occurring ≤ 28 day s before 
screening)
Prior and concomitant m edicat ion evaluat ion (including those taken ≤ 28 day s before 
screening, except for those taken for disease)
Com plete p hysical examinat ion (can be sourc e docum ented only ), height, wei ghtand 
BSA
c-DAPSA (for eligibilit y, to be co nfirmed at Baseline V isit).Half of the subjects m ust 
have moderate disease activit yor bel ow
SPARCC , LEI and dactylit is assessment (for e ligibilit y, to be confirmed at B aseline 
Vis
it)
Vital signs (including blood pressure, temperature, and heart rate)
Approved  
  
EDMS Doc. Number: [ADDRESS_249505]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 57 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020Hem atology panel  including c omplete bl ood count (CBC) with different ial, including red 
blood cell (RBC) count, hemoglobin, hematocrit, white blood cell (WBC) count (with 
different ial), and platelet count
Chemistry  panel including sodium, potassium, calcium, chloride, blood urea nitrogen
(BUN) , creatinine, creatinine clearance, glucose, albumin, total  protein, al kaline 
phosphatase, bilirubin (total and direct), aspartate aminotransferase/serum glutamic 
oxaloacetic transaminase (AST/SGOT), alanine aminotransferase /serum  glutamic py ruvic 
transaminase (ALT/SGPT) and lipid profile
Urinalysis 
Pregnancy test is required for all FCBP subjects .Serum beta human chorionic 
gonadotropin ( β-hCG)pregnancy  test will  be perform ed at screening. Urine pregnancy  
test will be performed to a ssess subject eligibilit y within [ADDRESS_249506] 
administration of IP (negative results required for dispensing IP)
Contraception educat ion: counseling about pregnancy precaut ions and the potential risks 
of fetal exposure m ust be conducted (see Secti on4.3)
Adverse event assessment begins when the subject signs the informed consent form .
6.2. Treatment Period
The subject will begin treatment upon confirmat ion of eligibilit y.The subject must start 
treatm ent wi thin 28days of signing the informed consent form (ICF).
The fo llowing will be perfo rmed at the frequency  specified in the Table of Events, Table 13. 
Inclusio n/Exclusio n criteria
Concomitant medicat ions evaluat ion
Concomitant procedures evaluat ion
Physical examinat ion 
Vital signs
Weight (see Secti on6.5.2 )
Hem atology panel  including co mplete blood count (CB C) with different ia
l and platel et 
count
Chemistry  panel 
Hem oglobin A1c
Approved  
  

EDMS Doc. Number: [ADDRESS_249507]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 58 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020Urinalysis 
Subject -reported outcomes 
Adverse event evaluat ion (continuously)
Assessment of diarrhea (see Section6.5.5 )
Efficacy assess ment s, including MRI (see Section 6.4)
Pregnancy test (prior to dosing on Day 1 and as specified in the Table of Events )
A pregnancy  test shoul d be perform ed if the FCBP subject has missed a menstrual period 
or the contraception method has changed
Contraception educat ion: counseling about pregnancy precaut ions and the potential risks 
of fetal exposure m ust be conducted (see Secti on4.3)
Dispensing IP
IP accoun tabilit y
6.2.1. End of Treatment /Early Termination Visi t
An Early  Terminati on Visi twillbe perform ed for subjects who are withdrawn fro m treatment for 
any reason ,as soon as possible ,after the decision to permanently discont inue treatment has been 
made. 
The fo llowing will be performed as specified in the Table o f Events:
Com plete p hysical examinat ion (sour ce documented only ), wei ght
Vital signs 
Concomitant medicat ions evaluat ion
Concomitant procedures evaluat ion
Subject -reported outcomes
Adverse event /Seri ous Adverse Event evaluat ion/assessment
Assessment of diarrhea
Hem atology panel  including com plete bl ood count (CBC) with different ial and platel et
Chemistry  panel
Hem oglobin A1c
Urinalysis 
Serum β-hCG (for FCBP subjects )
Efficacy assessment s, including MRI
IP accoun tabilit y
Approved  
  

EDMS Doc. Number: [ADDRESS_249508]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 59 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249509] igator at any time following the protocol -requi red reporti ng 
period or after end of study t, as described in Section 10.1.Safet y assessments are specified in 
the Table o f Events, Table 13.
6.4. Efficacy Assessment s
The fo llowing assessments will be conducted as outlined in the Table of Events, Section 5.
6.4.1. Magnetic Resonance Imaging (MRI)
The MRI assessments will be conducted fo llowing the procedures outlined in the MRI manual, at 
scheduled visits according to Section 5(Tabl e of Events). The clinical and the MRI assessments 
shoul d be perform ed on the sam e day , with the MRI scans always performed after the clinical 
visit. Except ionally , MRI scans can be performed within [ADDRESS_249510] administration o f IP. The 
subsequent MRIs shoul d be perform edat Week 24 + 7 day s and Week 48 + 7days. All MRI 
visits should be scheduled well in advance to allo w for proper planning. In addit ion, it is 
recommended to schedule 2 MRI visits (an init ial and a repeat vi sit) for each MRI time point i n 
order to be assured of a high -quali ty MRI scan at each protocol -specified time point. The init ial 
and repeat MRI visits should be scheduled approximately [ADDRESS_249511] ical analysis. 
Approved  
  

EDMS Doc. Number: [ADDRESS_249512]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 60 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249513] PsAMRIS is a validated scoring system that assesses metacarpophalangeal, 
proximal interphalangeal ,and distal  interphalangeal  joints of fingers 2 to 5, eval uating syno vitis 
(score 0 -3), flexor tenosynovit is (score 0 -3), periarticular inflammat ion(absent o r present), bone 
edem a (score 0 -3), bone erosion (score 0 -10) and bone proliferat ion/enthesophy tes (absent or 
present). It will beobtained by  [CONTACT_208875] ( Appendix P).
6.4.3.
WB- MRI 
Selected peripheral  joints and entheses, the sacro iliac jo ints (SIJ) and the spi[INVESTIGATOR_208830]-MRI ( Appendix Q). 
Selected peripheral joints will be scored at each side (right and left) for synovit is and BME, 
including glenohumeral, acromioclavicular, sternoclavicular, hip and knee. Selected entheses 
will be scored bilaterally  for entheseal  BME and entheseal soft ti ssue inflammat ion. The entheses 
will include supraspi[INVESTIGATOR_208831], ischial tuberosit y, pubic symphysis, 
greater femoral trochanter, tendon insertions at the knee, calcaneal Achilles tendon insert ion and 
plantar fascia insertion . 
Thefinal WB-MRI as sessment protocol will be developed based on the prevalent 
recommendat ions by [CONTACT_208876]. The final detailed MRI manual will be available before any reading starts.
[IP_ADDRESS]. Definition of WB -MRI I ndices
WB-MRI indices will be constructed to assess synovit is, BME, and soft tissue inflammat ion per 
regions, including pre -specified entheses and peripheral jo ints, SIJ and the spi[INVESTIGATOR_050].
The final list of WB -MRI indices may be updated based on the prevalent knowledge, including 
recommendat ions by [CONTACT_208877], at the time o f reading 
initiation. The final detailed imaging charter with a reading manual will be available before any 
reading starts .
Approved  
  

EDMS Doc. Number: [ADDRESS_249514]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 61 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May [ZIP_CODE].4.5. Clinical Efficacy Assessments 
[IP_ADDRESS]. Joint Assessments
A modified ACR jo int count that includes the distal interphalangeal jo ints of the fingers and toes 
(the “78 tender and 76 swollen” jo int scores; Appendix C) will  be perform ed at every  visit.The 
joints to be evaluated are illustrated in Figure 2.Joint tendern ess and swelling will be noted as 
“present” or “absent,” with no quantitation of severity . 
In case of digit(s) with dactylit is, each jo int of the affected digit must be evaluated for tenderness 
and swelling.
Joints that are swollen or tender should be mar ked wi th a tick. 
In the event that a joint is injected with intra -articular gl ucocorti coid (allowed only after Week 
24 assessments are completed, and up to the Week 36 Visit), this jo int shoul d be m arked by  [CONTACT_1629] 
“X” and won’t be assessed if the study visit occur s within 4 weeks (28 day s) of the intra -articular 
(IA) injection. 
In order to m aintain consistency throughout the study , the sam e evaluator shoul d perform  the 
joint assessments for a given subject at a study  site at each study  visit.
Approved  
  

EDMS Doc. Number: [ADDRESS_249515]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 62 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249516] and Evaluator ’s Global Assessments of Disease Activity
The Pati ent’s (Subject ’s) and Physician’s ( Evaluator ’s) Global Assessments of Disease Act ivity 
are assessments of how active a subject ’s PsA was on average during the past week. Both, 
subjects and evaluator s should mark the box with an X on a 0- to-
10-unit numeric rating scale 
(NRS) ,on which the left -hand box of 0 represents “not active,” and the right -hand box represents 
“very act ive” ( Appendix D; Felso n, 1995; Sieper, 2009 ).
[IP_ADDRESS]. Subject ’s Pain Numeric Rating Scale 
The pain NRS is the subject ’s assessment of how much pain he/she had, on average, during the 
past week in his/her jo ints due to PsA. The subject will be asked to mark the box with an X on a 
0-to 10 -unit NRS ,on which the left -hand box of 0 represents “no pain,” and the right -hand box 
represents the “ pain as bad as y ou can imagine ”
(Appendix D; Felson, 1995; Sieper, 2009 ;
Hjermstad, 2011 ).
[IP_ADDRESS]. HAQ- DI
The HAQ -DI (Appendix E;Fries, 1980 ) is a [ADDRESS_249517] ’s functional abilit y on a 4 -level  difficul ty scale (0 to 3, wi th 0 represent ing 
norm al or no difficult y; and 3 representing an inabilit y to perform ).Eight categori es of  
funct ioning are included: dressing, rising, eating, walking, hygiene, reach, grip, and usual 
activi ties (Bruce, 2003 ).This scale is sensit ive to change and is a good predictor of future 
disabili ty (Aletaha, 2006 ).
Approved  
  

EDMS Doc. Number: [ADDRESS_249518]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 63 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May [ZIP_CODE].4.5.7. Enthesitis
Enthesit is, or the inflammat ionof the si tes where tendons or ligaments insert into the bone, is a 
prominent clinical manifestation in subjects withPsA. In this study , 2 clinical indices will be 
used to evaluate entheseal inflammat ion.The Leeds Enthesit is Index ( Appendix F; Healy , 
2008b )will be assessed through physical examinatio n of the fo llowing sites. Tenderness (y es/no) 
will be assessed at 6 sites of tendon insertions (0 -6) as depi[INVESTIGATOR_48393]: 
Lateral  epi[INVESTIGATOR_100757], l eft and ri ght
Medial  femoral condyle, l eft and ri ght
Achilles tendon insert ion, left and right
Tenderness on physical examinat ion is recorded as either present ( 1) or absent (0) for each of the 
6 sites, for an overall score range of 0 to 6. Higher count represents a greater enthesit is burden.
The SPARCC Enthesi tis Index (Appendix G) will  be assessed through physical examinat ion of 
the following si tes:
Medial epi[INVESTIGATOR_100757] (left/right [L/R] )
Lateral  epi[INVESTIGATOR_100757] (L/R)
Supraspi[INVESTIGATOR_208832] y of hum erus (L/R)
Greater trochanter (L/R)
Quadri ceps inserti on into superi or border of patella (L/R)
Patellar ligament insert ion into inferior pole of patella or tibial tubercle (L/R)
Achilles tendon in sertion into cal caneum (L/R)
Plantar fascia insertion into calcaneum (L/R)
Tenderness on examinat ion is recorded as either present (1) or absent (0) for each of the 16 sites, 
for an overall score range of 0–
16. Hi gher count represents greater enthesit is burden.
Approved  
  

EDMS Doc. Number: [ADDRESS_249519]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 64 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May [ZIP_CODE].4.5.8. Dactylitis
Dactylit is (“sausage digit”) is characterized by [CONTACT_208878] o f the ent ire finger or toe. It will be 
assessed using the Leeds Dact ylitis Index ( LDI) (Appendix H;Helliwell, 2005 ).
The score is a function of finger circumference and tenderness, assessed and summed across all 
dactylit ic digits.
[IP_ADDRESS]. Clinical Disease Activity Index for Psoriatic Arthritis (c -DAPSA)
The c -DAPSA is a measure of PsA disease act ivity, associated with funct ional and structural 
outcom es(Aletaha, 2017). It will be perform ed programmat ically by [CONTACT_208879] y variables: TJC andSJC, subject global and pain assessment. Cut-offsfor cDAPSA are:
≤ 4: remissio n
>4 and ≤
13: low disease act ivity
>13 and ≤
27: moderate disease act ivity
>
27: high disease activit y. 
[IP_ADDRESS]. Psoriatic Arthritis Disease Activity Score (PASDAS)
ThePASDAS is a weighted index comprising assessments of jo ints, fun ction, acute phase 
response, QoL,and patient and physician visual analogue scores (VAS) (Coates, 2014 ). 
Note: This study  does not utilize VASs, but rather NRSs. The patient’s and physician’s global 
assessment of disease act ivity captured on a NRS will be mult iplied by  a factor of 10 to derive 
the VAS, used to calculate PASDAS.
The calculat ion of the PASDAS will be performed programma tically  using the form ula bel ow:
PASDAS =(((0.18× √physician global VAS)+(0.159×√pat ient global 
VAS) −(0.253×√SF36−PCS)+(0.101×LN (SJC +1))+(0.048×LN (TJC +))+(0.23×LN (Leeds 
enthesit is count+1))+(0.377 LN (dactylit is count+1))+(0.102× LN (CRP+1))+2)*1.5.
CRP = C- reactive protein; LN = natural logarithm ;PCS = physical component summary scale of SF36 ;SF36 = 
Medical Outcomes Study Short Form -36; SJC = swollen joint count; TJC = tender joint count; VAS = visual 
analogue scale . All VAS scores are 0–100 mm. Swo llen joint count is 66 joints, and tender joint count 68. 
The score range of the PASDAS is 0 –10, wi th worse di sease activit y represented by  [CONTACT_208880]. Response criteria for the Psoriat ic Arthri tis Disease Act ivity Score (PASDAS) i s detailed 
below.
Approved  
  
EDMS Doc. Number: [ADDRESS_249520]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 65 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May [ZIP_CODE].4.5.12. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
The BASDAI is a composite score based on a subject se lf-administered survey  of six questions 
using a [ADDRESS_249521] ’s five m ajor symptoms rel evant to 
spondylo arthropathi es: 1) fatigue; 2) spi[INVESTIGATOR_18172]; 3) peripheral jo int pain/swelling; 4) areas of 
localized tenderness; 5) morning st iffness severit y upon wakening; 6)morning st iffness duration 
upon wakening ( Appendix J; Calin, 1999 ; Sieper, 2009 ). The subjec t will  be asked to m ark wi th 
an X a 0-to [ADDRESS_249522] igators and individual study  personnel, 
AEs, serious adverse events (SAEs), discont inuat ions and laboratory findings will be reviewed 
internally  by [CONTACT_208881] . 
The study  will be conducted in com pliance wi th the I nternational Council forHarm onisation 
(ICH) of Technical Requirements for Registration of Pharmaceut icals for Hum an Use/Good 
Clinical Practice (GCP) and applicable regulatory  requi rements.
The fo llowing assessments will be conducted as outlined in the Table of Events, Section 5.
6.5.1. Serum and Urine Pregnancy Tests for Females of Childbearing Potential 
A serum pregnancy test with a sensit ivity of ≤ 15 mIU/mL will be requi red for FCBP subjects at 
screening, at the last treatment visit or the Early  Terminati on 
Visit for subjects who discont inue 
Approved  
  

EDMS Doc. Number: [ADDRESS_249523]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 66 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249524] igator, a 
serum  pregnancy  may be done.
6.5.2. Vital Signs, Height and Weight
Vital signs, including temperature, pulse, and seated blood pressure, will be taken during the 
visits indicated in Section 5, Tabl e of Events. Height wi ll be m easured and recorded at s creening; 
weight will be measured and recorded at every visit.
In the event of u nexplained and clinically significant weight loss, subjects should be evaluated and
discontinuat ion of study  treatm ent shoul d be considered by  [CONTACT_3170].
6.5.3. Complete/Limited Physical Examination
A co mplete physical examinat ion includes evaluations of s kin, nasal cavit ies, eyes, ears, lymph 
nodes, and respi[INVESTIGATOR_696] , cardi ovascular, gastrointestinal, neurological, and musculoskeletal 
system s.A co mplete p hysical examinat ion is done at s creening and other designated visits as 
indicated in Section 5.A limited physical examination includes eval uations of skin, lymph 
nodes, and respi[INVESTIGATOR_696] , cardi ovascular, and m usculoskel etal systems. A limited physical 
examinat ion is done at Baseline Visit and other designated visit s as indicated in Section 5.
6.5.4. Psychiatric Evaluation
Treatment with apremilast is associated with an increase in adverse react ions of depressio n. 
Before using apremilast in subjects with a history  of depressio n and/or suicidal thoughts or 
behavior , the invest igator should carefully weigh the risks and benefit s of treatment with 
apremilast in such patients. Subjects should be advise d of the need to be alert for the emergence 
or worsening o f depressio n, suicidal thoughts or other mood changes, and if such changes occur 
to con tact the Invest igator . 
If a patient suffers fro m new or worsening psychiatric symptoms, or suicidal ideat ion or suicidal
attem pt is i dentified, it is reco mmended to discontinue study treatment (see Secti on11).
6.5.5. Diarrhea, Nausea and Vomiting
Apremilast has been associated with AE reports of diarrhea in clinical trials. Most diarrhea 
events were of mild or moderate severit y and reported wi thin the f irst 2 weeks of treatment, 
usually reso
lving within 4 weeks wit hout m edical intervent ion.
Diarrhea is the passage of three or more loose or liquid stools per day , or m ore frequent ly than is 
norm al for the individual ( World Heal th Organizatio n [WHO], 2013). F ollowing the definit ion of 
diarrhea by [CONTACT_208882] a more conservat iveapproach, the AE of diarrhea i n this 
protocol  is defined as having two or more watery /liquid stool s in a day . 
Approved  
  
EDMS Doc. Number: [ADDRESS_249525]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 67 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249526] ionary 
of Regulatory  Activities (MedDRA) preferred term o f diarrhea, subjects repor ting diarrhea or 
similar events (eg, frequent bowel movements, loose bowels, etc.) will be asked whether they 
have had two or more watery /liquid stool s in a day. Subj ects who respond “yes” to this question 
will be further asked how often, on average, have they experienced two or more watery /liquid 
stools in a day . Subjects who respond “no” to the question will not be asked any  further 
questions.
There have been post -marketing reports of severe diarrhea, nausea and vo miting associated with 
the use of apremil ast. Most events occurred within the first few weeks of treatment. In some 
cases, patients were hospi[INVESTIGATOR_057]. 
Subjects [ADDRESS_249527] s develop severe diarrhea, nausea 
and vo miting, discont inuation o f treatm ent wi th study  treatm ent m ay be necessary  (see 
Secti on11).
6.5.6. Tuberculosis 
After an extensive clinical development program, there is no current evidence that apremilast has 
the potenti al to activate l atent TB. Therefore, no TB testing will be done in this protocol. 
Invest igators can test for TB if clinically indicated, using the site ’s local or country  specific 
guidelines. If t he subject has active or latent TB, he/she should be treated according to local 
guidelines. Subjects who require TB treatment at any  time during the study  must be 
discontinued. 
6.5.7. Clinical Laboratory Evaluations
Clinical laboratory  evaluat ions will be perfor med by [CONTACT_2237] , and as indicated in 
Secti on 5.Clinical laboratory  eval uations include : RF, CBC (RBC count, hemoglobin, 
hematocri t, WBC count and differential, abso lute WBC counts, platelet count); serum 
chemistries (total protein, album in, calcium, phosphorous, glucose, triglycerides, total 
cholesterol  [TC], total  and di rect bilirubin, alkaline phosphatase, AST ,ALT ], sodi um, potassi um, 
chloride, bicarbonate [carbon dioxide, CO 2], BUN , creati nine, creat inine clearance, lactate 
dehydrogen ase [LDH], and m agnesium ); ; hemoglo bin A1c (HbA1c) ;and urinalysis 
(specific gravit y, pH, glucose, ketones, protein, blo od, bilirubin, leukocy te esterase, ni trite, and 
urobilinogen). Urinalysis will be performed by [CONTACT_2237]; microscopi c urinalysis 
(epi[INVESTIGATOR_1663], RBC, WBC, and casts) will be performed only  if the urinalysis is abnormal. 
6.5.8. Adverse Events
All subjects will be mo nitored for adverse events (AEs) during the study . Assessments m ay 
include mo nitoring of any or all the foll owing parameters: the subject ’s clinical symptoms, 
laboratory , 
pathol ogical, radi ological, or surgical findings; physical examinat ion findings; or 
other appropriate tests and procedures.
All AEs will be recorded by  [CONTACT_208883] m the time the subject signs informed consent to 
[ADDRESS_249528] dose of IP. A Esand SAEs will be recorded on the AE page of the case 
report form (CRF ), the paper SAE reporting form (SAEs) and in the subject ’s source docum ents. 
Approved  
  

EDMS Doc. Number: [ADDRESS_249529]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 68 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249530] igator ’s 
knowl edge of the event using the paper Serious Adverse Event Report Form by [CONTACT_6972]/email 
of the paper SAE Report Form direct ly to [COMPANY_010] Global Patient Safet y
Details o f AE/SAE reporting can be found in Section 10of the protocol.
It should be noted that worsening of a subject ’s PsA shoul d be considered as worsening of 
disease under study  and shoul d not be captured as an adverse event.
6.6. Biomarkers
6.7. Subject -reported Outcomes
The fo llowing asse ssments will be conducted as outlined in the Table of Events, Section 5.
6.7.1. Psoriatic Arthritis Impact of Disease 12 -domain Questionnaire ( PsAID -
12)
The PsAID is a validated score reflect ing the impact of disease in PsA. The PsAID -
12is a 12-
item, self -administered questionnaire that reflects the impact of PsA from the perspect ive of the 
patient. It i s composed of 12 physical and psycho logical do mains. Each domain is rated from 0 to 
10 with a different weight ing. The total score is divide d by 20. The final  score has a range from  0 
(best status) to 10 (worst status) with a cut -off of 4 (Appendix K;Gossec, 2014).
Approved  
  

EDMS Doc. Number: [ADDRESS_249531]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 69 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020
Approved  
  

EDMS Doc. Number: [ADDRESS_249532]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 70 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249533](s)
The chemical name o f apremilast (CC -[ZIP_CODE]) i s N-[2-[(1S) -1-(3-ethoxy -4- methoxyphenyl) - 2-
(methylsulfo nyl)ethyl] -2,3-dihydro -1,3-dioxo -
1H-isoindo l-4-yl] acetamide.  
Apremilast will be provided by [CONTACT_21931]. and labelled appropri ately as IPfor this study .  
Apremilast will be provided as 10, 20, or [ADDRESS_249534] will also be provided as 30 mg tablets in high-densit y polyethylene 
(HDPE )bottles (approximately 80 tablets) with child -resistant caps.  The apremilast dosing 
schedule and dose adjust ments to be fo llowed for this study  are described in Sect ion 7.2. Please 
refer to the IBfor more details on approved indicatio ns, known precaut ions, warnings, and 
adverse reactions of apremil ast. 
Addit ional information may  be included on the l abel as needed or applicable. Label(s) for IP will 
contain informat ion as required per local health authority.
7.2. Treatment Administration and Schedule
Tablets will be taken by [CONTACT_104744], in the mor ning (AM) and in the evening (PM), 
approximately  12 hours apart, wi th no food restri ctions.To mit igate potenti al gastrointestinal  
(GI) adverse events, dose titration shall be implemented over a 5 -dayperiod(Table 14).At the 
Week [ADDRESS_249535] tablets at 
designated visits.
Table 14: Treatment Schema for Dose Titration at Baseline
Week [ADDRESS_249536] develops severe renal impairment (creatinine clearance 
of less than 30 m L per minute estimated by  [CONTACT_94486] –Gaul t equati on), interrupti on of  study  
medicat ionis required.
7.2.1. Overdose
Overdose, as defined for this protocol, applies to protocol -requi red dosing of the IP(s) only.
Therefore, for a drug to be subject to the overdose definit ion it must be both required and an
investigational drug. In this study the only requi red and investigational drug is apremilast and 
there is no control arm drug, hence overdose definition will apply to only apremilast. Other 
requi red or opti onal non -study  drugs intended for prophylaxis of certain side effects, etc, are 
excluded fro m this definit ion.
Approved  
  
EDMS Doc. Number: [ADDRESS_249537]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 71 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249538] be co llected on the Adverse Events page of the
CRF (see Sect ion 10) f or all overdosed subjects, but the overdose itself is not considered an AE.
7.3. Method of Treatment Assigned
After the informed consent is signed, subjects will be assigned a subject ident ificat ion number 
using a centralized interactive web response system (IWRS) . 
At the Baseline Visit, a centralized 
schema will be applied to assign subjects who meet the inclusio n and none of the exclusion 
criteria to receive apremilast [ADDRESS_249539] 30 mg tablets will be supplied in HDPE 
bottles wi th child -resistant caps.
The l abel(s) for IP will include S ponsor nam e, address and telephone number, the protocol 
number, IP name, dosage form and strength (where applicable), amount of IP per container, lot 
number, expi[INVESTIGATOR_5695] (where applicable), medicat ion identificat ion/kit number, dosing 
instructi ons, storage condit ions, and required caution statements and/or regu latory statem ents as 
applicable. Addit ional informat ion may be included on the label as applicable per local 
regul ations.
7.5. Investigational Product Accountability and Disposal 
The invest igator, or designee, is responsible for taking an inventory of each shi pment of 
apremilast received, and co mpar ing it with the accom panying apremilast shippi[INVESTIGATOR_208833]/packing 
list. 
The Investigator(s) or designee(s) will verify the accuracy o f the informat ion on the form, sign 
and date it, retain a copy  in the study  file, and record the inform ation in the IRT.
Invest igational product will be stored per the storage condit ions identified on the drug l abel.At 
the study  site, all  IP will be stored in a l ocked, safe area to prevent unauthorized access.
[COMPANY_010] (or desi gnee) will rev iew with the Investigator and relevant site personnel the process for 
investigat ional p roduct return, disposal and/or destruction including responsibilit ies for the si te 
versus [COMPANY_010] (or desi gnee). 
Approved  
  
EDMS Doc. Number: [ADDRESS_249540]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 72 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May [ZIP_CODE].5.1. Dosing
[IP_ADDRESS]. Study Medication Dispensing and Counting
After the informed consent is signed, subjects will be assigned a subject ident ificat ion number 
using a centralized interactive web response system (IW RS). At the Baseline Visit, a centralized 
schema will be applied to assign subjects who meet the inclusio n and none of  the exclusion 
criteria to receive apremilast [ADDRESS_249541] ’s record. Subjects must be instructed to return all 
previously issued empt y blister card(s), empt y study drug bottle(s) and/or unused study 
medicat ion at the time that new medication is issued. A detailed record of tablets issued and 
returned at each visit must be maintained in the subject ’
s reco rd.
During the study  visits, the pharmacy  or authori zed study  personnel at the invest igational site 
will dispense coded IP kits in accordance wi th the number assigned by  [CONTACT_208884]. 
7.6. Investigational Product Compliance
Study  personnel will review the instruct ions printed on the package with the study  subjects pri or 
to dispensing the IP. Invest igational p roduct will be di spensed as noted in the Table of Events, 
Secti on 5.The subjects will be instructed to return the IP containers, including any unused 
medicat ion, to the study  site at each visi t for tabl etcounts and reconciliat ion.Subjects will be 
asked whether they  have taken thei r IP as instructed at each study  visit.Any problems wit h IP 
compliance will  be reviewed wi th the subject. If thesubject misses [ADDRESS_249542] should be terminated from the Treatment Phase of the study , and enter into the 
Observational Fo llow
-up Phase.
Gross compliance problems (eg, missing 4 or more consecutive days o f dosing or taking less 
than 75% of the doses between study  visits) shoul d be discussed with [COMPANY_010] .Com pliance is 
defined as taking between 75% and 120% of dispensed IP.
Approved  
  
EDMS Doc. Number: [ADDRESS_249543]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 73 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May [ZIP_CODE]. CONCOMITANT MEDICATI ONS AND PROCEDURES
All medications and therapi[INVESTIGATOR_208834]/used by  [CONTACT_198506] 30 days prior to the 
Screening Visit (Visit 1) or at any t ime during the study should be recorded. Prior medicat ions 
for the treatm ent of  PsA must be recorded at any time. Other key  medicat ions and therapi[INVESTIGATOR_014], such 
as previous treatment fo r TB or relevant diseases, should be recorded.  
All medications and therapi[INVESTIGATOR_014], including physical therapy, for PsA and their reasons for 
discontinuat ion, shoul d be recorded. The stop dates for all medications and therapi[INVESTIGATOR_208835] d be recorded. Addit ional instructi ons can be found in the CRF Co mpletion 
Guidelines.
8.1. Permitted Concomitant Medications and Procedures
All medications (prescript ion and non -prescripti on), treatments and thera pi[INVESTIGATOR_208836] s creening throughout their entire partici pation in the study , including those init iated 
prior to the start of the study , must be recorded on the subject ’s source docum ent and on the 
appropriate page of the CRF. The dose, unit, frequency, route, indicat ion, the date the medica tion 
was started and the date the medicat ion was stopped (if not ongoing) must be recorded. Subjects 
may cont inue receiving standard of care therapy (eg ,folic acid for those on MTX) if not 
explicit ly prohibi ted as per protocol . The fo llowing concomitant m edicat ions and procedures are 
permitted: 
Oral glucocorti coids, (on a stabl e dose of prednisone ≤ 10 m g/day or equivalent for at 
least 4 weeks prior to Baseline Visit [i e, Day  1]).
Note: The stable dose of glucocorti coids must be con tinued and maintained from Day 
1through the W eek 24 Visit. Change in doses, increase or decrease, and/or 
discontinuat ion of glucocorti coids will not be allo wed except for safet y reasons or for 
lack of availabilit y. After the Week 24 Visit, the dose of glucocorti coids may be 
adjusted as clinically required.
MTX (≤ 25 m g/week, if total treatm ent durati on is ≥ [ADDRESS_249544] 3months prior to baseline ).
At Week 12, subject s will be allowed to receive IA glucocortico ids, administrati on of  
up to 2 injecti ons of  ≤ 40 m g triamcino lone hexacetonide or equivalent (each jo int). 
NSAIDs or narcotic analgesics (must be on a stable dose for at least 4 weeks prior to
theBaseline Visit [ie, Day  1]).
Note: The stable dose of NSAIDs or narcotic analgesics must be con tinued and 
maintained fro m Day 1through the W eek 24 Visit. Change in doses, increase or 
decrease, and/or discont inuat ion of NSAIDs or narcotic analgesics will not be 
allowed except for safet y reasons or for lack of availabilit y. After the Week 24 Visit, 
the dose of NSAIDs or narcotic analgesics may be adjusted as clinically required.
NSAIDs or narcotic analgesics that are administered on an as needed basis (PRN) 
shoul d be recorded on the Prior/Concomitant Medications page of the CRF. 
Loperamide and antidiarrheal drugs with ant isecretory  effect (eg, racecadotril) .
Approved  
  
EDMS Doc. Number: [ADDRESS_249545]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 74 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020Low dose aspi[INVESTIGATOR_248] (acet ylsalicylic acid, up to 325 mg per day) for cardiovascular 
prophylaxis.
Birth control  medicati ons/barri er methods for FCBP subjects .
Low-potency topi[INVESTIGATOR_208837](or locally available equivalent) as background 
therapy  for treatm ent of psori asis on the face, axillae and groin in accordance with the 
manufacturers ’suggested usage during the course of the study .  
Coal tar shampoo and/or salicylic acid scalp preparat ions on scalp psoriasis lesio ns. 
A nonmedicated skin emo llient (eg, Eucerin® cream) for body  psori asis lesi ons only.
Medicat ions for condit ions other than PsA and psoriasis, which are not prohibited in Section 8.2, 
are permitted and must be recorded in the subject ’s source docum ents and as a concomit ant 
medicat ion on the CRF.
The fo llowing therapy  will be permitted after the Week 24 V isitfor subjects with worsening 
arthri tic symptom s of PsA:
Change of NSAID ty pe and/or dose
Administrati on of  no m ore than 40 m g intram uscular (IM) or intra-articular ( IA)
glucocorti coid(triamcino lone hexacetoni de or equivalent) at a single visit, up to 
Week 36 , not to exceed two glucocortico id IM and/or IA administrations in any  [ADDRESS_249546] ion.
Short course ( ≤ 2 weeks) of low-dose oral glucocorti coids(prednisone ≤ 10 m g/day 
or equivalent) , to be completed up to Week [ADDRESS_249547] ’s worsening PsA symptoms. After Week 24, if 
subjects exper ience a decrease in PsA clinical disease activit y, the invest igator may opt to taper 
the background treatment; however, only one agent may be reduced or tapered at any  one time. 
After the first agent ’s taper has been co mpleted (not required to be zero), th e dose m ust be stable 
for at least [ADDRESS_249548] a reduction of background therapy  in the fo llowing order: first MTX, second 
glucocorti coids and thi rd NSAIDs or other pain medicat ion. If clinically indicated, the 
investigator may  opt to reduce the m edicat ions in a different order. Any  further 
questions/concerns regarding dose reductions can be discussed wit h the Sponsor.
All other prohibited medicat ions listed in Sect ion 4.4(Exclusio n Cri teria) and Sect ion 8.2
(Prohibited Conco mitant Medi cations and Pro cedures) remain in effect through the end of the 
subject ’s parti cipat ion in the study .
8.2. Concomitant Medications Not Recommended
It has been observed that co -administration with strong cytochrome P450 3A4 (CYP3A4) 
enzyme inducer, rifampi[INVESTIGATOR_2513], resulted in a re ducti on of  systemic exposure of apremilast, which 
may result in a loss of efficacy  of apremilast. Therefore, the use of strong CYP3A4 enzyme 
Approved  
  
EDMS Doc. Number: [ADDRESS_249549]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 75 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020inducers (eg, rifampi[INVESTIGATOR_2513], phenobarbital, carbamazepi[INVESTIGATOR_050], phenyto in and St. John’s Wort) with 
study  treatm ent is not recommended.
8.3. Prohibited Concomitant Medications and Procedures
The fo llowing concomitant medicat ions and concomitant procedures are prohibited, except as 
permitted in Sectio n 8.1.
DMARDs (convent ional synthetic or bio logic) for treatm ent of PsA, except for MTX
(≤ 25 mg/week) if on stable dose at least 3 months pri or to Baseline Visitand with 
total treatm ent durati on ≥ 6 m onths.   
Treatment with IA glucocorti coids outsi de the time points specified in Section 8.1, or 
administration of more than [ADDRESS_249550] ions of ≤ 40 mg tri amcino lone hexacetonide or 
equivalent (each jo int) 
8.4. Required Concomitant Medications and Procedures
There are no required concomitant medicat ions or procedures.
Approved  
  
EDMS Doc. Number: [ADDRESS_249551]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 76 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249552] ionoutlines the statistical analysis strategy  for the data collected in the study . A detailed 
Statistical Analysis Plan (SAP), including data handling and imputation rules, will be prepared 
and finalized before database lock or any  analysis procedures are con ducted. 
9.2. Study Population Definitions
The Full Analysis Set (FAS) will consist of all subjects who are enrolled in the study .Amo ng the 
FAS, specific analysis populat ions will be defined in detail in the SAP.
The Per Protocol (PP) populat ion will consist o f all subjects who receive at least one dose of 
study  medicat ionand have no major protocol deviati onsduring the first [ADDRESS_249553], assumpt ions used for the sample size calculat ion 
are primaril y derived from  the li terature (Glinatsi, 2015 ). With an approximate 20% dropout rate, 
a sam ple size of 120 i s requi red to produce a two -sided 95% confidence interval, for the 
expected change from baseline in the composite score of BME, synovit is, and tenosynovit is, with 
a distance fro m the mean to the limit equal to 1.24, assuming the standard deviat ion is 6.2.
9.4. Background and Demographic Characteristics
Subjec t’sage, wei ght, hei ght and other con tinuous demographic and baseline characterist ics will 
be summarized using descriptive statist ics (mean, standard deviation, minimum and maximum), 
while gender, race, and other categorical variables will be summarized wi th frequency  
tabul ations. Medical history  data will be classified using the MedDRA classificat ion system and 
summarized using frequency  tabulat ions by [CONTACT_6657]. Treatment 
history  (including previous csDMARD and invest igational agents) will be summarized using 
frequency  tabulat ions. The Anatomical Therapeutic Chemical (ATC) coding scheme of the 
World Heal th Organizat ion (WHO) will be used to group medicat ions into relevant categori es 
for these tabul ations.
9.5. Subject Disposition
Subject disposit ion (subjects enrolling into and complet ing or discont inuing from the study , 
along wi th primary reason for discont inuat ion) will be summarized using frequency  and percent 
by [CONTACT_208885]. A summary  of subjects enrolled by [CONTACT_27707]. Protocol  deviat ions will 
be summarized using frequency tabulat ions.
Approved  
  
EDMS Doc. Number: [ADDRESS_249554]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 77 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May [ZIP_CODE].6. Efficacy Analysis
9.6.1. Primary Endpoint
The primary endpo int, change fro m baseline in the composite score of BME, synovit is, and 
tenosynovit is assessed by [CONTACT_208886] 24, will be analy zed descript ively. The 95% 
confidence interval will be provided for the mean change, and the composite score over time will 
be presented graphically .
9.6.2. Secondary Endpoints
All secondary efficacy endpo ints listed in Section 2will be analyzed descript ively, wit h 
summary statist ics for continuous endpo ints and frequency  distribut ion for binary  endpoints. The 
95% confidence intervals will also be provided. Separate analyses for the responders and non -
responders will also be perf ormed for each imaging endpo int. The PsAMRIS will also be 
analyzed separately  based on the presence or absence of different imaging parameters at 
baseline .In addit ion, data will be reported based on the proportion of subjects above or below 
the smallest d etectable change s(SDC).
9.6.3. Exploratory Endpoints
9.7. Safety Analysis
The safet y analyses will be performed using the safet y popul ation as defined in Section 10.2.
Adverse events will be classified using the MedDRA classificat ion system. All adverse events 
will be summarized by  [CONTACT_73001]; in addit ion, also by  [CONTACT_208887] . Adverse events l eading to death or to discontinuation fro m treatm ent, seri ous adverse 
events, study  drug-related adverse events, and events of interest will be summarized separately. 
A subject having the same event more than once will be counted only once using the maximum 
severit y.
Laboratory  data will be summarized by [CONTACT_208888]  (mean, standar d deviat ion, median, 
minimum, and maximum). Number and percentage of subjects with marked laboratory  
abnorm alities will be provided. In addit ion, shift tables showing the number of subjects with 
values low, normal, and high based on the normal ranges pre -treatment versus post -treatm ent 
will be provided. 
Vital sign m easurements, including weight, will be summarized by [CONTACT_208889]. In 
addition, shift tabl es showing the number of subjects with values low, normal, and high based on 
the norm al reference ranges pre -treatm ent versus post -treatm ent will be provided.
To accoun t for the exposure to the study  medicat ion, the exposure adjusted incidence rate will 
also be calculated for adverse events and marked laboratory  abnorm alities. 
Approved  
  

EDMS Doc. Number: [ADDRESS_249555]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 78 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249556] Compliance (Tablets)
Study  medicati on informat ion will be summari zed and subject list ings will be provided. 
Com pliance will  be estimated by [CONTACT_198518] 75% and 120% of 
the intended quant ity of study  medicat ion.
9.8.2. Concomitant Therapy
All conco mitant treatm ents docum ented during the study  period will be summarized in frequency  
tabul ations. The ATC coding scheme o f the WHO will be used to group medicat ions into 
relevant categori es for these tabulat ions. Separate data summaries of background medicat ions 
will be provided.
9.8.3. Steering Committee 
Guidance in protocol development and interpretation of data analysis will be provided by a 
scientific steering co mmit tee (SSC). Details for the SSC are pre -specified in a separate SSC 
charter.
Approved  
  
EDMS Doc. Number: [ADDRESS_249557]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 79 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249558] ’s heal th, including 
laboratory  test val ues (as specified by  [CONTACT_81677]10.3), regardl ess of eti ology. Any 
worsening (ie, any  clinically significant adverse change in the frequency  or intensi ty of a pre -
exist ing condit ion) should be considered an AE. A diagnosis or syndrome should be recorded on 
the AE /SAE page of the CRF rather than the individual signs or symptoms of the diagnosis or 
syndro me. 
Abuse, wi thdrawal , sensi tivity or toxi city to apremilast should be reported as an AE. Overdose, 
accidental  or intent ional, whether or not it is associated with an AE ,shoul d be reported on the 
overdose CRF. (See Section 7.2.1 for the definit ion of overdose.) Any sequela of an accidental or 
intentional overdose of an IPwhich meets the definit ion of an adverse event should be reported 
as an AE on the CRF. If the se quela eof an overdose meet seriouscriteria, then it must be marked 
as serious on the CRF and the paper SAE Report form .The overdose itself shoul d not be 
reported as an AE .
In the event of overdose, the subject should be monitored as appropriate and shoul d receive 
supportive measures as necessary . There is no known specific ant idote for apremilast overdose. 
Actual  treatm ent shoul d depend on the severit y of the clinical situation and the judgment and 
experience o f the treating physician.
All subjects will b e monitored f or AEs during the study .Assessments may include monitoring of 
any or all o f the following parameters: the subject ’s clinical symptoms, laboratory , pathol ogical , 
radiological  or surgical  findings, physical examination findings, or findings fro m other tests 
and/or procedures.
All AEs will be recorded by  [CONTACT_11856] f rom the time the subject signs informed consent 
until [ADDRESS_249559] igator at any  time 
following the protocol -requi redreporting period or after end of study  will also be reported for 
these subjects. All adverse events ( serious/non -serious) will be recorded on the CRF , the paper 
SAE Report form (SAEs) and in the subject ’s source docum ents. All SAEs m ust be reported to 
Amg en Gl obal Patient Safet ywithin [ADDRESS_249560] igator ’s knowl edge of  the event by 
[CONTACT_208890]/email of the paper SAE Report Form  directly to Am gen Gl obal Patient Safet y.
10.1.1. Monitoring, Recording ,and Reporting AEs of Diarrhea
The PDE4 inhibitors, including apremilast, have been associated with AE reports of diarrhea. To 
better characterize and understand all reported AEs of diarrhea, further information will be 
collected as described in Secti on5, in the Table of Events. Please refer to Secti on10.[ADDRESS_249561] such AEs.
Approved  
  
EDMS Doc. Number: [ADDRESS_249562]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 80 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249563] igator will evaluate all adverse events as to: 
10.2.1. Seriousness 
An SAE is any  AE occurring at any dose that:
Results in death;
Is life -threatening (i e, in the opi[INVESTIGATOR_3078] n of the Invest igator, the subject is at immediate 
risk of death fro m the AE);
Requi res inpat ient hospi [INVESTIGATOR_24508] 
(hospi [INVESTIGATOR_208838] n, regardl ess of l ength of stay );
Results in persistent or significant disabilit y/incapacit y (a substant ial disrupt ion of the 
subject ’s abilit y to conduct normal life functions);
Is a congenital ano maly/birth defect;
Const itutes an important medical event.
Important m edical events are defined as those occurrences that may not be immediately  life-
threatening or result in death, hospi[INVESTIGATOR_3094], or disabilit y, but may  jeopardi ze the subject or 
requi re medical or surgi cal intervent ion to prevent one of the other outcomes listed above. 
Medical and scientific judgment should be exercised in deciding whether such an AE should be 
considered serious.
Events not considered to be SAEs are hospi[INVESTIGATOR_208839]:
astandard procedure for protocol therapy  administrati on.However, hospi[INVESTIGATOR_208840] a com plicat ion of therapy  administrati on will be 
reported as an SAE. 
routine treatm ent or m onitoring of the studied indication not associated with any  
deteri oration in cond ition.
the administration o f blood or pl atelet transfusio n as routine treatment of studied 
indicat ion.However, hospi[INVESTIGATOR_27589] a complication 
of such transfusion remains a reportable SAE.
aprocedure for protocol/disease -related invest igations (eg, surgery , scans, endoscopy , 
sampling for laboratory  tests, bone m arrow sam pling). However, hospi[INVESTIGATOR_208840] a com plicat ion of such procedures remains a reportable 
SAE.
hospi[INVESTIGATOR_208841] , practical , or s ocial 
reasons, in absence of an AE.
aprocedure that is planned (ie, planned prior to start of treatment on study); must be 
docum ented in the source document and the CRF. Hospi[INVESTIGATOR_208842] a com plicati on remains a reportable SAE.
Approved  
  
EDMS Doc. Number: [ADDRESS_249564]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 81 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020an elect ive treatment of or an elect ive procedure for a pre -exist ing condit ion, 
unrelated to the studied indicat ion, that has not worsened fro m baseline. 
emergency outpatient treatment or observat ionthat does not result in admissio n, 
unless fulfilling other seriousness criteria above.
If an AE i s considered serious, both the AE page/screen of the CRF and the paper SAE Report 
Form  must be completed. All SAEs must be reported to [COMPANY_010] Glo bal Pat ient Safety within 24 
hours of the Investigator’s knowledge by  [CONTACT_208891]/email directly to [COMPANY_010] Glo bal Pat ient Safety.
For each AE, the Invest igator will provide information on severit y, start and stop dates, 
relationship to apremilast , acti on taken regarding apremilast , and outcome.
10.2.2. Severity/Intensity
For each AE, the Invest igator must assess the severity/ intensit y of the event. 
Mild
Asymptomat ic or mild symptoms; clinical or diagnostic observat ions only
Intervention not indicated
Activities o f daily  life (ADLs) minimally or not affected
No or minimal intervention/therapy may be required 
Moderate 
Symptom (s) cause m oderate di scomfort
Local  or noninvasive intervent ion indicated
More than minimal interference wit h ADLs but able to carry  out daily  soci al and 
funct ional activit ies.
Drug therapy  may be requi red
Severe (could be non -serious or seri ous) 
Symptom s causing severe disco mfort/pain
Symptom s requi ring m edical/surgi cal attenti on/int ervent ion
Interference wit h ADLs i ncluding inabilit y to perf orm daily  soci al and funct ional 
activit ies (eg, absenteeism and/or bed rest)
Drug therapy  is requi red
The term  “severe” is often used to describe the intensit y of a specific event (as in mild, moderate 
or severe myocardial infarct ion); the event itself, however, may be of relat ively minor medical 
significance (such as severe headache). This criterion is notthe sam e as “serious ,” which is 
based on subject/event outcome or action criteria associ ated wi th events that pose a threat to a 
subject ’s life or funct ioning.
Seriousness, not severit y, serves as a gui de for defining regul atory  obligat ions.
Approved  
  
EDMS Doc. Number: [ADDRESS_249565]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 82 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249566] and 
the occurrence of an AE as Not Susp ected or Suspected as defined below:
Not suspected: a causal relat ionship of the adverse event to IP administration is 
unlikely or remote , or other m edicat ions, therapeutic 
intervent ions, or underlying condit ions provi de a sufficient 
explanat ion for the ob served event.
Suspected: there is a reasonable possibility that the administration of IP 
caused the adverse event. “Reasonable possibilit y”means there 
is evidence to suggest a causal relat ionship between the IP and 
the adverse event.
Causalit y shoul d be assessed and provided for e achAE based on current ly available information.
Causalit y is to be reassessed and provided as addit ional  informat ion beco mes available.
If an event is assessed as suspected of being related to a comparator, ancillary or addit ional non-
IP that has not been manufactured or provided by [CONTACT_11337] , please provi de the name [CONTACT_208924].
10.2.4. Duration
For each AE, the Invest igator will provide a record of the start and stop dates of the event.
10.2.5. Action Taken
The Investigator will report the action taken with apremilast as a result of each AE, as applicable 
(eg, di scont inuat ionorinterruption, as appropriate) and report if conco mitant and/or addi tional 
treatm ents were given for the event. 
10.2.6. Outcome
The Investig ator will report the outcome of the event for each AE.
All SAEs that have not resolved upon discont inuatio n of the subject ’s parti cipat ion in the study  
must be fo llowed until recovered (returned to baseline), recovered with sequelae, or death (due to 
the SAE).
10.3. Abnormal Laboratory Values
An abnormal laboratory  value is considered an AE ifthe abnorm ality:
resul ts in discont inuat ion from the study;
requi res treatm ent, m odificat ion/ interruption of dose, or any  other therapeuti c 
intervent ion; or
is judged to b e of significant clinical importance, eg, one that indicates a new disease 
process and/or organ toxicit y or is an exacerbat ion or worsening o f an exist ing 
condi tion.
Approved  
  
EDMS Doc. Number: [ADDRESS_249567]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 83 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020Regardless of severit y grade, only  laboratory  abnorm alities that fulfill a seriousness cri terion 
need to be document ed as a serious adverse event.
If a laboratory  abnorm ality is one com ponent of a di agnosis or syndrome, then only the diagnosis 
or syndrome should be recorded asthe AE. If the abnormalit y was not a part of a diagnosis or 
syndro me, then the l aboratory  abnorm ality should be recorded as the AE. If possible, the 
laboratory  abnorm ality shoul d be recorded as a m edical term  and not simply  as an abnorm al 
laboratory  resul t (eg, record thrombocy topeni a rather than decreased platelets).
10.4. Preg nanc y
All pregnancies or suspected pregnancies occurring in a female subject of childbearing potential 
are immediately reportable events .  
10.4.1. Collection of Pregnancy and Infant Health Information
Pregnancies and suspected pregnancies (including elevated β-subunit of human chorionic
gonadotropin [β -hCG] or posit ive pregnancy test in a female subject of childbearing potential
regardl ess of disease state) occurring while the subject is on IP, or within [ADDRESS_249568]’s
last dose of IP, must be report able within [ADDRESS_249569] be reported to [COMPANY_010]
Global Patient Safet y immediately by [CONTACT_6972], email or other appropriate method, using the 
Pregnancy Notificat ion Form or approved equivalent form ( refer to Appendix V).  The 
Pregnancy Notificat ion Form  must be submitted to [COMPANY_010] Global Pat ient Safet y within [ADDRESS_249570]’ s pregnancy . (Note:  Si tes are not requi red to provi de any  information on 
the Pregnancy Notificat ion Form that vio lates the country  or regi ons l ocal privacy laws). 
After obtaining the female subject ’s signed consent for release of pregnancy  and infant healt h 
inform ation, the invest igator will collect pregnancy and infant health info rmation and complete 
the pregnancy  questi onnai re for any  female subject who becomes pregnant while taking IP 
through [ADDRESS_249571] ’s last dose of IP . This informat ion will be forwarded to [COMPANY_010] 
Global Patient Safety . Generally , infant follow -up wi ll be conducted 12 months after the birth of 
the child (if applicable).         
The female subject may be referred to an obstetrician- gyneco logist or another appropriate
healt hcare professio nal for further evaluat ion.
The Investigator will fo llow the female subject until co mpletion of the pregnancy  and must
notify [COMPANY_010] Glo bal Pat ient Safet yimmediately  about the outcom e of the pregnancy  (either 
norm al orabnormal outcome) .
If the outcome of the pregnancy was abnormal (eg, spontaneous abortion), the I nvest igator
shoul d report the abnorm al outcom e as an AE. If the abnormal outcome meets any o f the seri ous
criteria, i t must be reported as an SAE to [COMPANY_010] Glo bal Pat ient Safet y using the paper Serious 
Adverse Event Report Form within [ADDRESS_249572] igator’s knowledge of the event. 
All neonatal  deaths that occur within [ADDRESS_249573] igator suspects is
related to in utero exposure to the IP shoul d also be reported as an SAE to [COMPANY_010] Glo bal Pat ient 
Approved  
  
EDMS Doc. Number: [ADDRESS_249574]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 84 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020Safetyby [CONTACT_6972], email, or other appropriate method within 24 hours of the Investigator’s 
knowl edge of the event , using the paper SAE Report form . 
10.4.2. Male Subjects With Partners Who Beco me Pregnant 
In the event a male subject fathers a child during treatment, and for an addit ional 28 days after 
discontinuing IP, the informat ion will be recorded on the Pregnancy Notificat ion Form  (refer to 
Appendix V). The form must be submitted to [COMPANY_010] Glo bal Pat ient Safet y with 24 hours of the 
investigator’s/site’s aware ness o f the pregnancy  (Note:  Si tes are not required to provide any 
inform ation on the Pregnancy  Notificat ion Form that vio lates the country  or regi ons l ocal 
privacy  laws). 
The invest igator will attempt to obtain a signed consent for release of pregnancy and infant 
healt h informat ion directly from the pregnant female partner to obtain addit ional pregnancy 
inform ation.   
After obtaining the female partner ’s signed consent for release of pregnancy  and infant healt h 
inform ation the investigator will co llect pregnancy outcome and infant healt h informat ion on the 
pregnant partner and her baby  [CONTACT_208892]. This information will 
be forwarded to [COMPANY_010] Glo bal Pat ient Safety .     
Generally , infant follow -up will be conducted up to 12 m onths after the birth of the child (if 
applicable). 
Any terminat ion of the pregnancy will be reported to [COMPANY_010] Global Pat ient Safet y regardl ess of 
fetal status (presence or absence of ano malies) or indicat ion for procedure .
10.4.3. Collection of Lactation Informa tion 
Invest igator will co llect lactation informat ion on any female subject who breastfeeds 
while taking IP through [ADDRESS_249575] dose of IP.  
Inform ation will be recorded on the Lactation Notificat ion Form  (refer to Appendix W) 
and submitted by  [CONTACT_208893] y within [ADDRESS_249576] igator’s knowledge of event.
Study  treatm ent will be discont inued if female subject breastfeeds during the study.
With the female subjects signed consent for release of mother and infant healt h 
inform ation, the invest igator will collect mother and infant healt h informat ion and 
complete the l actati on questi onnaire on any female subject who breastfeeds while taking 
IP through [ADDRESS_249577] igator ’s knowledge of the event . Thi s instructi on pertains to init ial SAE reports as well as 
any fo llow-up reports.
This requirement applies to all SAEs (regardless of relat ionship to apremilast ) that occur during 
the study  (from the time the subject signs informed consent until [ADDRESS_249578] ) and any SAE m ade known to the Investigator at any time following the protocol -
requi red reporti ng period or after end of study .Serious adverse events occurring prior to 
treatm ent (after signing the ICF) are to be collected/ recorded /reported.
Approved  
  
EDMS Doc. Number: [ADDRESS_249579]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 85 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249580] igator’s knowledge of the event by [CONTACT_208894] , in addit ion,ensuring the event is recorded on the CRF as well.
Where required by  [CONTACT_81689], the Invest igator is responsible for informing the Inst itutional 
Review Board/Ethics Co mmittee (IRB/EC) of the SAE and providing them wit h all relevant 
initial and fo llow-up informati on about the event. The Investigator must keep copi[INVESTIGATOR_208843] h [COMPANY_010] and the IRB/EC.
Serious Adverse Event Reporting transmitted via paper Serious Adverse Event Report 
Form: 
Facsimile tra nsmissio n of the Serious Adverse Event Report Form is the preferred 
method to transmit this informat ion. If facsimile is unavailable, the email method to 
transmit this informat ion is acceptable ( refer to Appendix U).    
In rare circumstances and in the absence of facsimile equipment, this form may be sent 
via email, or notificat ion by [CONTACT_9337] a copy  of the Seri ous Adverse 
Event Report Form in English language sent by  [CONTACT_208895] m ail or courier service.     
Initial notificati on via telephone does not replace the need for the invest igator to 
complete and sign the Serious Adverse Event Repor t Form wit hin the designated 
reporting t imeframes.  
Once the study  has ended, serious adverse events (regardless of causalit y) should be 
reported to [COMPANY_010] Global Patient Safet y if the investigator becomes aware of them and 
may use the paper Serious Advers e Event Report Form  (refer to Appendix U).    
10.5.1. Safety Queries
Queri es pertaining to SAEs will be communicated /generated from [COMPANY_010] Global Patient Safet y 
to the site via [COMPANY_010]’s safet y query  paper process or other appropriate method. Pertaining, to 
urgent queries (eg, missing causalit y assessment) , these may be handled by [CONTACT_648], facsimile or 
email.  
10.6. Expedited Reporting of Adverse Events
For the purpose sof regul atory  reporting, [COMPANY_010] Glo bal Pat ient Safet ywill determine the 
expectedness of events suspected of being related to apremilast , 
based on the investigator ’s
brochure.
In the [LOCATION_002], all s uspected unexpected serious adverse reactions (S[LOCATION_003]Rs) will be 
reported in an expedited manner in accordance wit h 21 CFR 312.32.
For countri es wi thin the European Economic Area, [COMPANY_010] or its authori zed representative will 
report in an expedited manner to R egulatory  Authori ties and Ethics Co mmittees concerned, 
S[LOCATION_003]Rs in accordance wit h Directive 2001/20/EC and the Detailed Guidance on collect ion, 
verification and presentation of adverse react ion reports arising from clinical trials on IPsfor 
human use (ENTR /CT3) and also in accordance with c ountry-specific requirements.
Approved  
  
EDMS Doc. Number: [ADDRESS_249581]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 86 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249582] igator of the fo llowing informat ion:
Any AE suspected of being related to the use of IP in this study  or in other studi es 
that is both seri ous and unexpected (ie, S[LOCATION_003]R);
Any finding fro m tests i n laboratory  animals that suggests a significant risk for 
human subjects including reports of mutagenicit y, teratogeni city, or carcinogenicit y.
Where required by  [CONTACT_81689], the Invest igator shall notify his/her IRB/EC promptly o f 
these new serious and unexpected AE(s) or significant risks to subjects.
The Investigator must keep copi[INVESTIGATOR_81646] y informat ion on file including 
correspondence with [COMPANY_010] and the IRB/EC. (See Section 14.[ADDRESS_249583] retention 
inform ation).
[COMPANY_010] Global Patient Safety Contact [CONTACT_7171] (fax/email):
For Am gen Gl obal Patient  Safet y contact [CONTACT_35666] n, please refer to y our si te’s  paper Seriou s 
Adverse Event Report Form, paper Pregnancy  Notificat ion Form and/or paper Lactation 
Notificat ion Form (Appendix V, Appendix U, Appendix W).
Approved  
  
EDMS Doc. Number: [ADDRESS_249584]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 87 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249585] from the IP
(apremilast ):
Adverse event(s)
Lack of efficacy
Non-compliance wi th study  drug
Withdrawal ofconsent
Study  terminat ionby [CONTACT_3211]
Lostto follow -up
Pregnancy
Death
Protocol deviat ion
Other (to be specified on the CRF)
Subjects have the right to withdraw from the study at any  time and for any reason. The reason for
discontinuat ion should be recorded i n the CRF and in the source documents.
When a subject discont inues from treatment, the Investigator willmake every  attem ptpossible to 
have the subject evaluated at the Early Terminat ion Visit within [ADDRESS_249586] from the
study :
Screen failure
Adverse event
Withdrawal by [CONTACT_1130]
Death
Lostto follow -up
Other (to be specified on the CRF)
The reason for study  discont inuat ion shoul d be recorded in the CRF and in the source 
docum ents.
Approved  
  
EDMS Doc. Number: [ADDRESS_249587]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 88 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249588] the 
responsible Clinical Research Physician/Medical Monitor or designee by [CONTACT_97535] e at the 
number(s) listed on the Emergency Contact [CONTACT_27723] (after title page).
In the unlikely  event that the Clinical Research Physician/Medical Monitor or designee cannot be 
reached, the invest igator may also contact [CONTACT_208896] 1 - 800-77-
AMGEN ([PHONE_4479]) . The representatives are responsible for obtaining y our call -back 
inform ation and contact[CONTACT_81694] -call / contract research organizat ion Medical Monitor, who will 
then contact y ou prom ptly.
12.2. Emergency Identification of Investigational Products
This is an open -label study; therefore, IP will be ident ified on the package labeling.
Approved  
  
EDMS Doc. Number: [ADDRESS_249589]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 89 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249590] igator abide by [CONTACT_27727], as described in ICH Guideline E6 and in accordance wit h the general 
ethical principles outlined in the Decla ration of Helsinki. The study  will receive approval  from 
an IRB/EC prior to commencement. The Invest igator will conduct all aspects of this study  in 
accordance with applicable nat ional, state, and local laws of the pertinent regulatory  authori ties.
13.2. Investi gator Responsibilities
Invest igator responsibilit ies are set out in the ICH Guideline for Good Clinical Practice and in 
the local regulat ions.[COMPANY_010] staff or an authorized representative will evaluate and approve all 
Invest igators who in turn will select t heir staff.
The Investigator should ensure that all persons assisting wit h the study  are adequately  informed 
about the protocol, amendments, study  treatm ents, as well as study -related duti es and funct ions, 
including obligat ions of confident iality of [COMPANY_010] inform ation. The Investigator should maintain 
a list of Sub -invest igators and other appropriately qualified persons to whom he or she has 
delegated si gnificant study -related duti es.
The Investigator is responsible for keepi[INVESTIGATOR_007] a record of all subjects who s ign an ICFand are 
screened for entry  into the study .Subjects who fail screening must have the reason(s) recorded in 
the subject ’s source docum ents.
The Investigator, or a designated member of the Investigator ’s staff, must be available during 
monitoring visits to review data, resolve queries and allow dire ct access to subject records (e g, 
medical records, office charts, hospi[INVESTIGATOR_1332], and study -related charts) for source data 
verification. The Invest igator must ensure timely and accurate completion o f CRFs and queries.
The informat ion contained in the protocol and amendments (with the except ion of the 
inform ation provi ded by  [CONTACT_208897]) is considered [COMPANY_010] confident ial 
inform ation.Only informat ion that is previously disclosed by [CONTACT_208898] a public registry  
website may be freely disclosed by [CONTACT_81699], or as outlined in the Clinical 
Trial Agreement. [COMPANY_010] protocol ,amendment and IB informat ion is not to be made publicly 
available (for example on the Investi gator ’s or their inst itution’s website) without express written 
approval  from [COMPANY_010] .Inform ation proposed for posting on the Invest igator ’s or their 
institution’s website must be submitted to [COMPANY_010] for review and approval, providing at least [ADDRESS_249591] and/or their caregiver as agreed by [CONTACT_1560] .
Approved  
  
EDMS Doc. Number: [ADDRESS_249592]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 90 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249593] and/or a subject ’slegal representative 
prior to any  study  related procedures.
Docum entati on that inform ed consent occurred prior to the study  subject ’s entry  into the study  
and of the informed consent process should be recorded in the study  subject ’s source documents 
including the date. The original ICF signed and dated by [CONTACT_208899] ’s entry  into the study , must be m aintained 
in the Invest igator ’s study  files and a copy  given to the study  subject. In addition, if a protocol is 
amended and i t impacts on the content of the informed c onsent, the ICF must be revised. Study  
subjects participat ing in the study  when the am ended protocol is implemented must be re -
consented with the revised versio n of the ICF. The revised ICF signed and dated by [CONTACT_208900] m ust be m aintained in the Invest igator ’s 
study  files and a copy  given to the study  subject.
13.4. Confidentiality
[COMPANY_010] affirms the subject ’s right to protection against invasio n of privacy  and to be in 
compliance with ICH and other l ocal regul ations (whichever i s most stringent). [COMPANY_010] requi res 
the Invest igator to permit [COMPANY_010] ’s representatives and, when necessary , representatives from 
regul atory  authori ties, to review and/or copy  any medical records relevant to t he study in 
accordance with local laws.
Shoul d direct access to m edical records require a waiver or authorization separate from the 
subject ’s signed ICF, it is the responsibilit y of the Invest igator to obtain such permissio n in 
writing fro m the appropri ateindividual.
13.5. Protocol Amendments
Any amendment to this protocol must be approved by  [CONTACT_208901]/Medical Monitor. Amendments will be submitted to the IRB/EC for written approval.
Written approval  must be obtained before implementat ion of the amended versio n occurs. The 
written si gned approval  from the IRB/EC shoul d specifically  reference the Investigator name, 
protocol  number, study  title and amendment number(s) that is applicable. Amendments that are 
administrative in nature do not require IRB/IEC approval but will be submitted to the IRB/IEC 
for inform ation purposes.
13.6. Institutional Review Board/Independent Ethics Committee Review 
and Approval
Before the start of the study , the study  protocol , ICF, and any  other appropri ate docum ents will 
be submitted to the IRB/EC with a cover letter or a form list ing the documents submitted, their 
dates of issue, and the site (or region or area of jurisdiction, as applicable) for which approval is 
sought. If applicable , the docum ents will  also be su bmitted to the authorit ies in accordance with 
local legal  requirements.
IP can only  be supplied to an Invest igator by [CONTACT_208902]. Number: [ADDRESS_249594]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 91 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249595] of the 
members of the IRB/EC and their occupation and qualificat ions. If the IRB/EC will not disclo se 
the names, occupations and qualificat ions of the committee members, it shoul d be asked to i ssue 
a statement confirming that the composit ion of the committee is in accordance wit h GCP. For 
example, the IRB General Assurance Number may be accepted as a subst itute for this list. 
Formal approval by [CONTACT_1201]/EC should ment ion the protocol t itle, number, amendment number 
(if applicable), study  site (or regi on or area of jurisdict ion, as applicable), and any other 
docum ents reviewed. It must ment ion the date on which the decisio n was made and must be 
officially signed by  a commi ttee member. Before the first subject is enrolled in the study , all 
ethical and l egal requi rements m ust be m et.
The IRB/EC and, if applicable, the authorities, must be informed of all subsequent protocol 
amendments in accordance wit h local legal requirements . Amendments must be evaluated to 
determine whether formal approval must be sought and whether the ICFshoul d also be revised.
The Investigator must keep a record of all co mmunicat ion with the IRB/EC and, if applicable, 
between a Coordinat ing Invest igator and the IRB/EC. This statement also applies to any  
communicat ion between the Invest igator (or Coordinat ing Investigator, if applicable) and 
regul atory  authori ties.
Any advertisements used to recruit subjects for the study  must be reviewed by [CONTACT_208903]/EC prior to use.  
13.7. Ongoing Information for Institutional Review Board/ Ethics 
Committee
If required by  [CONTACT_81704]/EC, the Investigator must submit to the IRB/EC:
Inform ation on serious or unexpected adverse events as soon as possible; 
Periodic reports on the progress of the study;
Deviat ions from  the protocol  or any thing that may  involve added risk to subjects.
13.8. Termination of the Study
[COMPANY_010] reserves the right to terminate this study  prem aturely  at any  time for reasonable medical 
or administrative reasons. Any premature discont inuat ion will be appropriately documented 
according to l ocal requi rements (e g, IRB/EC, regulatory  authori ties, etc).
In addit ion, the Invest igator or [COMPANY_010] has the right to discont inue a single site at any  time during 
the study  for medical  or administrative reasons such as:
Unsat isfactory  enro llment;
GCP nonco mpliance;
Inaccurate or inco mplete data collect ion;
Falsificat ion of records;
Failure to adhere to the study  protocol .
Approved  
  
EDMS Doc. Number: [ADDRESS_249596]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 92 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 202014. DATA HANDLING AND RE CORDKEEPI[INVESTIGATOR_1645]
14.1. Data/Documents
The Investigator must ensure that the records and documents pertaining to the conduct of the 
study  and the di stribut ion of the IPare complete, accurate, filed and retained. Examples of source 
docum ents include hospi[INVESTIGATOR_1097]; clinic and office charts; laboratory notes; memoranda; 
subject ’s diaries or eval uation checklists; dispensing records; recorded data from automated 
instrum ents; copi [INVESTIGATOR_208844]; 
microfiche; x -ray film and reports; and records kept at the pharmacy , and the l aboratori es, as 
well as copi[INVESTIGATOR_014] o f CRFs or CD -ROM.
14.2. Data Management
Data will be co llected via CRF and entered into the clinical database per [COMPANY_010] standard 
operating p rocedures ( SOPs ). Thesedata will be electronically  verified through use of 
programmed edit checks specified by [CONTACT_6098]. Discrepancies in the data will be brought 
to the attention of the clinical team, and invest igational site personnel, if neces sary.Reso lutions 
to these issues will be reflected in the database. An audi t trail  within the system will track all 
changes made to the data.
14.3. Record Retention
Essential documents must be retained by [CONTACT_208904] d 
in the clinical trial agreement . The I nvest igator must retain these documents for the time period 
described above or according to local laws or requirements, whichever is lo nger. Essent ial 
docum ents include, but are not limited to, the follo wing:
Signed ICFs for all  subjects;
Subject identificat ion code list, screening log (if applicable), and enrollment log;
Record of all co mmu nicati ons between the Invest igator and the IRB/EC;
Com position of  the IRB/EC;
Record of all co mmu nicati ons between the Invest igator, [COMPANY_010] , and thei r authori zed 
representative(s);
List of Sub -invest igators and other appropriately qualified persons to whom the 
Invest igator has delegated significant study -related duti es, together wi th their roles in the 
study , curri culum  vitae, and their si gnatures;
Copi [INVESTIGATOR_208845];
IP accoun tabilit y records;
Record of any body  fluids or ti ssue samples retained;
All other source documents (subject records, hospi[INVESTIGATOR_1097], laboratory  records, etc.); 
All other docum ents as listed in Secti on 8 of the ICH consolidated guideline on GCP 
(Essent ial Docum ents for the Conduct of a Clinical Trial).
Approved  
  
EDMS Doc. Number: [ADDRESS_249597]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 93 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249598] notify  [COMPANY_010] if he/she wishes to assign the essent ial docum ents to 
someone else, remove them to anot her locat ion or is unable to retain them for a specified period.
The Investigator must obtain approval in writ ing from [COMPANY_010] prior to destruction of any records. 
If the Investigator is unable to meet this obligat ion, the Invest igator must ask [COMPANY_010] for 
permission to make alternat ive arrangements. Details of these arrangements should be 
docum ented. 
All study  docum ents shoul d be made available if required by [CONTACT_208905] h authorities. 
Invest igator or institution shoul d take m easures to prevent accidental o r premature destruction of 
these documents.
Approved  
  
EDMS Doc. Number: [ADDRESS_249599]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 94 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249600] igator and the staff at a study  
initiation visit and/or at an Invest igators ’Meeting. Prior to enrolling subjects into the study , an
[COMPANY_010] representative will review the protocol, CRFs, procedures for obtaining informed 
consent, record keepi[INVESTIGATOR_007], and reporting of AEs/SAEs with the Invest igator. Monitoring will 
include on -site visi ts with the Investi gator and his/her staff as well as any  appropri ate 
communicat ions by [CONTACT_2319], email, fax, or telephone. During m onitoring visi ts, the f acilities, IP
storage area, CRFs, subject ’s source documents, and all o ther study  docum entati on will be 
inspected/reviewed by [CONTACT_208906] h the Study  Moni toring Pl an.
Accuracy  will be checked by [CONTACT_81706] i s a di rect com parison of 
the entries made onto the CRFs agai nst the appropri ate source documentation. Any result ing 
discrepancies will be reviewed with the Investigator and/or his/her staff. Any necessary  
correcti ons will be made direct ly to the CRFs or via queries by [CONTACT_81707]/or his/her 
staff. Monitori ng procedures require that informed consents, adherence to inclusio n/exclusion 
criteria and docum entati on of  SAEs and their proper recording be verified. Addit ional 
monitoring act ivities may be outlined in a study -specific m onitoring pl an.
15.2. Audits and Inspe ctions
In addit ion to the routine monitoring procedures, a Qualit y, Com pliance & Audit, Learning & 
Perform ance unit exists wi thin [COMPANY_010] .  Representatives of this unit will conduct audits of 
clinical research act ivities in accordance with [COMPANY_010] SOPs to evaluate compliance wit h Good 
Clinical Practice guidelines and regulat ions.
The Investigator is required to permit direct access to the facilit ies where the study  took place, 
source documents, CRFs and applicable supporting records of study  subject parti cipation for 
audits and inspect ions by [CONTACT_1744]/ ECs, regul atory  authori ties (egg,Food and Drug Administration 
[FDA ], European Medicines Agency [ EMA ], Health Canada) and com pany authorized 
representatives. The Invest igator should make every effort to be available for the audi ts and/or 
inspections. If the Investigator is contact[CONTACT_81709], 
he/she shoul d contact [CONTACT_208907].
15.3. Product Complaint
A product complaint (PC) is any written, electronic, or oral co mmu nicat ion that alleges 
deficiencies related to the identit y, qualit y, durability , reliabilit y, safet y, effect iveness, or 
perform ance of a drug, combination product or device after they  are rel eased for di stributi on to 
market or clinic by [CONTACT_208908], and partners with who m [COMPANY_010] 
manufactures the material.  This includes any drugs, devices, or combination products 
provi sioned and/or repackaged/modified by [CONTACT_11337].  Drugs or devices include invest igational 
product.  Any product complaints associated w ith an invest igational product, or non -
Approved  
  
EDMS Doc. Number: [ADDRESS_249601]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 95 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249602] Complaint to [COMPANY_010]:  
Com plete [COMPANY_010]’s paper Clinical Product Complaint Intake Form and email the form to the 
following [COMPANY_010] email address: 
Clinical -Complaint -[EMAIL_4072]
Approved  
  
EDMS Doc. Number: [ADDRESS_249603]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 96 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249604], presentatio n 
and/or publicat ion development.
Approved  
  
EDMS Doc. Number: [ADDRESS_249605]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 97 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249606] functional status and structural progression. Ann Rheum 
Dis. 2017;76(2):418 -21.
Aletaha D, Smo len JS. The definit ion and m easurement of disease modificat ion in inflammatory  
rheumat ic diseases. Rheum Dis Clin North Am. 2006;32(1):9 -44, vii.
Altho ff CE, Appel H, Rudwaleit M, Sieper J, Eshed I, Hamm B, et al. Who le-body  MRI as a 
new screening tool for detecting axial and peripheral manifestations of spondyloarthrit is. Ann 
Rheum  Dis. 2007;66(7):[ADDRESS_249607] ive bio marker for clinical response to 
biologics in rheumat oid arthri tis? Ann Rheum Dis. 2017;76(11):e45.
Braun J, Baraliakos X, Golder W, Hermann KG, List ing J, Brandt J, et al. Analyzing chroni c 
spi[INVESTIGATOR_208846]: a systematic co mpar ison of convent ional x rays with 
magnet ic resonance imagi ng using established and new scoring systems. Ann Rheum Dis. 
2004;63(9):[ADDRESS_249608] Health Assessment Questionnaire: a review of its history , issues, 
progress, and documentation. J Rheumatol. 2003;30(1):[ADDRESS_249609] ivity 
in ankylo sing spondylit is: is a combinat ion of variables (Bath Ankylosing Spondylit is Disease 
Activity Index) an appropriate instrument? Rheumatology  (Oxford). 1999;38(9):[ADDRESS_249610] ional 
Assessment of Chronic Illness Therapy Fat igue Scale relative to other instrumentation in patients 
with rheumatoi d arthri tis. J Rheumatol. 2005;32(5):[ADDRESS_249611] ional assessment of Chronic Illness 
Therapy -Fatigue Scale is valid in pat ients with psori atic arthrit is. Ann Rheum Dis. 
2007;66(7):[ADDRESS_249612]. 2012;89:[ADDRESS_249613] 11. J Rheumatol. 2014;41(4):782-91.
Coates LC, Hodgson R, Conaghan PG, Freeston JE. MRI and ultrasonography  for diagnosi s and 
monitoring of psori atic arthritis. Best Pract Res Clin Rheumatol. 2012;26(6):[ADDRESS_249614] in pat ients with psor iatic arthrit is: results of 
the PALACE 2 trial. J Rheumatol. 2016;43(9):1724-34.
Edwards CJ, Blanco FJ, Crowley  J, Bi rbara CA, Jaworski J, Aelio n J, et al . Apremilast, an oral 
phosphodiesterase 4 inhibitor, in patients with psoriat ic arthrit is and current skin invo lvement: a 
phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016;75(6):1065 -73.
Approved  
  
EDMS Doc. Number: [ADDRESS_249615]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 98 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249616] D, Goldsmith C, et al. American Co llege 
of Rheumatol ogy. Preliminary  defini tion of  improvement i n rheumatoid arthrit is. Arthrit is 
Rheum . 1995;38(6):727 -35.
Fredri ksson T, Pettersson U. Severe psoriasis --oral therapy  with a new retino id. Dermatologica. 
1978;157(4):238 -44.
Fries JF, Spi[INVESTIGATOR_7316] P, Kraines RG, Holman HR. Measurement of patient outcome in arth ritis. 
Arthri tis Rheum. 1980;23(2):137-45.
Gladman DD. Mortalit y in psori atic arthritis. Clin Exp Rheumatol. 2008;26([ADDRESS_249617] 51):S62 -S5.
Gladman DD, Antoni  C, Mease P, Cl egg DO, Nash P. Psoriat ic arthrit is: epi[INVESTIGATOR_145975], clinical  
features, course, and outc ome. Ann Rheum  Dis. 2005;[ADDRESS_249618]  2):ii14 -ii7.
Gladman DD, Farewell VT. The role of HLA ant igens as indicators of disease progression in 
psori atic arthrit is. Mult ivariate relative risk model. Arthritis Rheum. 1995a;38(6):845-50.
Gladman DD, Farewell VT, Na deau C. Clinical indicators of progression in psoriat ic arthrit is: 
multivariate relat ive risk model. J Rheumatol. 1995b;22(4):[ADDRESS_249619], Cook RJ, Maksymowych WP, Braun J, Davis JC, et al. Internat ional 
spondylo arthri tis interobserver reli ability exercise --the INSPI[INVESTIGATOR_208847] : II. Assessment of 
peripheral  joints, enthesit is, and dact ylitis. J Rheumatol. 2007;34(8):[ADDRESS_249620] Psoriat ic Arthrit is Magnet ic Resonance Imaging Score (PsAMRIS) for the hand and 
foot in a rando mized placebo -controlled trial. J Rheumatol. 2015;42(12):2473-9.
Gossec L, de Wit M, Kiltz U, Braun J, Kalyo ncu U, Scrivo R, et al. A pat ient-derived and 
patient-reported outcome mea sure for assessing psoriat ic arthrit is: elaboration and preliminary 
validat ion of the Psoriat ic Arthri tis Impact of  Disease (PsAID) quest ionnaire, a 13 -country  
EULAR init iative. Ann Rheum Dis. 2014;73(6):1012 -9.
Healy PJ, Groves C, Chandramo han M, Helliwel l PS. MRI changes in psoriatic dactylit is--extent 
of pathol ogy, relationship to tenderness and correlation with clinical indices. Rheumatology  
(Oxford). 2008a;47(1):92- 5.
Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriat ic arthrit is: assessm ent of exist ing 
measures and development of an instrument specific to psoriat ic arthrit is. Arthrit is Rheum. 
2008b;59(5):[ADDRESS_249621], Shah I, Turner DE. Development of an 
assessment tool for dactylit is in pat ients with psoriati c arthri tis. J Rheumatol . 2005;32(9):1745-
50.
Helliwell PS, Ruderman EM. Natural history , prognosis, and socioeconomic aspects of psoriat ic 
arthri tis. Rheum  Dis Clin North Am. 2015;41(4):581-91.
Herm ann KG, Alt hoff CE, Schneider U, Zuhlsdorf S, Lembcke A, Hamm B, et al. Spi[INVESTIGATOR_208848]: co mpar ison of MR imaging and radiographic 
appearances. Radiographics. 2005;25(3):559- 69; discussio n 69-70.
Approved  
  
EDMS Doc. Number: [ADDRESS_249622]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 99 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020Herm ann KG, Eshed I, Bollow M. Bildgebung der enthesit is: ein neues feld für den radio logen? 
[Imaging of enthesit is: a new field for the radio logist?]. Rofo. 2006;178(6):578 -89. German.
Hjermstad MJ, Fayers PM, Haugen DF, Caraceni A, Hanks GW, Loge JH, et al. Studies 
comparing numerical rating scales, verbal rating scales, and visual analogue scales for 
assessment of pain intensit y in adults: a system atic literature review. J Pain Symptom Manage. 
2011;41(6):[ADDRESS_249623], Sengupta R, Night ingale A, Lindsay M, Korendowy ch E, Robinson G, et al. Axial 
Disease in Psori atic Arthri tis study : defining the clinical and radiographic phenoty pe of  psori atic 
spondylo arthri tis. Ann Rheum Dis. 2017;76(4):[ADDRESS_249624] Filter: Data from the 
Osteoarthrit is Init iative. J Rheumatol. 2017;44: [ADDRESS_249625] response through 5 y ears of treatm ent of subjects with psoriatic arthrit is 
[abstract]. Presented at the Annual Meet ing of the American Academy of Dermatology ; 2018 
February  16-20; San Diego, CA.
Kavanaugh A, Meas e PJ, Gom ez-Reino JJ, Adebajo AO, Wo llenhaupt J, Gladman DD, et al. 
Treatment of psoriat ic arthrit is in a phase [ADDRESS_249626], 
an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73(6):[ADDRESS_249627] M. Inflammatory and structural changes in 
vertebral bodies and posterior elements of the spi[INVESTIGATOR_208849]: construct validit y, 
responsiv eness and di scriminatory  abilit y of the anatomy -based CANDEN scoring system in a 
rando mised placebo -controlled trial . RMD Open 2018;4:e000624. doi:10.1136/rmdopen -2017-
000624
Kruit hof E, Baeten D, De Ry cke L, Vandooren B, Foell D, Roth J, et al. Synovial h istopathol ogy 
of psori atic arthrit is, both oligo -and polyart icular, resembles spondyloarthropathy  more than i t 
does rheumatoid arthritis. Arthrit is Res Ther. 2005;7(3):R569 -
80.
Mager AK, Alt hoff CE, Sieper J, Hamm B, Hermann KG. Role of who le-body  magnet ic 
resonance imaging in diagnosing early spondyloarthrit is. Eur J Radio l. 2009;71(2):[ADDRESS_249628], Salonen D, et al. Spondyloarthrit is research Consortium o f 
Canada magnetic resonance imaging index for assessment of sacroiliac jo int inflammat ion in 
ankylo sing spondylit is. Arthrit is Rheum 2005;53:703-9.
Maksymowych WP, Mallo n C, Morrow S, Shojania K, Olszynski WP, Wong RL, et al. 
Development and validation o f the Spondyloarthritis Research Consortium o f Canada 
(SPARCC) Enthesit is Index. Ann Rheum Dis. 2009;68(6):948-53.
Maksymowych WP, Pi[INVESTIGATOR_7929] M Budak MJ, Gracey  D, Lambert RG, McDougall D, Pi[INVESTIGATOR_208850] M, 
Rennie WJ, Wichuk S, Winn N, Jaremko JL. Development and preliminary validat ion of a 
digital overlay -based learning module for semiquant itative ev aluat ion of magnet ic resonance 
imaging lesio ns in osteoarthrit is of the hip. J Rheumatol. 2016 ;43: 232 -8.
Approved  
  
EDMS Doc. Number: [ADDRESS_249629]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 100 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020Mathew AJ, Coates LC, Danda D, Conaghan PG. Psoriat ic arthritis: lessons from imaging 
studi es and implicat ions for therapy . Expert Rev Clin Immunol . 2017;13(2):133 -42.
Meaney JF, Fagan A. Who le-body  MR imaging in a m ultimodality worl d: current applicat ions, 
limitations, and future potential for comprehensive musculoskeletal imaging. Semin 
Musculoskelet Radiol. 2010;14(1):14-21.
Mease PJ, Ganguly R, Wanke L, Yu E, Singh A. How much improvement in funct ional status is 
considered important by  [CONTACT_208909]: applying the outcome measures in 
rheumatoi d arthri tis clinical trials (OMERACT) group guidelines [abstract]. Ann Rheum Dis. 
2004;[ADDRESS_249630]  1):Abstract SAT0015 .
Mease PJ, Gladman DD, Gomez -Reino JJ, Hall S, Kavanaugh A, Lespessailles E, et al. 
Consistent safet y profile wi th up to [ADDRESS_249631] treatment: analysis o f data from  1,493 
subjects wi th psori atic arthrit is in 3 la rge, phase III, l ong-term studi es [abstract]. Arthrit is 
Rheumatol. 2017;[ADDRESS_249632] 10): Abstract 604.
Nash P, Ohson K, Walsh J, Delev N, Nguy en D, Teng L, et al. Early and sustained efficacy  with 
apremilast m onotherapy  in biological -naive pat ients with psoria tic arthri tis: a phase IIIB, 
rando mised controlled trial (ACTIVE). Ann Rheum Dis. 2018 ;77(5):[ADDRESS_249633] M, Eshed I, Althoff CE, Poggenborg RP, Diekho ff T, Krabbe S, et al. Whole -body  
magnet ic resonance imaging in inflammatory  arthri tis: systematic literature revi ew and first steps 
toward standardizat ion and an OMERACT scoring sy stem . J Rheumatol . 2017;44(11):1699-705.
Ostergaard M, McQueen F, Wiell C, Bird P, Boy esen P, Ejbjerg B, et al. The OMERACT 
psori atic arthrit is magnet ic resonance imaging sco ring system (PsAMRIS): definit ions of key  
pathol ogies, suggested MRI sequences, and preliminary  scoring system  for PsA hands. J 
Rheumatol. 2009;36(8):[ADDRESS_249634] ivity state -a cross -sectional study  correlat ing conventional MRI and clinical 
composite measures [abstract 1042]. Arthrit is Rheum. 2012;64([ADDRESS_249635]):S451 -S2.
Poggenborg RP, Eshed I, Ostergaard M, Sorensen IJ, Moller JM, Madsen OR, et al. Enthesit is in 
patients wi th psoriatic arthrit is, axial spondylo arthri tis and h ealthy subjects assessed by 'head -to-
toe' who le-body  MRI and clinical examinat ion. Ann Rheum Dis. 2015a;74(5):823 -9.
Poggenborg RP, Pedersen SJ, Eshed I, Sorensen IJ, Moller JM, Madsen OR, et al. Head -to-toe 
whole-body  MRI in psori atic arthritis, axial spo ndyloarthrit is and healt hy subjects: first steps 
towards gl obal inflammat ion and damage scores of peripheral and axial jo ints. Rheumatol ogy 
(Oxford). 2015b;54(6):[ADDRESS_249636] M. Magnetic resonance imaging for
diagnosing, m onitoring and prognosticat ion in psoriat ic arthrit is. Clin Exp Rheumatol. 
2015c;33([ADDRESS_249637] 93):S66-
9.
Poggenborg RP, Wiell C, Boyesen P, Boonen A, Bird P, Pedersen SJ, et al. No overall damage 
progression despi[INVESTIGATOR_208851] -treated psori atic arthrit is pat ients: 
Approved  
  

EDMS Doc. Number: [ADDRESS_249638]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 101 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249639] igator -initiated 48 -week comparative magnet ic resonance imaging, 
computed tom ography  and radi ography  trial. Rheumatol ogy (Oxford). 2014;53(4):[ADDRESS_249640] ivity. Rheumatol ogy (Oxford). 2006;45(7):885 -9.
Quei ro-Silva R, Torre -Alonso JC, Tinture -Eguren T, Lopez -Lagunas I. A polyart icular onset 
predi cts erosive and deforming disease in psoriat ic arthri tis. Ann Rheum Dis. 2003;62(1):[ADDRESS_249641] ivity Impairment Questi onnai re in ankylo sing 
spondylit is. Rheumatol ogy (Oxford). 2010;49(4):[ADDRESS_249642] worse qualit y of life than those with psoriasis alo ne. Rheumatology  
(Oxford). 2012;51(3):[ADDRESS_249643], 
an oral phosphodiesterase 4 inhibitor, on circulat ing levels of inflammatory  biomarkers in 
patients wi th psoriatic arthrit is: substudy  resul ts from a phase III, randomized, placebo-
contro lled trial (PALACE 1). J Immuno l Res. 2015;2015:906349. DOI: 10.1155/2015/ 906349.
Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos -Vargas R, et al. The Assessment 
of Spondylo Arthri tis internati onal Soci ety (ASAS) handbook: a guide to assess spondyloarthrit is. 
Ann Rheum Dis. 2009;[ADDRESS_249644] 2:ii1
-44.
Sokoll KB, Helliwell PS. Comparison of disabilit y and qualit y of life in rheumatoid and psoriat ic 
arthri tis. J Rheumatol . 2001;28(8):1842-6.
Tan YM, Ostergaard M, Doyle A, Dalbeth N, Lobo M, Reeves Q, et al . MRI bone oedema scores 
are higher in the arthrit is mutilans form of psoriat ic arthrit is and correlate with high radiographic 
scores for jo int damage. Arthrit is Res Ther. 2009;11(1):R2.
Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Miel ants H. Cl assificat ion criteria 
for psori atic arthritis: development of new criteria fro m a large internati onal study . Arthri tis 
Rheum . 2006;54(8):2665-73.
Ware JE, Jr., Sherbourne CD. The MOS 36- item short -form health survey  (SF-36). I. Conceptual 
framewo rk and item select ion. Med Care. 1992;30(6):473- 83.
Weber U, Kissling RO, Hodler J. Advances in musculoskeletal imaging and their clinical ut ility 
in the early diagnosis of spondyloarthrit is. Curr Rheumatol Rep. 2007;9(5):353 -60.
Weber U, Maksymowych WP. H ow does imaging help the clinician in the evaluat ion and 
management of spondylo arthri tis? Skeletal  Radi ol. 2008;37(6):[ADDRESS_249645] convent ional mag netic resonance imaging for scoring acute 
inflammatory  lesions in the sacroiliac jo ints of pat ients with spondylarthrit is. Arthrit is Rheum. 
2009;61(7):893 -9.
Weckbach S, Schewe S, Michaely  HJ, Steffinger D, Rei ser MF, Gl aser C. Who le-body  MR 
imaging in pso riatic arthritis: addit ional value for therapeut ic decisio n making. Eur J Radio l. 
2011;77(1):149 -55.
Approved  
  
EDMS Doc. Number: [ADDRESS_249646]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 102 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249647] -naive psoriat ic arthrit is pat ients: results of a p hase 3 randomized, 
controlled trial (PALACE 4) [abstract L4]. Arthrit is Rheum. 2013;65(10 Suppl12):[ADDRESS_249648] P, Nguyen D, Paris M, et al. Long -tern (4 -year) efficacy 
and safet y of apremilast m onotherapy  in DMARD- naive su bjects with act ive psoriatic arthrit is 
[abstract]. Arthrit is Rheumatol. 2017;[ADDRESS_249649] 10:Abstract 601.
World Heal th Organizat ion. Di arrhoea. [Internet]. Available from
http://www.who.int/topi[INVESTIGATOR_1102]/diarrhoea/en/. Accessed November 27, 2013.
Approved  
  
EDMS Doc. Number: [ADDRESS_249650]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 103 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 202018. APPENDICES
Approved  
  
EDMS Doc. Number: [ADDRESS_249651]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 104 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020APPENDIX A.TABL E OF ABBREVIATIONS
Table 15: Abbreviations and Specialist Terms
Abbreviation or 
Specialist Term Explanation
ACR Amer ican College of Rheumatology
ADL Activity of daily life
AE Adverse event
ALT Alanine aminotransferase
APR Apremilast
AST Aspartate aminotransferase
ATC Anatomical Therapeutic Chemical
β-hCG Serum beta huma n chorionic gonadotropin
BASDAI Bath Ankylosing Spondylitis Disease Activity Index
BID Twice per day
BME Bone marrow edema
BSA Body surface area
BUN Blood urea nitrogen
CASPAR Classification Criteria for Psoriatic Arthritis
CBC Complete blood count
c-DAPSA Clinical Disease Activity Index for Psoriatic Arthritis
CI Confidence interval
CRF Case report form
CRP C-reactive protein
csDMARD Conventional synthetic disease -modifying antirheumatic drug
DAS Disease Activity Score
DEMRIQ Dynamic Contrast -enhanced MRI Quantification
DMARD Disease -modifying antirheumatic drug
EC Ethics Committee
EDC Electronic data capture
EE Early escape
EULAR European League Against Rheumatism
Approved  
  

EDMS Doc. Number: [ADDRESS_249652]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 105 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020Table 15: Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term Explanation
FAS Full Analysis Set
FCBP Fema le of childbearing potential
FDA Food and Drug Administration
GCP Good Clinical Practice
GEI Gladma n Enthesitis Index
GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis
HAQ -DI Health Assessment Questionnaire –Disability Index
HDPE High-density p olyethylene
HIMRISS Hip Inflammation Magnetic Resonance Imaging Scoring System
HLA Hum an leukocyte antigen
IA Intra -articular
IB Investigator’s brochure
ICF Infor med consent form
ICH International Co uncil for Harm onisation
IL Interleukin
IM Intramuscular
IP Investigational product
IRB Institutional Review Board
IWRS Interactive web response system
JAK Janus kinase
KIMRISS Knee Inflammation Magnetic Resonance Imaging Scoring System
LDI Leeds Dactylitis Index
LEF Leflunomide 
LEI Leeds Enthesitis Index
LOCF Last observation carried forward
L/R Left/right
MCID Minima l clinically important difference
MedDRA Medical Dictionary for Regulatory Activities
Approved  
  

EDMS Doc. Number: [ADDRESS_249653]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 106 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020Table 15: Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term Explanation
MRI Magnetic resonance imaging
MTX Methotrexate
NRI Non-responder imputation
NRS Numeric rating scale
NSAID Nonsteroidal anti -inflammatory drug
OMERACT Outcome Measures in Rhe umatology
PASDAS Psoriatic Arthritis Disease Activity Score
PASI Psoriasis Area and Severity Index
PBO Placebo
PDE Phosphodiesterase enzyme
PP Per protocol
PC Product Complaint
PsA Psoriatic arthritis
PsAID -[ADDRESS_249654] operating procedure
SpA Spondyloarthropathy
SPARCC Spondyloarthritis Research Consortium of Canada
Approved  
  

EDMS Doc. Number: [ADDRESS_249655]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 107 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020Table 15: Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term Explanation
SRO Subject -reported outcomes
SSC Scientific steering committee
SSZ Sulfasalazine
S[LOCATION_003]R Suspected unexpected serious adverse reaction
TB Tuberculosis
TEAE Treatment -emer gent adverse event
TJC Tender joint count
TNF Tumor necrosis factor
VAS Visual analog scale
vs versus
WBC White blood cell 
WB-MRI Whole -body m agnetic resonance imaging
WHO World Health Organization
Approved  
  

EDMS Doc. Number: [ADDRESS_249656]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 108 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020APPENDIX B.THE CLASSIFICATION CRITE RIA FOR PSORIATIC 
ARTHRITIS (CASPAR) CRITERIA
To m eet the CASPAR1criteria , a pati ent m ust have inflammatory  articular di sease (j oint, spi[INVESTIGATOR_050], 
or entheseal) w ith ≥ 3 points fro m the following 5 categories:
1.Evidence of current psori asis, a personal history  of psori asis, or a family  history  of 
psori asis.
Current psoriasis is defined as psoriat ic skin or scalp disease present today  as judged 
by a rheumatol ogist or dermatologist.2
A personal history  of psori asis is defined as a history  of psori asis that m ay be 
obtained fro m a pati ent, f amily  physician, dermatologist, rheumatologist, or other 
qualified health care provider.
A family history  of psori asis is defined a s a history of psori asis in a first - or second-
degree relative according to patient report.
2.Typi[INVESTIGATOR_208852], pi[INVESTIGATOR_22940], and hyperkeratosis 
observed on current physical examinat ion.
3.A negat ive test result for the presenc e of rheumatoid factor by  [CONTACT_208910] l atex 
but preferably  by [CONTACT_28745] -linked immunosorbent assay or nephelo metry , according to the 
local laboratory  reference range.
4.Either current dactylit is, defined as swelling of an ent ire digit, or a hi story  of dactylitis 
recorded by  a rheumatol ogist.
5.Radiographic evidence of juxta -articular new bone format ion, appearing as ill -defined 
ossification near jo int margins (but excluding osteophy te formation) on plain radiographs 
of the hand or foot.
                                               
1The CASPAR criteria have specificity of 98.7% and sensitivity of 91.4%.
2Current psoriasis is assigned a score of 2; all other features are assigned a score of 1 
(from Taylor, 2006 ).
Approved  
  
EDMS Doc. Number: [ADDRESS_249657]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 109 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020
Approved  
  

EDMS Doc. Number: [ADDRESS_249658]
Protocol  CC-[ZIP_CODE]- PSA-014 [COMPANY_010] Inc.
Confident ial and Propri etary 110 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249659] ’s Assessment of Pain
Subject ’s Global Assessment of Di sease Act ivity
Evaluator ’s Global Assessment of Disease Act ivity
Adapted from Felson, 1995.
Pain As Bad As 
You Can Imagine
Approved  
  
EDMS Doc. Number: [ADDRESS_249660]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 111 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020APPENDIX E.DISABILITY INDEX OF THE HEALTH ASSESSMEN T 
QUESTIONNAIRE (HAQ -DI)
In this section we are interested in learning how your illness affects your ability to function in daily life. Please 
feel free to add any comments on the back of this page.
Please check the response which best describes your usual abilities OVER THE PAST WEEK:
DRESSING & GROOMING
Are you able to:Without
ANY
DifficultyWith
SOME
DifficultyWith
MUCH
Diffic ultyUNABLE
To Do
-Dress yourself, including tying shoelaces and 
doing buttons?_____ _____ _____ _____
-Shampoo your hair? _____ _____ _____ _____
ARISING
Are you able to:
-Stand up from a straight chair? _____ _____ _____ _____
-Get in and out of bed? _____ _____ _____ _____
EATING
Are you able to:
-Cut your meat? _____ _____ _____ _____
-Lift a full cup or glass to your mouth? _____ _____ _____ _____
-Open a new milk carton? _____ _____ _____ _____
WALKING
Are you able to:
-Walk outdoors on flat ground? _____ _____ _____ _____
-Climb up five steps? _____ _____ _____ _____
Please check any AIDS OR DEVICES that you usually use for any of these activities:
_____ Cane _____ Devices used for dressing (button hook, zipper 
pull, long handled shoe horn, etc.)
_____ Walker _____ Built up or special utensils
_____ Crutches _____ Special or built up chair
_____ Wheelchair _____ Other (Specify:______________________)
Please check any categories for which you usually need HELP FROM ANOTHER PERSON:
_____ Dressing and Grooming _____ Eating
_____ Arising _____ Walking
Approved  
  
EDMS Doc. Number: [ADDRESS_249661]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 112 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249662] 
WEEK:
HYGIENE
Are y ou able to:Without
ANY
Difficult yWith
SOME
Difficult yWith
MUCH
Difficult yUNABLE
To Do
-Wash and dry  your body? _____ _____ _____ _____
-Take a tub bath? _____ _____ _____ _____
-Get on and off the toilet? _____ _____ _____ _____
REACH
Are y ou able to:
- Reach and get down a 5- pound object
(such as a bag of sugar) from just above 
your head?_____ _____ _____ _____
-Bend down to pi[INVESTIGATOR_208853] m the 
floor?_____ _____ _____ _____
GRIP
Are y ou able to:
-Open car doors? _____ _____ _____ _____
-Open jars which have been previously 
opened?_____ _____ _____ _____
-Turn faucets on and off? _____ _____ _____ _____
ACTIVITIES
Are y ou able to:
-Run errands and shop? _____ _____ _____ _____
-Get in and out of a car? _____ _____ _____ _____
-Do chores such as vacuuming or 
yardwork?_____ _____ _____ _____
Please check any AIDS OR DEVICES that you usually use for any of these activities:
Approved  
  
EDMS Doc. Number: [ADDRESS_249663]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 113 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020_____ Raised toilet seat _____ Bathtub bar
_____ Bathtub seat _____ Long -handled appliances for reach
_____ Jar opener (for jars _____ Long -handled appliances in bathroom
previously opened) _____ Other (Specify: 
______________________)
Please check any categories for which you usually need HELP FROM ANOTHER 
PERSON:
_____ Hygiene _____ Grippi[INVESTIGATOR_36123]
_____ Reach _____ Errands and chores
We are also interested in learning whether or not you are affected by  [CONTACT_208911] y our 
illness .
How much pain have you h ad because of your illness IN THE PAST WEEK:
PLACE A VERTICAL (I)MARK ON THE LINE TO INDICATE THE SEVERIT Y OF THE PAIN .
NO
PAIN
0______________________________________________ _____________SEVERE
PAIN
100
Source :Bruce, [ADDRESS_249664] -RA (MAY99 -Phase 31) –English, [LOCATION_003]
HAQ -DI -[LOCATION_002]/English -Mapi.
HAQ -DI_AU1.0 -eng-USori.doc
Approved  
  
EDMS Doc. Number: [ADDRESS_249665]
Protocol  CC-[ZIP_CODE]- PSA-014 [COMPANY_010] Inc.
Confident ial and Propri etary 114 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020APPENDIX F.LEEDS ENTHESITIS INDEX (LEI)
Leeds Enthesit is Index (Healy , 2008b ):
Enthesit is 
is measured by [CONTACT_208912] j oints.Tenderness (yes/no) will 
be assessed at 6 sites of tendon insert ions (0 -6) as depi[INVESTIGATOR_48393]: 
Lateral  epi[INVESTIGATOR_100757], l eft and ri ght
Medial femoral condyle, left and right
Achilles tendon insert ion, left and right
Tenderness on physical examinat ion is recorded as either present (1) or absent (0) fo r each of the 
6 sites, for an overall score range of 0 to 6. Higher count represents a greater enthesit is burden.
Approved  
  
EDMS Doc. Number: [ADDRESS_249666]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 115 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020APPENDIX G.THE SPONDYLOARTHRITI S RESEARCH 
CONS ORTIUM OF CANADA ( SPARCC )ENTHESITIS 
INDEX
Enthes eal sites examined include:
Medial epi[INVESTIGATOR_100757] (left/right [L/R])
Lateral  epi[INVESTIGATOR_100757] (L/R)
Supraspi[INVESTIGATOR_208832] y of hum erus (L/R)
Greater trochanter (L/R)
Quadri ceps inserti on into superi or border of patella (L/R)
Patellar ligament insert ion into inferior pol e of patella or tibial tubercle (L/R)
Achilles tendon insert ion into cal caneum (L/R)
Plantar fascia insertion into calcaneum (L/R)
Tenderness on examinat ion is recorded as either present (1) or absent (0) for each of the 16 sites, 
for anoverall score range of 0 –16. Higher count represents greater enthesit is burden.
The video describing the approach to the physical exam can be seen at www.carearthrit is.com 
under “Physician Tools”.
Source: Maksymowych, 2009 .
Approved  
  
EDMS Doc. Number: [ADDRESS_249667]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 116 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020APPENDIX H.LEEDS DACTYLITIS IND EX(LDI)
The LDI (Healy, 2008a ; Helliwell, 2005 )measures the ratio of the circumference of the affec ted 
digit to the ci rcumference of the digit on the opposite hand or foot, using a minimum difference 
of 10% to define a dactylit ic digit. The ratio of circumference is mult iplied by a tenderness score.
Affected fingers are marked on a diagram displaying fingers and toes. Circumferences o f the 
affected and contralateral fingers are then measured around the proximal phalanx, as close as 
possible to the web space, using eit her a m easuring tape or a pre -calibrated l oop. 
The clinician then squeezes the affected fingers with moderate pressure and documents the 
patient’s response: 0 = no tenderness, 1 = tender, 2 = tender and winces, and 3 = tender and 
withdraws. 
Approved  
  
EDMS Doc. Number: [ADDRESS_249668]
Protocol  CC-[ZIP_CODE]- PSA-014 [COMPANY_010] Inc.
Confident ial and Propri etary 117 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020APPENDIX H. LEEDS DACTYLITIS INDEX (LDI) (CONT INUED)
The rati o of circumference between an affected finger and the contralateral unaffected finger is 
recorded. If both sides are affected, the circumference o f the affected finger is co mpared to 
norm ative data supplied in a table. The tenderness score ( 0-3) for a finger with dactylit is 
is 
recorded, and a total score is generated for each finger. If mult iple fingers are affected, each 
score i s added together to produce a total for the patient.
In addi tion, as part of the LDI, number of affected digits wil l be evaluated. Each digit on the 
hands and feet will be rated as zero for no dactylit is or 1 for dactylit is present. The dactylit is 
score i s the sum o f the individual scores for each digit.
Approved  
  
EDMS Doc. Number: [ADDRESS_249669]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 118 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020
Approved  
  

EDMS Doc. Number: [ADDRESS_249670]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 119 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020APPENDIX J.BATH ANKYLOSING SPONDYLITIS DISEASE 
ACTIVITY INDEX (BASD AI)
Please check the box that represents y our answer. (i.e. )
All quest ions refer to the last 7 days .
1.How woul d you describe y our overall  level of fat igue/tiredness?
0 1 2 3 4 5 6 7 8 9 10
       none                                                                                                                 very severe
2.How would you describe your overall level of neck, back or hip pain resulting from AS?
0 1 2 3 4 5 6 7 8 9 10
       none                                                                                                                 very severe
3.How woul d you describe y our overall  level of pain/swelling in jo ints other than the 
neck, back or hips?
0 1 2 3 4 5 6 7 8 9 10
       none                                                                                                                 very severe
4.How woul d you describe y our overall  level of discomfort from any areas t ender to the 
touch or pressure?
[ADDRESS_249671] iffness fro m the time y ou wake 
up?
[ADDRESS_249672] from the time y ou wake up?
0 1 2 3 4 5 6 7 8 9 10
0    
hr1 
hr2 or m ore 
hrs
Source: Calin, 1999 ; Sieper, 2009 .
BASDAI © Andrei Calin, 1994. All Rights Reserved
BASDAI -[LOCATION_002]/English -Version of 09 Dec 15 -Mapi.
ID051206/ BASDAI_TS1.0_eng -US2.doc
Approved  
  
EDMS Doc. Number: [ADDRESS_249673]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 120 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249674] OF 
DISEASE 12DOMAINS (PSAID -12) QUESTIONNAIRE 
The PsAID -[ADDRESS_249675] ive of the patient. It is composed of 12 physical and psycho logical 
domains. Each dom ain is rated fro m 0 to 10 wi th a different weight ing. The total score is divided 
by 20. The final score has a range from 0 (best status) to 10 (worst statu s), with a cut -off of 4. 
The outputs of the P sAID calculat ion should be printed and added to the source documents.
We want y ou to indicate how much y our psori atic arthrit is impacts y our heal th. Please tell us 
how y ou have been feeling this last week. 
1.Pain 
Circle the number that best describes the pain y ou fel t due to y our psori atic arthrit is during the 
last week:
2. Fati gue 
Circle the number that best describes the overall level of fatigue due to y our psori atic arthrit is 
you have experi enced during the l ast week: 
3. Skin problems 
Circle the number that best describes the skin problems including itching y ou felt due to y our 
psori atic arthrit is during the last week: None 0 1 2 3 4 5 6 7 8 9 10 Extreme
No 
fatigue0 1 2 3 4 5 6 7 8 9 10 Totally 
exhausted
None 0 1 2 3 4 5 6 7 8 9 10 Extreme
Approved  
  
EDMS Doc. Number: [ADDRESS_249676]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 121 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020APPENDIX K: THE EULAR PSORIATIC ARTHRITIS IMPACT OF 
DISEASE 12 DOMAINS (PSAID- 12) QUESTIONNAIRE 
(CONTINUED)
4. Work and/or leisure activit ies 
Circle the number that best describes the difficult ies you had to parti cipate fully in work and/or 
leisure act ivities due to y our psori atic arthrit is during the last week:
5. Funct ional capacit y 
Circle the number that best describes the difficult y you had in doing daily physical act ivities due 
to your psori atic arthrit is during the last week: 
6. Di scomf ort 
Circle the number that best describes the feeling of discomfort and anno yance with everyday 
tasks due to y our psori atic arthritis during the last week:
7. Sleep disturbance 
Circle the number that best describes the sleep difficult ies (i.e., resting at night) y ou felt due to 
your psori atic arthrit is during the last week: None 0 1 2 3 4 5 6 7 8 9 10 Extreme
No 
difficulty0 1 2 3 4 5 6 7 8 9 10 Extreme 
difficulty
None 0 1 2 3 4 5 6 7 8 9 10 Extreme
No 
difficulty0 1 2 3 4 5 6 7 8 9 10 Extreme 
difficulty
Approved  
  
EDMS Doc. Number: [ADDRESS_249677]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 122 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020APPENDIX K: THE EULAR PSORIATIC ARTHRITIS IMPACT OF 
DISEASE 12 DOMAINS (PSAID -12) QUESTIONNAIRE 
(CONTINUED)
8. Copi[INVESTIGATOR_208854] y our psori atic arthrit is overall, how well did you cope (manage, deal, make do) with 
your psori atic arthrit is during the last week?  
9. Anxiet y, fear and uncertaint y 
Circle the number that best describes the level of anxiet y, fear and uncertaint y (for example 
about the future, treatments, fear of loneliness) due to y our psori atic arthrit is you have 
experienced during the last week: 
10. Em barrassment and/or shame
Considering y our psori atic arthrit is overall, circle the number that best describes the level o f 
embarrassment and/or shame due to y our appearance experienced during the last week:
11. Soci al parti cipat ion
Circle the number that best describes the difficult ies you had to parti cipate fully in soci al 
activit ies (including relat ionships wit h family and/or peopl e very  close to y ou) due to y our 
psori atic arthrit is during the l ast week:Very 
well0 1 2 3 4 5 6 7 8 9 10 Very 
poorly
None 0 1 2 3 4 5 6 7 8 9 10 Extrem e
None 0 1 2 3 4 5 6 7 8 9 10 Extreme
None 0 1 2 3 4 5 6 7 8 9 10 Extrem e
Approved  
  
EDMS Doc. Number: [ADDRESS_249678]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 123 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020APPENDIX K: THE EULAR PSORIATIC ARTHRITIS IMPACT OF 
DISEASE 12 DOMAINS (PSAID -12) QUESTIONNAIRE 
(CONTINUED)
12. Depression
Circle the number that best describes the level of depressio n due to y our psori atic arthrit is you 
have experienced during the last week:
THANK YOU FOR ANSWERING THIS QUESTIONNAIRE
Source: Gossec, 2014.None 0 1 2 3 4 5 6 7 8 9 10 Extreme
Approved  
  
EDMS Doc. Number: [ADDRESS_249679]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 124 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020APPENDIX K: THE EULAR PSORIATIC ARTHRITIS IMPACT OF 
DISEASE 12 DOMAINS (PSAID -12) QUESTIONNAIRE 
(CONTINUED)
PsAID -12SCORING AND CALCULATION RULES 
The PsAID is calcula tedbased on 12 NRS questions. Each NRS is assessed as a number between 
0 and 10. 
Calculators and translat ions are available at 
http://www.eular.org/index.cfm?framePage=/st_com_clinical_tools.cfm .
1.Calculation  
PsAID final value = 
(PsAID1 (pain) NRS value (range 0 -10) x 3) 
+ (PsAID2 (fat igue) NRS value (range 0- 10) x 2) 
+ (PsAID3 (skin) NRS value (range 0- 10) x 2) 
+ (PsAID4 (Work and/or leisure activit ies) NRS value (range 0- 10) x 2) 
+ (PsAID5 (funct ion) NRS value (range 0- 10) x 2) 
+ (PsAID6 (disco mfort) NRS va lue (range 0- 10) x 2) 
+ (PsAID7 (sleep) NRS value (range 0 -10) x 2) 
+ (PsAID8 (copi[INVESTIGATOR_007]) NRS value (range 0- 10) x 1) 
+ (PsAID9 (anxiet y) NRS value (range 0- 10) x 1) 
+ (PsAID10 (embarrassment) NRS value (range 0- 10) x 1) 
+ (PsAID11 (social life) NRS valu e (range 0 -10) x 1) 
+ (PsAID12 (depression) NRS value (range 0- 10) x 1) 
The total is divided by 20 . Thus, the range of the final PsAID value is 0 -10, where 
higher figures indicate worse status. 
2. Missing data imputation 
If one of the 12 NRS values composing the PsAID is missing, the imputation is as fo llows:
a.calculate the m ean value of the 11 other (non -missing) NRS values (range, 0 -10)
b.impute this value for the missing NRS value
c.then, calculate the PsAID score as explained above. 
If 2 or more of the NRS values are missing, the PsAID score is considered a missing value 
(no imputation) .
Approved  
  
EDMS Doc. Number: [ADDRESS_249680]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 125 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020
Approved  
  

EDMS Doc. Number: [ADDRESS_249681]
Protocol  CC-[ZIP_CODE]- PSA-014 [COMPANY_010] Inc.
Confident ial and Propri etary 126 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020
Approved  
  

EDMS Doc. Number: [ADDRESS_249682]
Protocol  CC-[ZIP_CODE]- PSA-014 [COMPANY_010] Inc.
Confident ial and Propri etary 127 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020
Approved  
  

EDMS Doc. Number: [ADDRESS_249683]
Protocol  CC-[ZIP_CODE]- PSA-014 [COMPANY_010] Inc.
Confident ial and Propri etary 128 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020
Approved  
  

EDMS Doc. Number: [ADDRESS_249684]
Protocol  CC-[ZIP_CODE]- PSA-014 [COMPANY_010] Inc.
Confident ial and Propri etary 129 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020
Approved  
  

EDMS Doc. Number: [ADDRESS_249685]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 130 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020
 
  

EDMS Doc. Number: [ADDRESS_249686]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 131 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020
Approved  
  

EDMS Doc. Number: [ADDRESS_249687]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 132 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020
Approved  
  

EDMS Doc. Number: [ADDRESS_249688]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 133 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020
Approved  
  

EDMS Doc. Number: [ADDRESS_249689]
Confident ial and Propri etary 134 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020
Approved  
  

EDMS Doc. Number: [ADDRESS_249690]
Protocol  CC-[ZIP_CODE]- PSA-014 [COMPANY_010] Inc.
Confident ial and Propri etary 135 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020
Approved  
  

EDMS Doc. Number: [ADDRESS_249691]
Protocol  CC-[ZIP_CODE]- PSA-014 [COMPANY_010] Inc.
Confident ial and Propri etary 136 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020
Approved  
  

EDMS Doc. Number: [ADDRESS_249692]
Protocol  CC-[ZIP_CODE]- PSA-014 [COMPANY_010] Inc.
Confident ial and Propri etary 137 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249693] EM (PSAMRIS)
Source: Glinatsi, 2015 .
Approved  
  
EDMS Doc. Number: [ADDRESS_249694]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 138 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020APPENDIX Q.WHOLE -BODY ( WB)–MRI ASSESSMENTS
Thefinal WB-MRI assessment protocol will be developed based on the prevalent 
recommendat ions by [CONTACT_208876]. The final detailed MRI manual will be available before any reading starts.
Approved  
  
EDMS Doc. Number: [ADDRESS_249695]
Protocol  CC-[ZIP_CODE]- PSA-014 [COMPANY_010] Inc.
Confident ial and Propri etary 139 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020
Approved  
  

EDMS Doc. Number: [ADDRESS_249696]
Protocol  CC-[ZIP_CODE]- PSA-014 [COMPANY_010] Inc.
Confident ial and Propri etary 140 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020
Approved  
  

EDMS Doc. Number: [ADDRESS_249697]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 141 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020
Approved  
  

EDMS Doc. Number: [ADDRESS_249698]
Protocol  CC-[ZIP_CODE]- PSA-014 [COMPANY_010] Inc.
Confident ial and Propri etary 142 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249699] 31 days and then swi tch to the bottl e.
Approved  
  
EDMS Doc. Number: [ADDRESS_249700]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 143 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: [ADDRESS_249701]’s chosen form of contraception must be effective by [CONTACT_208913]  (for example, horm onal contracepti on shoul d be ini tiated 
at least 28 days before screening).
At screening and at baseline, and at any  time during the study , when an FCBP’s contraceptive 
measures or abilit y to beco me pregnant changes, the invest igator (or a representative as a study  
nurse) will educate the s ubject regarding contraception options and the correct and consistent use 
of effect ive contraceptive methods in order to successfully prevent pregnancy.
                                               
3A female of childbearing potential is a sexually mature female who 1) has not undergone a hysterectomy (the 
surgical removal of the uterus )or bilat eral oophorectomy (the surgical removal of both ovaries) or 2) has not been 
postmenopa usal for at least 24 consecutive months (that is, has had menses at any time during the preceding 24 
consecutive months). A tubal ligation alone is not sufficient to qualify a female as of non -childbearing potential.
Approved  
  
EDMS Doc. Number: [ADDRESS_249702]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 144 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020APPENDIX U.SAMPLE SERIOUS ADVERSE EVENT REPORT FORM 
Approved  
  
EDMS Doc. Number: [ADDRESS_249703]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 145 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020APPENDIX U: SAMPLE SERIOUS ADVERSE EVENT REPORT FORM
(CONTINUED)
Approved  
  
EDMS Doc. Number: [ADDRESS_249704]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 146 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020APPENDIX U: SAMPLE SERIOUS ADVERSE EVENT REPORT FORM
(CONTINUED)
Approved  
  
EDMS Doc. Number: [ADDRESS_249705]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 147 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020APPENDIX V.PREGNANCY NOTIFICATION FORM 
Approved  
  
EDMS Doc. Number: [ADDRESS_249706]
Protocol  CC-[ZIP_CODE]- PSA- 014 [COMPANY_010] Inc.
Confident ial and Propri etary 148 CC-[ZIP_CODE]- PSA-014Amendment 4 Final: 04 May 2020APPENDIX W.LACTATION NOTIFICATI ON FORM 
Approved  
  
EDMS Doc. Number: [ADDRESS_249707]
Summary  of Changes CC -[ZIP_CODE]- PSA- 01 4 [COMPANY_010] Inc.
Confident ial and Propri etary 1 Amendment # 3 Final: 04May 2020TITLE PAGE
–SUMMARY OF CHANGES –
APHASE 4, MULTICENTER , SINGLE -ARM, OPEN -
LABEL STUDY TO EVALU ATE THE IMPACT OF 
APREMILAST (CC -[ZIP_CODE]) ON MRI OUTCOM ES IN 
SUBJECTS WITH PSORIATIC ARTHRITIS
AMENDMENT NO. [ADDRESS_249708] (IP) : Apremilast
PROTOCOL NUMBER : CC-[ZIP_CODE]- PSA -014
ORIGINAL DATE: 14 AUG 2018
AMENDMENT No. 1 DATE: 21 SEP 2018
AMENDMENT No. 2 DATE: 12 FEB 2019
AMENDMENT No
. 3 DATE: 17MAY 2019
AMENDMENT No. 4DATE: 04MAY [ADDRESS_249709] NUMBER: 2018-002748-10
IND NUMBER: [ADDRESS_249710] Information: 
Name: , MD
Title: Medical Director Global Development
[COMPANY_010] Inc.
Address: [COMPANY_010] Inc,
[COMPANY_010] Center Dr, Thousand Oaks, CA [ZIP_CODE]
[LOCATION_003]
Phone:
E
-mail:
Note : Only call [COMPANY_010] Medical Information, if you are not able to reach the Clinical 
Research Physician(s) or Medical Monitor or designee for emergency calls .
[COMPANY_010] Medical Information: 1- 800-77- AMGEN (1 800- 772-6436)

EDMS Doc. Number: [ADDRESS_249711]
Summary  of Changes CC -[ZIP_CODE]- PSA- 01 4 [COMPANY_010] Inc.
Confident ial and Propri etary 2 Amendment # 3 Final: 04May 2020Confidentiality Notice 
This document contains confident ial information of [COMPANY_010]. This document 
must not be disclo sed to any one other than the site study  staff and members 
of the inst itutional review board/independent ethics committee/inst itutional 
scientific review board or equi valent. The informatio n in this document 
cannot be used for any  purpose other than the evaluation or conduct of the 
clinical invest igation without the pri or wri tten consent of [COMPANY_010]. If y ou have 
questions regarding how this document may be used or shared, call the 
[COMPANY_010] Medical Informat ion number: 1 - 800-77- AMGEN
EDMS Doc. Number: [ADDRESS_249712]
Summary  of Changes CC -[ZIP_CODE]- PSA- 01 4 [COMPANY_010] Inc.
Confident ial and Propri etary 3 Amendment # 3 Final: 04May 2020CELGENE THERAPEUTIC AREA HEAD SIGNATURE [CONTACT_1783]
{See appended electronic signature [CONTACT_3264]}
Signature [CONTACT_208925] y
, Vice President and Head of Immuno logy &Fibrosi s Clinical 
Development
Printed Name [CONTACT_208919] [CONTACT_27616], I i ndicate I have reviewed this summary  of changes and find i ts 
content to be acceptable. NOTE: Signed by [CONTACT_208914]. Number: [ADDRESS_249713]
Summary  of Changes CC -[ZIP_CODE]- PSA- 01 4 [COMPANY_010] Inc.
Confident ial and Propri etary 4 Amendment # 3 Final: 04May [ZIP_CODE]. JUSTIFICATION FOR AM ENDMENT
The purpose of this amendment is to update the change in Sponsor, as well as key contact [CONTACT_208915], and to update safet y reporting and product complaint s to align wit h 
[COMPANY_010] processes.
All references to “Celgene Corporation ” were removed and replaced with “[COMPANY_010] Inc” 
and “ Celgene” changed to “[COMPANY_010]” throughout th e protocol. 
Cover Pages were updated with [COMPANY_010] contact [CONTACT_3031]
Secti on 10 Moni toring and Reporting of Adverse Events was updated to align with 
[COMPANY_010] Global Drug Safet y processes. 
Secti on 10 .4 Pregnancy was m odified according to the [COMPANY_010] Glo bal Drug Safet y 
process:
oCollect ion of Pregnancy  Information and Infant Health Information
oCollect ion ofinformat ion: Male Subjects with Partners Who Become Pregnant 
oCollect ion of Lactati on Inform ation
Secti on 10. 5Reporti ng of Serious Adverse Events was updated to include instructions for 
paper reporting of SAEs 
Secti on 12.[ADDRESS_249714] 
inform ation.
Secti on 15.[ADDRESS_249715] Com plaint Secti on added
The amendment also includes minor clarifications and corrections to align with [COMPANY_010] 
process :
Secti on 7.5-Invest igational Product Accountabilit y
Secti on 15 .2Audits and Co mpliance 
Secti on 16 Publicat ions. 
EDMS Doc. Number: [ADDRESS_249716]
Summary  of Changes CC-[ZIP_CODE] -PSA-01 4 Celgene Corporati on
Confident ial and Propri etary 1 CC-[ZIP_CODE]-PSA- 014 Amendment 3Final: 17May 2019TITLE PAGE
–SUMMARY OF CHANGES –
AMENDMENT NO. [ADDRESS_249717] (CC -[ZIP_CODE] ) ON MRI OUTCOMES IN
SUBJECTS WITH PSORIATIC ARTHRITIS
INVESTIGATIONAL PRODUCT ( IP): Apremilast
PROTOCOL NUMBER: CC-[ZIP_CODE]-PSA-014
ORIGINAL DATE: 14 AUG 2018
AMENDMENT No. 1 DATE: 21 SEP 2018
AMENDMENT No. 2 DATE: 12FEB 2019
AMENDMENT No. 3 DATE: 17MAY [ADDRESS_249718] NUMBER: 2018-002748-10
IND NUMBER: [ADDRESS_249719] Information: 
Name:
[CONTACT_1641]: Medical Director
Address: [COMPANY_003]I
[ADDRESS_249720]
Morrisville, NC [ZIP_CODE]
Phone:
E
-mail:
CONFIDENTIAL
This protocol is provided to you as an Investigator, potential Investigator, or consultant for review by 
[CONTACT_10825], your staff, and ethics committee/institutional review board.  The information contained in this 
document is regarded as confidential and, except to the extent necessary to obtain informed consent, 
may not be disclosed to another party unless such disclosure is required by [CONTACT_27614].  
Persons to whom the information is disclosed must be inform ed that the information is confidential 
and may not be further disclosed by [CONTACT_476] .

EDMS Doc. Number: [ADDRESS_249721]
Summary  of Changes CC-[ZIP_CODE] -PSA-01 4 Celgene Corporati on
Confident ial and Propri etary 2 CC-[ZIP_CODE]-PSA- 014 Amendment 3Final: 17May 2019CELGENE THERAPEUTIC AREA HEAD SIGNATURE [CONTACT_1783]
{See appended electronic signature [CONTACT_3264]}
Signature [CONTACT_208925] y
, Execut ive Director, Inflammat ion and Immunology
Global Medical Affairs Rheumatology
Printed Name [CONTACT_208919] [CONTACT_27616], I i ndicate I have reviewed this summary  of changes and find i ts 
content to be acceptable.

EDMS Doc. Number: [ADDRESS_249722]
Summary  of Changes CC-[ZIP_CODE] -PSA-01 4 Celgene Corporati on
Confident ial and Propri etary 3 CC-[ZIP_CODE]-PSA- 014 Amendment 3Final: 17May [ZIP_CODE]. JUSTIFICATION FOR AM ENDMENT
Significant changes included in this amendment are summarized below:
All references to“approved product labeling” and “ prescribing informat ion” were 
removed .
Based on comments from Healt h Authorit ies, there shoul d be one reference safety  
inform ation (RSI) for a trial. Therefore, Celgene clarifies that the invest igator brochure 
(IB) i s the i dentified RSI for th
istrial.The IB will be submitted to all sites and clearly 
ident ified as the RSI in the clinical tr ial applicat ion (CTA) package. 
Revised sect ions: 
Secti on 1.2 .2.2.2 ; 
Secti on 7.1.
Exclusio n criteria #22updated to include prior exposure to a ty k2inhibitor ,as prohibited 
medicat ion. 
The am endment al so includes several other minor clarifications and correcti ons:
References to the 
were corrected to reflect the appropriate nomenclature of such subject -reported outcome 
questionnaire.
Revised sect ions: 
Protocol  Summary;
Table of Contents;
Table 12; 
Secti on 5 (Tabl e 13);
Secti on 6.7.4;
Appendix A;

The BASDAI questionnaire will be performed for all subjects, at the timepoints specified 
as per the Table of Events.
Revised sect ions: 
Secti on 5 (Tabl e 13, f ootnote h).
Qualit y of Lifeabbreviature (QoL) was removed from the text in all the instances it was
placed together with “subject -reported outcomes” ,for clarity and consistency  across 
different sections of the protocol.
Revised sect ions: 
Secti on 6.2 ;

EDMS Doc. Number: [ADDRESS_249723]
Summary  of Changes CC-[ZIP_CODE] -PSA-01 4 Celgene Corporati on
Confident ial and Propri etary 4 CC-[ZIP_CODE]-PSA- 014 Amendment 3Final: 17May 2019Secti on 6.2.1 ;
Secti on 6.7 .
The word “electronic” was deleted in all the instances it was displayed right before the 
word CRF.
Revised sect ions: 
Secti on 7.2.1 ;
Secti on 8;
Secti on 8.1;
Secti on 10.1;
Secti on 10.2 .1;
Secti on 14.2 .
The following abbreviat ions were inserted: EDC, LOCF, NRI, SRO, vs.
Revised sect ion: 
Appendix A .
CASPAR Criteria replaced wit h a corrected versio n that includes an addit ional footnote. 
Revised sect ion: 
Appendix B.
Protocol  number updated from CC -[ZIP_CODE]- PsA - [ADDRESS_249724] ions: 
Headers and footers throughout the document and the protocol tit le on Tit le Page .
EDMS Doc. Number: [ADDRESS_249725]
Summary  of Changes CC-[ZIP_CODE] -PsA-014 Celgene Corporati on
Confident ial and Propri etary 1 CC-[ZIP_CODE]- PsA-014 Amendment 2 Final: 12 Feb 2019TITLE PAGE
–SUMMARY OF CHANGES –
AMENDMENT NO. [ADDRESS_249726] (CC -[ZIP_CODE] ) ON MRI OUTCOMES IN
SUBJECTS WITH PSORIATIC ARTHRITIS
INVESTIGATIONAL PRODUCT ( IP): Apremilast
PROTOCOL NUMBER : CC-[ZIP_CODE]- PsA-014
ORIGINAL DATE: 14 AUG 2018
AMENDMENT N o. 1DATE: 21 SEP 2018
AMENDMENT No. 2 DATE: 12FEB [ADDRESS_249727] NUMBER: 2018-002748-10
IND NUMBER: [ADDRESS_249728] Information: 
Name:
[CONTACT_1641]: Medical Director
Address: [COMPANY_003]I
[ADDRESS_249729]
Morrisville, NC [ZIP_CODE]
Phone:
E
-mail:
CONFIDENTIAL
This protocol is provided to you as an Investigator, potential Investigator, or consultant for review by 
[CONTACT_10825], your staff, and ethics committee/institutional review board.  The information contained in this 
document is regarded as confidential and, except to the extent nece ssary to obtain informed consent, 
may not be disclosed to another party unless such disclosure is required by [CONTACT_27614].  
Persons to whom the information is disclosed must be informed that the information is confidential 
and may not be further dis closed by [CONTACT_476] .

EDMS Doc. Number: [ADDRESS_249730]
Summary  of Changes CC-[ZIP_CODE] -PsA-014 Celgene Corporati on
Confident ial and Propri etary 2 CC-[ZIP_CODE]- PsA-014 Amendment 2 Final: 12 Feb 2019CELGENE THERAPEUTIC AREA HEAD SIGNATURE [CONTACT_1783]
{See appended electronic signature [CONTACT_3264]}
Signature [CONTACT_208925] y
, Execut ive Director, Inflammat ion and Immunology
Global Medical Affairs Rheumatol ogy
Printed Name [CONTACT_208919] [CONTACT_27616], I i ndicate I have reviewed this summary  of changes and find i ts 
content to be acceptable.

EDMS Doc. Number: [ADDRESS_249731]
Summary  of Changes CC-[ZIP_CODE] -PsA-014 Celgene Corporati on
Confident ial and Propri etary 3 CC-[ZIP_CODE]- PsA-014 Amendment 2 Final: 12 Feb [ZIP_CODE]. JUSTIFICATION FOR AM ENDMENT
Significant changes included in this amendment are summarized below:
Medical Monitor/Emergency  Contact [CONTACT_208916] m odified .
Change made to reflect [COMPANY_003]’s ( clinical research organizat ion) responsible personnel.
Revised sect ion: Medical Monitor/Emergency Contact [CONTACT_7171]
Deleted text: “Detai led information can be found in the Invest igator’s Brochure (IB)”
As thi s is a Phase [ADDRESS_249732] l abeling or the IB (depending on regional 
regul ations) shoul d be used as the reference for addit ional inform ation on apremilast 
in this approved indicat ion.Since selected countries, as per local regulat ions, will 
have the product label as the main document for addit ional inform ation on apremilast, 
the reference to IB in isolation was deleted.
Revised sect ions: 
- [IP_ADDRESS].1, Efficacy Data From Phase 3 Studi es CC -[ZIP_CODE] -PSA-002 (Pal ace 1), 
CC-[ZIP_CODE]- PSA-003 (Palace 2), and CC - [ZIP_CODE]- PSA-004 (Pal ace 3) Through 
Week 24 in Subjects Wit h Pri or csDMARDs and/or Bio logic DMARDs
-[IP_ADDRESS].2, Efficacy Data From Phase 3 Study  CC-[ZIP_CODE] -PSA-005 (Pal ace 4) 
Through Week 24 in Subjects Naïve to csDMARDs and Bio logic DMARDs
-[IP_ADDRESS].3, Efficacy Data From Phase 3 CC –[ZIP_CODE]- PSA-006 (ACTIVE) Through 
Week 24 in Subjects Wit h an Inadequate Response to [ADDRESS_249733] Monotherapy
Added text: “/approved product labeling”
As thi s is a Phase [ADDRESS_249734] l abeling or the IB (depending on regional 
regul ations) shoul d be used as the reference for addit ional inform ation on apremilast
in this approved indicat ion.
Revised sect ions: 
-Secti on1.[IP_ADDRESS] , Long -term Safety  Data From  CC-[ZIP_CODE]- PSA-006 (ACTIVE), 
CC-[ZIP_CODE] -PSA-002 (Palace 1), CC -[ZIP_CODE] -PSA-003 (Palace 2) and 
CC-[ZIP_CODE]- PSA-004 (Palace 3)
-Appendix T, Con tracepti on Educati on
Anote was added to inclusio n criterion #[ADDRESS_249735] ion: Sect ion 4.3 Inclusio n Cri teria
In exclusio n criterion #1, “history  of hypersensi tivity to gadolinium contrast agent” 
was added. In exclusio n criterion#8, the word “hypersensit ivity” was added. 
EDMS Doc. Number: [ADDRESS_249736]
Summary  of Changes CC-[ZIP_CODE] -PsA-014 Celgene Corporati on
Confident ial and Propri etary 4 CC-[ZIP_CODE]- PsA-014 Amendment 2 Final: 12 Feb 2019Exclusio n criterion #9 was added: “History  of rare hereditary problems of galactose 
intolerance, lapp lactase deficiency or glucose -galactose malabsorption ”.
Addit ions made to com ply with requests from  European Health Authori ties.
Revised sect ion: Sect ion 4.4 Exclusio n Cri teria
The Table of Events was updated to reflect: Weight will be captured at every  visit ; 
 
 
.
Weight will now be captured at every  visit to comply  withtherequest edfrom 
European Health Authorit ies. Other changes made for consistency with other sections 
of the protocol.
Revised section: Sect ion 5, Table of Events (Table 13)
Dem ographics: “init ials” deleted; “date” substituted by “year” of birth , for 
consistency wit h CRF ; Contraception Education: reference to Section 4.3 and 
Appendix T were added; Urinalysis: “a urine dipst ick ma y be used” deleted; 4) 
Chemistry  panel: “creat inine clearance added .Changes made for consistency with 
other sections of the protocol.
Revised sect ion: Sect ion 6.1, Screening Period
Weight: reference to Section 6.5.2 was added; Assessment of diarrhea: reference to 
Secti on 6.5.5 was added; Contraception Education: reference to Section 4.3 and 
Appendix T were added; Urinalysis: “a urine dipst ick may be used” deleted ; 
Chemistry  panel: “creat inine clearance added; “MRI assessments” moved to same 
bullet poin t as “Efficacy assessments” for consistency wit h protocol sect ions.
Revised sect ion: Sect ion 6.2, Treatment Period
Added “End of Treatment” for compliance wit h protocol template; Urinalysis: “a 
urine dipstick may be used” deleted; “MRI assessments” moved t o sam e bullet poi nt 
as “Efficacy  assessments” for consistency wit h protocol sect ions.
Revised sect ion:Section 6.2.1 Early terminat ion/End of Treatment
Cut-offs for cDAPSA put in bullet points for clarit y.
Revised sect ion: Sect ion [IP_ADDRESS], Clinical Disease Activity Index for Psori atic 
Arthri tis (cDAPSA )
Text was revised to delete reference to SMT, for consistency with wording in Phase [ADDRESS_249737] ion:Section 6.5, Safet y Assessment s
Aparagraph was added to ref erence country  guidelines for pregnancy testing.
Revised sect ion: Sect ion 6.5.1, Serum and Urine Pregnancy Tests for FCBP

EDMS Doc. Number: [ADDRESS_249738]
Summary  of Changes CC-[ZIP_CODE] -PsA-014 Celgene Corporati on
Confident ial and Propri etary 5 CC-[ZIP_CODE]- PsA-014 Amendment 2 Final: 12 Feb 2019Weight will now be captured at every  visit. A paragraph was added for considerat ion 
of study  treatm ent discont inuation of study  treatm entin the event of unexplained and 
clinically significant weight loss.
Revised sect ion: Sect ion 6.5.2, Vital Signs, Height and Weight 
A paragraph was added as a recommendat ion for study  treatm ent di scont inuat ionin 
the event of new/worsening psychiatric symptoms or suicidal ideat ion/attem pt.
Addit ion made to com ply wit h European Healt h Authorities ’requests.
Revised sect ion: Sect ion 6.5.4, Psy chiatri c Evaluatio n
A sect ion dedicated to “Diarrhea, Nausea and Vomiting” was added, including a 
statement that “discont inuat ion of study  treatm ent may be necessary  if severe 
diarrhea, nausea and vo miting occur”.
Addit ion made to com ply wit h European Healt h Authorities requests.
Revised sect ion: Sect ion 6.5.5, Diarrhea, Nausea and Vomiting
Text revised to add “creatinine clearance”.
Revised sect ion: Sect ion 6.5.7, Clinical Laboratory Evaluat ions
Text revised to reflect new safet y gateway  process, as agreed upon by  [CONTACT_208917] . Paragraphs referencing diarrhea were moved to newly created section 6.5.5 
“Diarrhea, Nausea and Vomiting”.
Revised sect ion: Sect ion 6.5.8, Adverse Events
“Conco mitant Medicat ions Not Recommended” sectionwas added .
Addit ion was made to comply  with European Health Authorit ies, for consistency wit h 
apremilast’s label. 
Revised sect ion: Sect ion 8.2 ,Concomitant Medications Not Recommended
The word “vio lation” was subst ituted by  “deviat ion” for com pliance wi th current 
SOP.
Revised sect ion: Sect ion 9.2, Study  Populati on Definit ions
Text was revised to reflect new safet y gateway  process, as agreed upon by  [CONTACT_208917] .
Revised sect ion: Sect ion 10, Adverse Events (10.1, 10.4, 10.5, 10.5.1)
Text was revised to reflect subjects’ right to withdraw fro m the study  (and proper 
docum entati on), as well as the importance of early  terminati on assessments.
Revised sect ion: Sect ion 11.1, Treatment Discont inuat ion
HAQ -DIquest ionnaire was updated to display  validated versi on used in the eRT 
tablet which the subjects will be responding to.
Revised sect ion: Appendix E, Health Assessment Quest ionnaire –Disabilit y Index 
(HAQ -DI)
EDMS Doc. Number: [ADDRESS_249739]
Summary  of Changes CC-[ZIP_CODE] -PsA-014 Celgene Corporati on
Confident ial and Propri etary 6 CC-[ZIP_CODE]- PsA-014 Amendment 2 Final: 12 Feb 2019A paragraph was added to reference the evaluat ion of the number of affected di gits,
for com pletion and consistency between Ph ase4 PsA protocol s.
Revised sect ion: Appendix H, Leeds Dact ylitis Index ( LDI)
The BASDAI questionnaire was updated to di splay  validated versi on used in the eRT 
tablet subjects will be responding to .
Revised sect ion: Appendix J, Bath Ankylosing Spondylit is Disease Act ivity Index 
(BASDAI )
Quest ions 9, [ADDRESS_249740] ion: Appendix K, Psori atic Arthri tis Impact of Disease 12- domain 
questionnaire ( PsAID -12)
A paragraph was added to clarify that the figure displayed is an approximate 
representation of the actual blister card and to better explain the transit ion from blister 
card to bottle.
Revised sect ion: Appendix S, Blister Card Configuration for the Titration Period
EDMS Doc. Number: [ADDRESS_249741]
Summary  of Changes CC-[ZIP_CODE] -PsA-014- MOSAIC ™ Celgene Corporati on
Confident ial and Propri etary 1 CC-[ZIP_CODE]- PsA-014- MOSAIC™
Amendment 1 Final : 21Sep 2018 TITLE PAGE
–SUMMARY OF CHANGES –
AMENDMENT NO. [ADDRESS_249742] (CC -[ZIP_CODE] ) ON MRI OUTCOMES IN
SUBJECTS WITH PSORIATIC ARTHRITIS
INVESTIGATIONAL PRODUCT ( IP): Apremilast
PROTOCOL NUMBER : CC-[ZIP_CODE]- PsA-014- MOSAIC ™
ORIGINAL DATE: 14 AUG 2018
AMENDMENT No. 1 DATE: 21SEP [ADDRESS_249743] NUMBER: 2018-002748-10
IND NUMBER: [ADDRESS_249744] Information: 
Name: , MD
Title: Medical Director
Address: Celgene Corporation
[ADDRESS_249745]
Summit, NJ `[ZIP_CODE] [LOCATION_003]
Phone:
E
-mail:
CONFIDENTIAL
This protocol is provided to you as an Investigator, potential Investigator, or consultant for review by 
[CONTACT_10825], your staff, and ethics committee/institutional review board.  The information contained in this 
document is regarded as confidential and, except to the extent necessary to obtain infor med consent, 
may not be disclosed to another party unless such disclosure is required by [CONTACT_27614].  
Persons to whom the information is disclosed must be informed that the information is confidential 
and may not be further disclosed by [CONTACT_476] .

EDMS Doc. Number: [ADDRESS_249746]
Summary  of Changes CC-[ZIP_CODE] -PsA-014- MOSAIC ™ Celgene Corporati on
Confident ial and Propri etary 2 CC-[ZIP_CODE]- PsA-014- MOSAIC™
Amendment 1 Final : 21Sep 2018 CEL GENE THERAPEUTIC AREA HEAD SIGNATURE [CONTACT_1783]
{See appended electronic signature [CONTACT_3264]}
Signature [CONTACT_208926] y
, Execut ive Director, Inflammat ion and Immunology
Global Medical Affairs Rheumatology
By [CONTACT_27616], I i ndicate I have reviewed this summary  of changes and find i ts 
content to be acceptable.

EDMS Doc. Number: [ADDRESS_249747]
Summary  of Changes CC-[ZIP_CODE] -PsA-014- MOSAIC ™ Celgene Corporati on
Confident ial and Propri etary 3 CC-[ZIP_CODE]- PsA-014- MOSAIC™
Amendment 1 Final : 21Sep 2018 1. JUSTIFICATION FOR AM ENDMENT
Significant changes included in this amendment are summarized below:
14-3- 3 eta bio marker was deleted fro m the protocol since it will no longer be part of 
the study , due to feasibi lity issues. Revised S ections: Secti on 2, Section 5, Section 6.2 
and Section 6.6.
Secti on 6.4.1 was revi sedto specify  the timeframes wi thin which the Magnet ic 
Resonance Im aging ( MRI )assessments should be performed.
Secti on 10.5.[ADDRESS_249748] the current safet y language.
Appendix S was revised to better represent this study’s design (open label, single -arm 
trial).The blister card configurat ion for the titration period was replaced by  a card 
with no pl acebo .